

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Jan Steffel^{1*}, Peter Verhamme², Tatjana S. Potpara³, Pierre Albaladejo⁴, Matthias Antz⁵, Lien Desteghe⁶, Karl Georg Haeusler⁷, Jonas Oldgren⁸, Holger Reinecke⁹, Vanessa Roldan-Schilling¹⁰, Nigel Rowell¹¹, Peter Sinnaeve², Ronan Collins¹², A. John Camm¹³, and Hein Heidbüchel^{6,14}

Advisors: Martin van Eickels, M.D. (Bayer Healthcare), Jutta Heinrich-Nols, M.D. (Boehringer Ingelheim), Markus Müller, M.D., Ph.D. (Pfizer), Wolfgang Zierhut M.D. (Daiichi-Sankyo) and Poushali Mukherjee, Ph.D. (Bristol-Myers Squibb)

Document reviewers (ESC scientific document group): Gregory YH Lip (EHRA Review Coordinator; UK, Denmark), Jeffrey Weitz (Canada), Laurent Fauchier (France), Deirdre Lane (UK), Giuseppe Boriani (Italy), Andreas Goette (Germany), Roberto Keegan (Argentina), Robert MacFadyen (Australia), Chern-En Chiang (Taiwan), Boyoung Joung (Korea), and Wataru Shimizu (Japan)

¹Department of Cardiology, University Heart Center Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland; ²Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; ³School of Medicine, Belgrade University, Belgrade, Serbia; ⁴Grenoble-Alps University Hospital, Grenoble, France; ⁵City Hospital Braunschweig, Braunschweig, Germany; ⁶Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; ⁷Center for Stroke Research Berlin and Department of Neurology, Charité—Universitätsmedizin Berlin, Berlin, Germany; ⁸Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden; ⁹Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany; ¹⁰University of Murcia, Murcia, Spain; ¹¹Middlesbrough, UK; ¹²Age-Related Health Care & Stroke-Service, Tallaght Hospital, Dublin Ireland; ¹³Cardiology Clinical Academic Group, Molecular & Clinical Sciences Institute, St George's University, London, UK, and Imperial College; and ¹⁴Antwerp University and University Hospital, Antwerp, Belgium

Online publish-ahead-of-print 19 March 2018

The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbüchel *et al.* European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. *Europace* 2013;**15**:625–651; Heidbüchel *et al.* Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. *Europace* 2015;**17**:1467–1507]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. The European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group identified 20 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. The 20 topics are as follows i.e., (1) Eligibility for NOACs; (2) Practical start-up and follow-up scheme for patients on NOACs; (3) Ensuring adherence to prescribed oral anticoagulant intake; (4) Switching between anticoagulant regimens; (5) Pharmacokinetics and drug–drug interactions of NOACs; (6) NOACs in patients with chronic kidney or advanced liver disease; (7) How to measure the anticoagulant effect of

* Corresponding author. Tel: +41 44 255 15 15, Fax: +41 44 255 8701, Email: j.steffel@gmx.ch

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

NOACs; (8) NOAC plasma level measurement: rare indications, precautions, and potential pitfalls; (9) How to deal with dosing errors; (10) What to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a potential risk of bleeding; (11) Management of bleeding under NOAC therapy; (12) Patients undergoing a planned invasive procedure, surgery or ablation; (13) Patients requiring an urgent surgical intervention; (14) Patients with AF and coronary artery disease; (15) Avoiding confusion with NOAC dosing across indications; (16) Cardioversion in a NOAC-treated patient; (17) AF patients presenting with acute stroke while on NOACs; (18) NOACs in special situations; (19) Anticoagulation in AF patients with a malignancy; and (20) Optimizing dose adjustments of VKA. Additional information and downloads of the text and anticoagulation cards in different languages can be found on an EHRA website (www.NOACforAF.eu).

Abbreviations

ACS	Acute Coronary Syndrome,	ELDERCARE-AF	Edoxaban low-dose for elder care AF patients,
ACT	Activated Clotting Time,	ELIMINATE-AF	Evaluation of Edoxaban compared with VKA in subjects undergoing catheter ablation of non-valvular atrial fibrillation,
AF	Atrial Fibrillation,	EMANATE	Eliquis evaluated in acute cardioversion compared to usual treatments for anticoagulation in subjects with NVAF,
AMPLIFY	Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy,	ENGAGE AF-TIMI 48	Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48,
ANNEXA	Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors study,	ENSURE-AF	Edoxaban versus warfarin in subjects undergoing cardioversion of Atrial Fibrillation,
aPCC	Activated Prothrombin Complex Concentrates,	ENTRUST AF-PCI	Evaluation of the Safety and Efficacy of an Edoxaban-Based Compared to a Vitamin K Antagonist-Based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention With Stent Placement,
aPTT	Activated Prothrombin Time,	ESC	European Society of Cardiology,
ARISTOTLE	Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation,	GFR	Glomerular filtration rate,
ATLAS ACS-TIMI	Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome – Thrombolysis in Myocardial Infarction,	ICB	Intracranial bleeding,
AUGUSTUS	Apixaban Versus Vitamin K Antagonist in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention,	INR	International Normalized Ratio,
AXAFA-AFNET	Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy – Atrial Fibrillation Network,	ISTH	International Society of Thrombosis and Hemostasis,
BMI	Body Mass Index,	LMWH	Low molecular weight heparin,
BMS	Bare metal stent,	MI	Myocardial infarction,
BRIDGE	Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery,	NOAC	Non-Vitamin K Antagonist Oral Anticoagulant,
CAD	Coronary artery disease,	Non-STEMI	Non- ST-elevation myocardial infarction,
CKD	Chronic kidney disease,	NSAID	Non-steroidal anti-inflammatory drug,
COMPASS	Cardiovascular Outcomes for People Using Anticoagulation Strategies,	PAUSE	Perioperative Anticoagulant Use for Surgery Evaluation,
CrCl	Creatinine clearance,	PCC	Prothrombin Complex Concentrates,
DAPT	Dual antiplatelet therapy,	PCI	Percutaneous Coronary Intervention,
DES	Drug-eluting stent,	P-gp	P-glycoprotein,
dTT	Diluted thrombin time,	PIONEER AF-PCI	Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention,
ECA	Ecarin chromogenic assay,	PPI	Proton pump inhibitor,
EHRA	European Heart Rhythm Association,		

PT	Prothrombin time,
RCT	Randomized clinical trial,
RE-CIRCUIT	Randomized Evaluation of Dabigatran Etexilate Compared to Warfarin in Pulmonary Vein Ablation: Assessment of an Uninterrupted Periprocedural Anticoagulation Strategy,
RE-DUAL PCI	Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention,
RE-LY	Randomized Evaluation of Long-Term Anticoagulation Therapy,
RE-VERSE AD	Reversal Effects of Idarucizumab in Patients on Active Dabigatran,
ROCKET AF	Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation,
SEE	Systemic embolic event,
SmPC	Summary of product characteristics,
STEMI	ST-elevation myocardial infarction,
TIA	Transient ischaemic attack,
TT	Thrombin time,
TTR	Time in therapeutic range,
UFH	Unfractionated heparin,
VENTURE-AF	Active-controlled multi-center study with blind-adjudication designed to evaluate the safety of uninterrupted Rivaroxaban and uninterrupted vitamin K antagonists in subjects undergoing catheter ablation for non-valvular Atrial Fibrillation,
VHD	Valvular heart disease,
VKA	Vitamin K Antagonist,
VTE	Venous thromboembolic event,
WOEST	What is the Optimal antiplatelet and anti-coagulant therapy in patients with oral anticoagulation and coronary stenting,
X-VeRT	Explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in patients with non- valvular atrial fibrillation scheduled for cardioversion

Introduction

Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on anticoagulation.^{1–3} The term NOAC has been used for many years, is used by the current European Society of Cardiology (ESC) AF guidelines³ and is widely recognized. Therefore, even though some authors refer to these

drugs as ‘direct oral anticoagulants’,⁴ we prefer to continue to use NOAC. Ultimately, both terms are interchangeable when referring to the direct factor Xa inhibitors apixaban, edoxaban, and rivaroxaban as well as the direct thrombin inhibitor dabigatran.

Non-vitamin K antagonist oral anticoagulants have an improved efficacy/safety ratio, a predictable anticoagulant effect without need for routine coagulation monitoring, and fewer food and drug interactions compared with VKAs. However, the proper use of NOACs requires a carefully considered approach to many practical aspects. Whereas the ESC Guidelines³ mainly discuss the indications for anticoagulation in general and of NOACs in particular, they offer less guidance on how to deal with NOACs in specific clinical situations. Moreover, there are still several less well researched aspects of NOAC use, which are nonetheless relevant when these drugs are used by cardiologists, neurologists, geriatricians, general practitioners, and other healthcare providers in daily clinical practice. Each of the NOACs available on the market is accompanied by the instructions for its proper use in many clinical situations [summary of product characteristics (SmPCs); patient card; information leaflets for patients; and physicians], but multiple, and often slightly different, physician education tools sometimes create confusion rather than clarity. Based on these premises, the European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of NOACs. The first edition of the Practical Guide was published in 2013 to supplement the AF guidelines as guidance for safe and effective use of NOACs when prescribed; a first update was published in 2015.^{1,2} This text is the 2018 update to the original Guide.

A writing group formulated practical answers to 20 clinical scenarios, based on available and updated knowledge. The writing group was assisted by medical experts from the manufacturers of the NOACs, who provided assurance that the latest information on the different NOACs was evaluated, and provided feedback on the alignment of the text with the approved SmPCs. However, the final responsibility of this document resided entirely with the EHRA writing group. In some instances, the authors opted to make recommendations that do not fully align with all SmPCs, with the goal to provide more uniform and simple practical advice (e.g. on the start of NOAC after cessation of VKA, on advice after a missed or forgotten dose, on perioperative management, and others).

An EHRA website, www.NOACforAF.eu, accompanies the Practical Guide. The Practical Guide is summarized in a Key Message booklet which can be obtained through EHRA and ESC; the website also provides EHRA members with a downloadable slide kit on the Practical Guide.

We hope that with the current revision the practical tool that EHRA envisioned has further improved. The authors realize that there will be gaps, unaddressed questions, and areas of uncertainty and debate. Therefore, readers can address their suggestions for change or improvement on the website. This whole endeavour should be one for and by the medical community with the ultimate goal of improving patient care and outcome.

1. Eligibility for non-vitamin K antagonist oral anticoagulants

Non-vitamin K antagonist oral anticoagulants are approved for stroke prevention in non-valvular atrial fibrillation. Strictly, the term ‘non-

Table 1 Selected indications and contraindications for non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation patients

Condition	Eligibility for NOAC therapy
Mechanical prosthetic valve	Contraindicated
Moderate to severe mitral stenosis (usually of rheumatic origin)	Contraindicated
Mild to moderate other native valvular disease (e.g., mild-moderate aortic stenosis or regurgitation, degenerative mitral regurgitation etc.)	Included in NOAC trials
Severe aortic stenosis	Limited data (excluded in RE-LY) Most will undergo intervention
Bioprosthetic valve (after > 3 months post operatively)	Not advised if for rheumatic mitral stenosis Acceptable if for degenerative mitral regurgitation or in the aortic position
Mitral valve repair (after > 3 months post operatively)	Some patients included in some NOAC trials
PTAV and TAVI	No prospective data yet May require combination with single or dual antiplatelet therapy
Hypertrophic cardiomyopathy	Few data, but patients may be eligible for NOACs

Hatched—limited data.

PTAV, percutaneous transluminal aortic valvuloplasty; TAVI, transcatheter aortic valve implantation.

valvular AF' refers to AF in the absence of a mechanical prosthetic heart valve or moderate to severe mitral stenosis (usually of rheumatic origin) (Table 1),^{3,5,6} which were exclusion criteria for all Phase III NOAC vs. warfarin trials in AF. In order to avoid confusion, the term 'non-valvular' has been eliminated in the 2016 ESC guidelines on the management of patients with AF, and reference is made to the specific underlying valvular heart disease (VHD).^{3,6} However, the term is still found in the individual SmPCs of each of the NOACs due to the original wording used in the exclusion criteria of the clinical trials on which their regulatory approval was based.

Based on these new developments, a novel classification has recently been suggested where a functional EHRA (Evaluated Heartvalves, Rheumatic or Artificial) categorization is proposed, depending on the type of OAC use in patients with AF.⁶ In this scheme, EHRA Type 1 refers to AF patients with VHD needing therapy with a vitamin K antagonist (VKA), including in particular moderate–severe mitral stenosis of rheumatic origin and mechanical prosthetic valve replacement. In contrast, EHRA Type 2 valvular heart disease refers to VHD patients needing thromboembolic prevention therapy for AF with a VKA or a NOAC, including essentially all other native valvular stenoses and insufficiencies as well as mitral valve repair, bioprosthetic valve replacements and transaortic valve intervention (TAVI).⁶ Patients with EHRA Type 2 valvular heart disease were variously included in these trials and NOACs demonstrated a comparable relative efficacy and safety vs. warfarin in patients with vs. without valvular disease, except for a higher risk of bleeding with rivaroxaban vs. warfarin in patients with valvular heart disease in a *post hoc* analysis of the ROCKET-AF trial.^{6–12} Non-vitamin K antagonist oral anticoagulants may therefore be used in such patients (Table 1).^{3,6,13}

Atrial fibrillation in patients with biological valves or after valve repair constitute a grey area, even though these patients were included in some of the landmark NOAC trials.^{6,7,9,10} Since most of these patients do not require long-term oral anticoagulation following their valve procedure, the use of a NOAC for the management of concomitant AF is considered to be a valid option. One exception may be AF in the presence of a biological mitral prosthesis implanted for rheumatic mitral stenosis. Although mitral valve flow is normalized post-mitral valve replacement in these patients, their atria usually remain large and severely diseased. As such, VKA may be the preferred option over NOACs in these patients, but more data are needed.

There are no prospective data available yet on NOACs in patients after percutaneous aortic valve interventions [percutaneous transluminal aortic valvuloplasty or transcatheter aortic valve implantation (TAVI)] in the presence of AF. Percutaneous transluminal aortic valvuloplasty or TAVI usually requires single or even transient dual antiplatelet therapy (DAPT).⁵ The addition of an anticoagulant increases the bleeding risk, and the optimal combination and duration is the subject of ongoing studies, in analogy to the situation in acute coronary syndrome (ACS) patients (see chapter 14).

In hypertrophic (obstructive) cardiomyopathy (HCM), AF is associated with a high rate of thromboembolism. There is limited experience with NOACs in this condition.^{14,15} In contrast to patients with AF in the setting of mechanical valves or rheumatic mitral stenosis, however, there does not seem to be a mechanistic rationale why NOACs should be inferior to warfarin in HCM. On the contrary, AF in HCM shares many similarities of HFpEF related AF, for which there has been no indication that NOAC would be inferior to VKA.^{16–18} Moreover, NOACs

demonstrate a sustained efficacy over VKA also in other high risk subgroups (e.g. patients with a high CHA₂DS₂-VASC score). As such, patients with HCM may be eligible for NOAC therapy.

2. Practical start-up and follow-up scheme for patients on non-vitamin K antagonist oral anticoagulants

Choice of anticoagulant therapy and initiation

Indication for anticoagulation and choice between vitamin K antagonist and non-vitamin k antagonist oral anticoagulant

Before prescribing a NOAC to a patient with AF, it needs to be decided that anticoagulation is indicated based on a risk/benefit analysis.³ The choice of anticoagulant (VKA or NOAC; choice of NOAC) should be made on the basis of indications approved by regulatory authorities and specified within guidelines from professional societies. Knowledge of kidney function is required, since all NOACs have precautions and contraindications based on creatinine clearance (CrCl) (see **chapter 6**). Also product characteristics (as explained in the SmPCs), patient-related clinical factors, and patient preference need to be taken into account.^{3,19,20}

European guidelines have expressed a preference for NOACs over VKA in stroke prevention for AF patients, especially if newly initiated. This recommendation (Class I, level of evidence A) is based on the overall clinical benefit of NOACs.³

In some countries, NOAC therapy can only be prescribed (and/or are reimbursed) if international normalized ratio (INR) control with VKA has been shown to be suboptimal (i.e. after a failed 'trial of VKA'). There is evidence that clinical scores such as SAME-TT₂R₂ may be able to predict poor INR control.^{21–27} However, further prospective studies would be required to validate and implement such strategies (which are not generally needed from a medical perspective, but may be a reasonable cost containment strategy). For the majority of patients, and in accordance with current ESC guidelines, NOACs need to be considered as the first choice anticoagulation based on the positive results of the large outcome trials.^{3,28–31}

Choosing the type and dose of non-vitamin K antagonist oral anticoagulant

With four NOACs available in different dosages for different indications and with different dose reduction criteria, identification of the correct dose has become more complicated and is one of the key challenges in the daily use and individualization of treatment (see **chapter 15**). Non-vitamin K antagonist oral anticoagulants do not have precisely the same rules for prescription and availability in every country. Local factors, such as regulatory approval, formulary committees and the cost of therapy, may influence NOAC availability.

All NOACs have been tested in large randomized prospective trials and resulted in documented efficacy and safety of the respective agent. Testing of different doses, however, was carried out differently. In ARISTOTLE (using apixaban) and ROCKET-AF (using

rivaroxaban), patients received one dose which was reduced in the presence of predefined patient characteristics.^{29,30} In contrast, in RE-LY (with dabigatran) and ENGAGE-AF (with edoxaban) both a lower and a higher dose were tested in fully powered patient cohorts (with further dose reduction for edoxaban in certain patients, see **chapter 15**).^{28,31} Dose reduction of NOACs is primarily recommended only according to the dose reduction criteria investigated in the large phase III trials (see **chapter 15**). Whenever possible, the tested standard dose of NOACs should be used. In addition, it is also important to consider co-medications, some of which may be contraindicated or result in unfavourable drug–drug interactions (see **chapter 5**). Also, patient age, weight, renal function (see **chapters 6 and 18**), and other comorbidities influence the choice. In some patients, proton pump inhibitors (PPIs) may be considered to reduce the risk for gastrointestinal (GI) bleeding, especially in those with a history of GI bleeding or ulcer and patients requiring concomitant use of (dual) antiplatelet therapy.^{32,33} This gastroprotective effect was especially demonstrated in patients receiving antiplatelet or VKA therapy,^{34–36} while data on the preventive effects in NOAC treated patients are limited.³⁷ Decision aids are available to guide clinicians about which NOAC may be best suited for a specific target group.^{38–41}

An anticoagulation card for non-vitamin K antagonist oral anticoagulants and the importance of education

Patients on VKAs have routinely been advised to carry information about their anticoagulant therapy to alert any healthcare provider about their treatment. It is equally important that those treated with NOACs carry details of this therapy. Each manufacturer provides proprietary information cards to be completed by physicians and carried by patients; however, we recommend that a uniform card should be used instead. The proposed NOAC card presented in this version of the Practical Guide has been updated and will be available for download in various languages at www.NOACforAF.eu.

It is critically important to educate patients at each visit about the modalities of intake [once daily (OD) or twice a day (BID); intake with food in case of 15 mg/20 mg of rivaroxaban], the importance of strict adherence to the prescribed dosing regimen, how to deal with any lapse in dosing, and to be careful not to leave their medication behind when travelling. Key educational aspects are also listed on the NOAC anticoagulation card. Education sessions can be further facilitated using specific checklists.^{3,20,42,43}

How to organize follow-up?

The follow-up of AF patients who are taking anticoagulant therapy needs to be carefully specified and communicated among the different caregivers of the patient. The use of any anticoagulant is associated with some drug–drug interactions which may increase the risk of serious bleeding or diminish stroke protection. Treatment requires vigilance due to potentially severe complications, particularly as the target patient population tends to be of older age and frail. Patients' treatment should be reviewed on a regular basis (preferably after 1 month initially and at least every 3 months thereafter). As clinical experience with NOACs grows,^{44,45} follow-up intervals may become longer, based on individual (patient-specific) or local (centre-specific) factors. Patient follow-up may be undertaken by general




Figure 1 Structured follow-up. Initiation and structured follow-up of patients on non-vitamin K antagonist oral anticoagulants. It is mandatory to ensure safe and effective drug intake. The anticoagulation card is intended to document each planned visit, each relevant observation or examination, and any medication change, so that every person following up the patient is well-informed. Moreover, written communication between different healthcare providers is required to inform them about the follow-up plan and execution. FU, follow-up.

practitioners with experience in this field and/or by appropriate secondary care physicians (Figure 1). Growing evidence shows that nurse-coordinated AF clinics may be very helpful in this regard.^{46–50} Each caregiver, including specially trained nurses and pharmacists, should indicate with a short input on the patient NOAC card whether any relevant findings were present, and when and where the next follow-up is due.

Table 2 and Figure 1 list the appropriate timing of the relevant aspects which need to be systematically assessed during follow-up. Importantly, the individual patient profile needs to be taken into consideration; for example, renal function needs to be assessed more frequently (Table 2) in compromised individuals including older patients (≥ 75 years), frail patients,^{52,53} or in those where an intercurrent condition (such as infection or cancer), which may affect hepatic or renal function. Also stroke risk factors alter over time and need to be reassessed at every patient visit.⁵⁴ Bleeding risk should be systematically assessed, e.g. by the HAS-BLED score, which has also been validated in patients on NOACs⁵⁵ and has shown a better prediction than an approach based only on modifiable bleeding risk factors.^{56–60} Also other bleeding risk scores have been proposed.^{59,60} Importantly, however, a high bleeding risk in itself should not automatically result in the decision not to anticoagulate as stroke risk tracks along with bleeding risk.^{3,61} For the practical management, correcting and minimizing modifiable

risk factors is of critical importance in order to minimize the risk of bleeding while on treatment with a NOAC. This approach is also the one recommended by current AF guidelines.³ Similarly, frailty and risk of falling should not generally be a reason not to anticoagulate patients, but rather to ensure careful education on the best choice of (N)OAC and dose selection, and follow-up of the patient (see chapter 18).

3. Ensuring adherence to prescribed oral anticoagulant intake

Strict adherence to NOAC intake is crucial as its anticoagulant effect wanes within 12–24 h after the last intake.⁶² Non-vitamin K antagonist oral anticoagulant plasma level as well as general coagulation tests cannot be considered as tools to monitor adherence since they only reflect intake over the last 24(–48) h and the measured level is heavily dependent on the time between last intake and sampling (see chapter 7). The absence of a need for routine plasma level monitoring means that NOAC patients are likely to be less frequently seen for follow-up compared with VKA patients. However, there are arguments in favour of regular follow-up assessment for patients on

Table 2 Checklist during follow-up contacts of atrial fibrillation patients on anticoagulation

	Interval	Comments
1. Adherence	Each visit	<ul style="list-style-type: none">● Instruct patient to bring NOAC card and complete list of medication: make note and assess average adherence● Re-educate on importance of strict intake schedule● Inform about adherence aids (special boxes; smartphone applications; ...). Consider specific adherence measuring interventions (review of pharmacy refill data; electronic monitoring⁵¹; special education session; ...)
2. Thromboembolism	Each visit	<ul style="list-style-type: none">● Systemic circulation (TIA, stroke, peripheral)● Pulmonary circulation
3. Bleeding	Each visit	<ul style="list-style-type: none">● 'Nuisance' bleeding: preventive measures possible? Motivate patient to diligently continue anticoagulation● Bleeding with impact on quality-of-life or with risk: prevention possible? Need for revision of anticoagulation indication, dose or timing?
4. Other side effects	Each visit	Carefully assess relation with NOAC: decide for continuation (and motivate), temporary cessation, or change of anticoagulant drug
5. Co-medications	Each visit	<ul style="list-style-type: none">● Prescription drugs; over-the-counter drugs (Pharmacokinetics and drug–drug interactions of non-vitamin K antagonist oral anticoagulants section).● Careful interval history: also temporary use can be risky
6. Blood sampling (incl. hemoglobin, renal and liver function)	Yearly	Patients other than those specified below
	6-monthly	≥75 years (especially if on dabigatran) or frail (see chapter 2)
	x-monthly	If renal function CrCl ≤60 mL/min: recheck interval = CrCl/10
	If needed	If intercurrent condition that may impact renal or hepatic function
7. Assessing and minimizing modifiable risk factors for bleeding	Each visit	<ul style="list-style-type: none">● As recommended by current guidelines³● Particularly: uncontrolled hypertension (systolic >160 mmHg), medication predisposing for bleeding (e.g. aspirin, NSAIDs), labile INR (if on VKA), excessive alcohol intake)
8. Assess for optimal NOAC and correct dosing	Each visit	Especially based on the above, re-assess whether <ol style="list-style-type: none">a. The chosen NOAC is the best for the patientb. The chosen dose is correct

For frequency of visits: see *Figure 1*.
CrCl, creatinine clearance (preferably measured by the Cockcroft–Gault method); NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitor; TIA, transient ischaemic attack.

NOACs, particularly in case of relevant co-morbidities such as renal failure, older age, multiple comorbidities, or frailty.

Available ‘real world’ data suggest variable adherence to NOAC intake from 38% to 99% depending on the setting and definition.^{63–78} Although caution is needed when interpreting these results, low adherence rates severely diminish the benefit of treatment. Some of these concerns have been alleviated by recent ‘real world’ implementation data which mostly confirm the improved risk/benefit profile in patients treated with NOACs vs. VKAs as observed in the randomized controlled trials suggesting adequate adherence also in daily clinical practice.^{66,72,79–98} Although there is evidence for significantly lower discontinuation rates with NOACs than with VKAs,

discontinuation is still a relevant issue.^{67,76,77,84,95,99–107} Despite limited data on how NOAC adherence can best be optimized, all means possible should be considered.

Practical considerations (Figure 1)

- (1) Patient education on the need for oral anticoagulation therapy and the importance of strict adherence is important.^{19,20,42,63,108–111} Many simultaneous approaches can be employed to provide education including leaflets and instructions at initiation of therapy, a patient anticoagulation card, group sessions, and re-education at every prescription renewal. Several organizations also offer online

patient support websites, including EHRA (<http://www.afibmatters.org/>), the AF Association in the UK (<http://www.atrialfibrillation.org.uk/>), Anticoagulation UK (www.anticoagulationuk.org/), and AFNET (<http://www.kompetenznetz-vorhofflimmern.de/de/vorhofflimmern/patienteninformation-vorhofflimmern>). Education may be more effective if directed to specific knowledge gaps of the patient, measured by validated questionnaires which can be administered to the patient at the time of a visit, or even via online platforms.^{64,109,112}

- (2) Family members should be involved in the care of the patient, so that they understand the importance of adherence and help the patient in this regard.
- (3) There should be a pre-specified follow-up schedule for the NOAC patient (as suggested in *Figure 1*) known to and shared by general practitioners, cardiologists, pharmacists, anticoagulation clinics, and other professionals providing care. Each of those involved has a responsibility to reinforce adherence. Everyone's efforts should be communicated to the others, e.g. by filling out a line on the NOAC anticoagulation card (see **chapter 2**). Nurse-coordinated AF centres may be helpful in coordinating patient follow-up and checking on adherence.^{46–50}
- (4) Some countries have a highly networked pharmacy database, which can help track the number of NOAC prescriptions that individual patients claim. In such countries, pharmacists could be involved in adherence monitoring, and this information should be used to cross-check appropriate prescription and dosing. It has been shown that an increased follow-up and adherence monitoring by pharmacists may improve NOAC adherence.¹¹³
- (5) Many technological aids are being explored to enhance adherence: the day-marked blister pack format; medication boxes (conventional or with electronic verification of intake); smartphone applications¹¹⁴ with reminders and/or SMS messages to alert the patient about the next intake some even requiring confirmation that the dose has been taken. Popular apps for both Android and iOS devices are Medisafe Pill Reminder (also available for watchOS), Dosecast, MyMeds, CareZone, and many others.¹¹⁵ Again, the long-term effects of such tools are unknown and one tool may not suit all patients.
- (6) Once daily dosing regimens generally results in greater adherence vs. BID regimens in cardiovascular patients.^{116–118} Most, but not all studies evaluating adherence for NOACs indicate that an OD dosing regimen is superior from a total tablet count perspective.^{66,67,70–74,95,112,119,120} However, it is still uncertain whether any regimen is superior in guaranteeing the clinical thromboembolic preventive effects and safety profile as seen in the clinical trials.^{73,83–86,90–95,121,122} Although there are modelling data suggesting that there is potentially a larger fluctuation in the anticoagulant activity when a single dose is omitted from an OD dosing regimen compared with when a single or even two doses are omitted from a BID regimen,¹²³ the clinical relevance of these fluctuations is unknown.¹²⁴ Therefore, it is essential to ensure that drugs are taken according to the prescribed regimen.
- (7) In cases where suboptimal adherence is suspected, electronic monitoring may help to educate the patient by exposing patterns of missed doses. Electronic medication intake monitoring can even be set up as a telemonitoring service, with the possibility of faster feedback to the patient.⁵¹ The health-economic validity of such an approach needs further study.

- (8) Some patients may explicitly prefer INR monitoring to no monitoring, or VKA over NOAC therapy. Patient education needs to discuss these preferences in the context of available clinical trial data (including reduction in ICH with NOACs even in the setting of high TTR).^{19,42}
- (9) In NOAC patients in whom low adherence is suspected despite proper education and additional tools, conversion to VKAs may be considered. It needs to be kept in mind, however, that poor adherence in VKA treated patients is equally associated with INR fluctuations and less preferable outcomes.

4. Switching between anticoagulant regimens

When switching between different anticoagulant therapies, it is important to ensure the continuation of anticoagulant therapy while minimizing the risk for bleeding. This requires insights into the pharmacokinetics and -dynamics of different anticoagulation regimens, interpreted in the context of the individual patient.

Vitamin K antagonist to non-vitamin K antagonist oral anticoagulant


The NOAC can immediately be initiated once the INR is ≤ 2.0 . If the INR is 2.0–2.5, NOACs can be started immediately or (better) the next day. For INR > 2.5 , the actual INR value and the half-life of the VKA need to be taken into account to estimate the time when the INR value will likely drop to below this threshold value [half-lives for acenocoumarol 8–24 h, warfarin 36–48 h, phenprocoumon 120–200 h (6 days)]. The proposed scheme (also shown in *Figure 2*, top panel) tries to unify different specifications from the SmPCs, which state that NOAC can be started when INR is ≤ 3 for rivaroxaban, ≤ 2.5 for edoxaban, and ≤ 2 for apixaban and dabigatran.

Non-vitamin K antagonist oral anticoagulant (NOAC) and Vitamin K antagonist (VKA)

Because of the slow onset of action of VKAs, it may take 5–10 days before the INR is in the therapeutic range, with large individual variations (see also **chapter 20**). Therefore, the NOAC and VKA should be administered concomitantly until the INR is in a range that is considered appropriate (*Figure 2*, lower panel)—similar to the situation when low molecular weight heparins (LMWHs) are administered during VKA initiation. A loading dose is not recommended for acenocoumarol and warfarin, but is appropriate with phenprocoumon (see **chapter 20**).

As NOACs may have an impact on INR measurements, it is important that the INR (i) is measured just before the next intake of the NOAC during concomitant administration and (ii) is re-measured early after stopping the NOAC (i.e. reflecting solely VKA therapy) to assure adequate anticoagulation. It is also recommended to closely monitor INRs within the first month until stable values have been attained (i.e. three consecutive measurements yielded values between 2.0 and 3.0). At the end of the ENGAGE-AF trial, patients on edoxaban transitioning to VKA received up to 14 days of a half dose of the NOAC until the INR was within range, in combination with the above intensive INR testing strategy.¹²⁵ Switching according to this scheme

From VKA to NOAC



From NOAC to VKA




Figure 2 Switching between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants and vice versa. TE, thromboembolic.

has proven to minimize the risks of stroke and bleeding¹²⁵ while, conversely, inadequate transitioning was associated with increased stroke rates.^{126,127} Whether the half-dose bridging regimen also applies to transitioning of NOACs other than edoxaban is unknown.

When concomitant administration of a NOAC during the initiation of the VKA is not deemed appropriate, initiation of the VKA can be performed after switching the NOAC to LMWH (see below), which may be considered especially in patients with a high thromboembolic risk.

Non-vitamin K antagonist oral anticoagulant to parenteral anticoagulants

The parenteral anticoagulant [unfractionated heparin (UFH) and LMWH] can be initiated when the next dose of the NOAC would be due.

Parenteral anticoagulant to non-vitamin K antagonist oral anticoagulant

Intravenous UFH: NOACs can usually be started 2 (to 4) h after intravenous UFH (half-life 2 h) is discontinued.

Low molecular weight heparin: NOACs can be initiated when the next dose of LMWH would be due. Care should be taken in patients with renal impairment where the elimination of LMWH may be prolonged.

Non-vitamin K antagonist oral anticoagulant to non-vitamin K antagonist oral anticoagulant

The alternative NOAC can be initiated when the next dose of the initial NOAC is due, except in situations where higher than therapeutic plasma concentrations are expected (e.g. in a patient with impaired renal function). In such situations, a longer interval in between NOACs is recommended.

Aspirin or clopidogrel to non-vitamin K antagonist oral anticoagulant

The NOAC can be started immediately and aspirin or clopidogrel stopped, unless combination therapy is deemed necessary (see chapter 14).

5. Pharmacokinetics and drug-drug interactions of non-vitamin K antagonist oral anticoagulants

Treatment with VKAs requires careful consideration of multiple food and drug-drug interactions. Despite fewer interactions with the

NOAC drugs, physicians should consider the pharmacokinetic interactions of accompanying drugs and comorbidities when prescribing NOACs. This section aims to provide a simple guide to deal with such situations. However, every patient may require more specific consideration, especially when a combination of interfering factors is present. Knowledge regarding interactions (with effect on plasma levels and/or on clinical effects of NOAC drugs) is expanding, so that new information may modify existing recommendations.

The absorption, distribution, metabolism, and excretion of the different NOACs are summarized in the previous version of the guide.² An important interaction mechanism for all NOACs consists of significant gastrointestinal re-secretion over a P-glycoprotein (P-gp) transporter after absorption in the gut. Competitive inhibition of this pathway will result in *increased* plasma levels. The P-gp transporter is also involved in renal clearance.¹²⁸ Many drugs used in AF patients are P-gp inhibitors (e.g. verapamil, dronedarone, amiodarone, and quinidine). CYP3A4-type cytochrome P450-dependent elimination is relevantly involved in the hepatic clearance of rivaroxaban and apixaban.¹²⁹ Strong CYP3A4 inhibition or induction may affect plasma concentrations, and should be evaluated in context (see [Tables 3–5](#) and colour coding, discussed below). Non-metabolic clearance of apixaban is diverse (including excretion of the unchanged compound by >50%), which reduces the potential for drug–drug interaction.¹³⁰ In general, NOAC use is not recommended in combination with drugs that are strong inhibitors of both CYP3A4 and P-gp. Conversely, strong inducers of P-gp and/or CYP3A4 (such as rifampicin, carbamazepine, etc.) will markedly *reduce* NOAC plasma levels; such combinations should be avoided or used with great caution and surveillance.

Specific dosing algorithms for the different NOACs have been evaluated in large Phase III clinical trials and resulted in documented efficacy and safety of the respective agent. Of note, only one Phase III study prospectively used concomitant therapy with certain drugs as a dose reduction criterion (dose reduction of edoxaban in ENGAGE-AF in patients treated with potent P-gp inhibitors verapamil, quinidine, or dronedarone). Dose reduction of all NOACs is primarily recommended along the published dose reduction criteria (see [chapter 15](#)). Whenever possible, the tested standard doses of NOACs should be used.

However, there is some rationale for reducing the dose of NOACs in patients with a high bleeding risk and/or when a higher plasma level of the drug can be anticipated based on a combination of factors.^{3,151–154} Prospective clinical trial data only exist for ‘lower doses’ of dabigatran (110 mg BID) and edoxaban (30/15 mg OD; but not approved). For dabigatran 110 mg BID, a similar stroke risk and reduced major bleeding vs. warfarin was observed²⁸; however, this was in an unselected AF population and not in selected high-risk patients in whom plasma levels may be increased and the benefit of a reduction in major bleeding may be lost.^{152,155} For edoxaban 30/15 mg OD a 41% higher ischaemic stroke risk compared with a well-controlled warfarin arm (median TTR >68%) was observed leading to non-approval of this dosing regimen; at the same time, a reduction in major bleeding, cardiovascular- and all-cause mortality was observed compared with warfarin.^{31,153} These data represent the only available RCT evidence of a ‘lower dose’ of a NOAC for stroke prevention in AF on hard clinical endpoints.^{28,31} In contrast, no ‘lower dose’ arm was included in ROCKET-AF (for rivaroxaban) or

ARISTOTLE (for apixaban) and as such, no clinical outcome data are available for the use of these doses outside the tested dose reduction algorithms. (Of note, a small study in Japanese patients investigated the use of 15 mg rivaroxaban as standard dose for stroke prevention in Japanese patients with apparently preserved efficacy, but the implications of these results outside this setting are unclear.)¹⁵⁶

The use of plasma level monitoring for NOAC dose-adjustment or in the setting of ‘off label’ lower dose prescription (see [chapters 7 and 8](#)) is discouraged for the vast majority of patients due to the lack of outcome data to support such an approach. Indeed, an increased risk of bleeding frequently goes along with an increased risk of stroke due to the overlapping risk factors (including advanced age, frailty etc.), and inappropriate use of a reduced dose may result in lack of stroke prevention.¹⁵⁷ However, in rare cases of potentially substantial drug–drug interactions or special situations in which a certain NOAC is preferred for certain reasons (e.g. patients after transplantation, patients on HIV medication etc.) this may be considered ([Figure 3](#)). Importantly, this approach should be limited to centres with extensive experience in the performance and interpretation of such assays as well as in the care of NOAC-treated patients.

In summary, possible drug–drug interactions, especially when combined with other clinical risk factors affecting NOAC plasma levels are important aspects for choosing a specific NOAC for a specific patient. [Table 3](#) gives an overview of the effect of various frequently used agents on NOAC plasma levels; [Table 4](#) focusses on common cancer drugs (see also [chapter 19](#)), [Table 5](#) on antiepileptic drugs (see also [chapter 18.4](#)). Taking into consideration these factors as well as the setup and results from the large randomized NOAC outcome trials the algorithm shown in [Figure 3](#) may assist in a rational selection of a specific NOAC and/or a ‘reduced dose’ based on drug–drug interactions and other clinical risk factors. Unfortunately, for many potential interactions with drugs that are often used in AF patients no detailed information is available yet (hatched in the tables).

Food intake, antacids, and nasogastric tube administration

Rivaroxaban 15 mg/20 mg for stroke prevention in AF needs to be taken with food [the area under the curve (AUC) plasma concentrations increases by 39% to a very high bioavailability of almost 100%], while there is no food interaction with the other NOACs. The concomitant use of PPIs and H2-blockers leads to a small reduction in bioavailability of dabigatran, but without effect on clinical efficacy.^{158,159} There is also no relevant antacid interaction for the other NOACs.^{140,160,161} There are no pharmacokinetic data on fish oil supplements for any of the NOACs, but interaction is unlikely.

Data have shown that administration in crushed form, e.g. via a nasogastric tube, does not alter the bioavailability for apixaban, rivaroxaban, and edoxaban.^{162–164} Also an oral solution of apixaban 5 mg (12.5 mL of 0.4 mg/mL oral solution administered via oral syringe together with 240 mL of water) has been developed, which has shown comparable exposure as the tablet formulation.¹⁶⁵ In contrast, dabigatran capsules must not be opened as it results in a substantial increase in drug bioavailability (+75% per SmPC).

Table 3 Effect of drug–drug interactions and clinical factors on NOAC plasma levels ('area under the curve')

	Via	Dabigatran etexilate	Apixaban	Edoxaban	Rivaroxaban
P-gp substrate		Yes	Yes	Yes	Yes
CYP3A4 substrate		No	Yes (≈25%)	No (<4%)	Yes (≈18%) ¹³¹
Antiarrhythmic drugs					
Amiodarone	moderate P-gp competition	+12 to 60% ^{SmPC}	No PK data ^a	+40% ^{132–134}	Minor effect ^a
Digoxin	P-gp competition	No effect ^{SmPC}	No effect ¹³⁵	No effect	No effect ^{SmPC}
Diltiazem	P-gp competition and weak CYP3A4 inhibition	No effect ^{SmPC}	+40% ¹³⁶	No data yet	No effect
Dronedaron	P-gp competition and CYP3A4 inhibition	+70 to 100% (US: 2 × 75 mg if CrCl 30–50 mL/min)	No PK or PD data: caution	+85% ^b	Moderate effect, should be avoided
Quinidine	P-gp competition	+53% ^{SmPC}	No data yet	+77% ¹³⁷ (no dose reduction required by label)	Extent of increase unknown
Verapamil	P-gp competition (and weak CYP3A4 inhibition)	+12 to 180% ^{SmPC} (if taken simultaneously)	No PK data	+53% (SR) ^{137,142} (no dose reduction required by label)	No effect
Other cardiovascular drugs					
Atorvastatin	P-gp competition and CYP3A4 inhibition	No relevant interaction	No data yet	No effect	No effect
Ticagrelor	P-gp competition	+25% ^{SmPC} (give loading dose 2h after dabigatran) ^d	No data	No data	No data
Antibiotics					
Clarithromycin; Erythromycin	Moderate P-gp competition and strong CYP3A4 inhibition	+15 to 20%	+60% AUC +30% C _{max}	+90% ^{SmPC}	+34% (Erythromycin)/ +54% (Clarithromycin) ^{SmPC129}
Rifampicin	P-gp/BCRP and CYP3A4/ CYP2J2 inducers	Minus 66% ^{SmPC}	Minus 54% ¹³⁸	Minus 35%, but with compensatory increase of active metabolites	Up to minus 50% ^{SmPC}
Antiviral drugs					
HIV protease inhibitors (e.g. ritonavir)	P-gp and BCRP competition or inducer; CYP3A4 inhibition	No data yet	Strong increase ^{SmPC}	No data yet	Up to +153% ¹²⁹

Fungostatics					
Fluconazole	Moderate CYP3A4 inhibition	No data yet	No data yet	No data yet	+42% (if systemically administered) ^{SmPC}
Itraconazole; Ketoconazole; Voriconazole	potent P-gp and BCRP competition; CYP3A4 inhibition	+140 to 150% (US: 2 x 75 mg if CrCl 30–50 mL/min)	+100% ¹³⁶	+87 to 95% ¹³² (reduce NOAC dose by 50%)	Up to +160% ^{SmPC}
Posaconazole	Mild to moderate P-gp inhibition	SmPC	SmPC		SmPC
Others					
Naproxen	P-gp competition; pharmacodynamically increased bleeding time	No data yet	+55% ¹³⁹	No effect	No data yet
H2B; PPI; Al-mg-hydroxide	GI absorption	Minus 12–30%	No effect	No effect ^{SmPC}	No effect ¹⁴⁰
St. John's wort	P-gp/BCRP and CYP3A4/CYP2J2 inducers				
Other factors					
Age ≥80 years	Potential for Increased plasma levels		b	c	
Age ≥75 years	Potential for Increased plasma levels			c	
Weight ≤60 kg	Potential for Increased plasma levels		b	b	
Renal function	Increased plasma level	See Figure 4			
Other increased bleeding risk		<ul style="list-style-type: none"> Concomitant antiplatelet drugs; NSAID; systemic steroid therapy; other anticoagulants History of GI bleeding Recent surgery on critical organ (brain; eye) Frailty/falls risk St.p bleeding or predisposition (anaemia, thrombocytopenia) 			

The hatched colour coding indicates no clinical or PK data available, and recommendations are based on the respective NOAC SmPC (where available) or expert opinion.

White: No relevant drug–drug interaction anticipated.

Yellow: Consider dose adjustment or different NOAC if 2 or more 'yellow' factors are present (see Figure 3).

Orange: Consider dose adjustment or different NOAC (see Figure 3).

Red: contraindicated/not recommended.

Brown: Contraindicated due to reduced NOAC plasma levels.

Blue: The label for edoxaban mentions that co-administration is possible in these cases, despite a decreased plasma level, which are deemed not clinically relevant. Since not tested prospectively, however, such concomitant use should be used with caution, and avoided when possible.

BCRP, breast cancer resistance protein; NSAID, non-steroidal anti-inflammatory drugs; H2B, H2-blockers; PPI, proton pump inhibitors; P-gp, P-glycoprotein; GI, gastrointestinal.

^aBased on *in vitro* investigations, comparing the IC₅₀ for P-gp inhibition to maximal plasma levels at therapeutic dose, and/or on interaction analysis of efficacy and safety end-points in the Phase-3 clinical trials.^{29,30} No direct PK interaction data available.

^bDose reduction based on published criteria (see Table 13, Figure 3).

^cAge had no significant effect after adjusting for weight and renal function.

^dData from Phase I study. Evidence from Re-DUAL PCI indicate safety in the (small) subgroup on dabigatran and ticagrelor.¹⁴¹

Table 4 Anticipated effects of common anticancer drugs on non-vitamin K antagonist oral anticoagulants plasma levels

	Via ¹⁴²	Dabigatran etexilate	Apixaban	Edoxaban	Rivaroxaban
P-gp substrate		Yes	Yes	Yes	Yes
CYP3A4 substrate		No	Yes (≈25%)	No (<4%)	Yes (≈18%)
Antimitotic agents					
Paclitaxel	Moderate CYP3A4 induction; CYP3A4/P-gp competition				
Vinblastine	Strong P-gp induction; CYP3A4/P-gp competition				
Docetaxel, Vincristine	Mild CYP3A4 induction; CYP3A4/P-gp competition				
Vinorelbine	Mild CYP3A4 induction; CYP3A4/P-gp competition				
Antimetabolites					
Metotrexate	P-gp competition; no relevant interaction anticipated				
Pemetrexed, Purine analogs, Pyrimidine analogs	No relevant interaction anticipated				
Topoisomerase inhibitors					
Topotecan	No relevant interaction anticipated				
Irinotecan	CYP3A4/P-gp competition; No relevant interaction anticipated				
Etoposide	Mild CYP3A4 inhibition; CYP3A4/P-gp competition				
Anthracyclines/Anthracenediones					
Doxorubicin	Strong P-gp induction, mild CYP3A4 inhibition; CYP3A4/P-gp competition				
Idarubicin	Mild CYP3A4 inhibition; P-gp competition				

Daunorubicin	P-gp competition; No relevant interaction anticipated				
Mitoxantrone	No relevant interaction anticipated				
Alkylating agents					
Ifosfamide	Mild CYP3A4 inhibition; CYP3A4 competition				
Ciclophosphamide	Mild CYP3A4 inhibition; CYP3A4 competition				
Lomustine	Mild CYP3A4 inhibition				
Busulfan	CYP3A4 competition; No relevant interaction anticipated				
Bendamustine	P-gp competition; No relevant interaction anticipated				
Chlorambucil, Melphalan, Carmustine, Procarbazine, Dacarbazine, Temozolomide	No relevant interaction anticipated				
Platinum-based agents					
Cisplatin, Carboplatin, Oxaliplatin	No relevant interaction anticipated				
Intercalating agents					
Bleomycin, Dactinomycin	No relevant interaction anticipated				
Mitomycin C	No relevant interaction anticipated				
Tyrosine kinase inhibitors					
Imatinib, Crizotinib	Strong P-gp inhibition, moderate CYP3A4 inhibition; CYP3A4/P-gp competition				
Nilotinib, Lapatinib	Moderate-to-strong P-gp inhibition, mild CYP3A4 inhibition; CYP3A4/P-gp competition				
Vemurafenib	Moderate CYP3A4 induction; CYP3A4/P-gp competition				

Dasatinib	Mild CYP3A4 inhibition; CYP3A4/P-gp competition				
Vandetanib, Sunitinib	Strong P-gp induction; CYP3A4 competition				
Erlotinib, Gefitinib	CYP3A4 competition; No relevant interaction anticipated				
Monoclonal antibodies					
Brentuximab	CYP3A4 competition; No relevant interaction anticipated				
Rituximab, Alemtuzumab, Cetuximab, Trastuzumab, Bevacizumab	No relevant interaction assumed				
Hormonal agents					
Abiraterone	Moderate CYP3A4 inhibition, strong P-gp inhibition; CYP3A4/P-gp competition				
Enzalutamide	Strong CYP3A4 induction, strong P-gp inhibition; CYP3A4/P-gp competition				
Bicalutamide	Moderate CYP3A4 inhibition				
Tamoxifen	Strong P-gp inhibition, mild CYP3A4 inhibition; CYP3A4 competition				
Anastrozole	Mild CYP3A4 inhibition				
Flutamide	CYP3A4 competition; No relevant interaction anticipated				
Letrozole, Fulvestrant	CYP3A4 competition; No relevant interaction anticipated				
Raloxifene, Leuprolide, Mitotane	No relevant interaction anticipated				
Immune-modulating agents					
Cyclosporine	Strong-to-moderate P-gp inhibition, moderate CYP3A4 inhibition; CYP3A4/P-gp competition	SmPC	SmPC	+73% ¹⁴³	

Dexamethasone	Strong CYP3A4/P-gp induction; CYP3A4/P-gp competition				
Tacrolimus	Strong-to-moderate P-gp inhibition, mild CYP3A4 inhibition; CYP3A4/P-gp competition	SmPC			
Prednisone	Moderate CYP3A4 induction; CYP3A4 competition				
Temsirolimus, Sirolimus	Mild CYP3A4 inhibition; CYP3A4/P-gp competition				
Everolimus	CYP3A4 competition; No relevant interaction anticipated				

Purine analogs: Mercaptopurine, Thioguanine, Pentostatin, Cladribine, Clofarabine, Fludarabine.

Pyrimidine analogs: Fluorouracil, Capecitabine, Cytarabine, Gemcitabine, Azacitidine, Decitabine.

Anticipated effects of common anticancer drugs on NOACs plasma levels.¹⁴⁴

The hatched colour coding indicates no clinical or PK data available, and recommendations are based on the respective NOAC SmPC (where available) or expert opinion.

Some of the colour codes will likely require adaptation as more data become available over time.

White: No relevant drug–drug interaction anticipated.

Yellow (light): Caution is needed in case of polypharmacy or in the presence of ≥ 2 bleeding risk factors.

Yellow: Consider dose adjustment or different NOAC if 2 or more ‘yellow’ factors are present (see Figure 3).

Orange: Consider dose adjustment or different NOAC (see Figure 3).

Red: contraindicated/not recommended.

Brown (dark): Contraindicated due to reduced NOAC plasma levels.

Brown (light): Use with caution or avoid. Either expert opinion or the NOAC label mentions that co-administration is possible despite a decreased plasma level, which is deemed not clinically relevant (nevertheless, since not tested prospectively, such concomitant use should be used with caution, and avoided when possible).

Where no data or SmPC instructions were available, expert opinion was based on the following principles:

- Strong CYP3A4 and/or P-gp inducer—should not be used (dark brown).
- Moderate CYP3A4 or P-gp inducer—use with caution or avoid (light brown).
- Strong CYP3A4 and/or inhibitor—should not be used (red).
- Moderate CYP3A4 or P-gp inhibitor—use with caution, consider dose reduction or different NOAC (orange).
- Mild CYP3A4 and/or P-gp inducers or inhibitors—caution is needed with polypharmacy or in the presence of ≥ 2 bleeding risk factors (yellow).

Rate and rhythm control drugs

Possible interactions are listed in Table 3. The P-gp inhibiting effects of verapamil on dabigatran levels are dependent on the verapamil formulation: when an immediate release preparation is taken within 1 h prior to dabigatran intake, plasma levels of dabigatran may increase up to 180%. Separating both drugs’ intake ≥ 2 h removes the interaction (but is hard to guarantee in clinical practice). With a slow-release verapamil preparation, there may be a 60% increase in dabigatran concentration. Pharmacokinetic data from the RE-LY trial showed an average 23% increase in dabigatran levels in patients taking verapamil.¹⁶⁶ It is advised to use the lower dose dabigatran (110 mg BID) when combining it with verapamil (‘orange’, Table 3).

A similar interaction had initially been noted for edoxaban.¹⁶⁷ However, after analysis of Phase III data, this interaction was considered not to be clinically relevant and no dose reduction is recommended in the European label. However, caution might be warranted in combination with other factors (‘yellow’, Table 3). On a more general level, these findings underline the difference between changes in plasma levels and influence on hard clinical endpoints. There are no specific

interaction pharmacokinetic data available for apixaban or rivaroxaban with verapamil. Diltiazem has a lower inhibitory potency of P-gp, resulting in non-relevant interactions,¹⁶⁶ although there is a 40% increase in plasma concentrations of apixaban (‘yellow’, Table 3).¹³⁶

For edoxaban a 40% increase in AUC was observed in patients on amiodarone with normal renal function.¹³² Of note, there was a significant interaction for amiodarone on the efficacy of the low-dose edoxaban regimen in the Phase III trial, exemplifying the potential impact of changed plasma levels.¹³³ Nevertheless, dose reduction is not recommended in case of concomitant administration.

There is a strong effect of dronedarone on dabigatran plasma levels, which constitutes a contraindication for concomitant use. The interaction potential is considered moderate for edoxaban (‘orange’), and dronedarone intake was a dose reduction criterion in the ENGAGE-AF protocol.³¹ There are no interaction pharmacokinetic data available for rivaroxaban and apixaban but effects on their plasma levels can be anticipated based on P-gp and CYP3A4 interactions, calling for caution (i.e. ‘yellow’) or avoidance (for rivaroxaban). Interestingly, a recent analysis of NOAC plasma levels before surgical

Table 5 Anticipated effects of common antiepileptic drugs on non-vitamin K antagonist oral anticoagulants plasma levels

	Via ^{142,145,146}	Dabigatran etexilate	Apixaban ¹³⁰	Edoxaban	Rivaroxaban
P-gp substrate		Yes	Yes	Yes	Yes
CYP3A4 substrate		No	Yes (≈25%)	No (<4%)	Yes (≈18%)
Drug					
Carbamazepine	Strong CYP3A4/P-gp induction; CYP3A4 competition	SmPC	−50% SmPC	−35% SmPC	SmPC, Ref. ¹⁴⁷
Ethosuximide	CYP3A4 competition; No relevant interaction known/assumed				
Gabapentin	No relevant interaction known/assumed				
Lamotrigine	P-gp competition; No relevant interaction known/assumed				
Levetiracetam	P-gp induction; P-gp competition				
Oxcarbazepine	CYP3A4 induction; P-gp competition				
Phenobarbital	Strong CYP3A4/P-gp induction; P-gp competition		SmPC	SmPC	SmPC
Phenytoin	Strong CYP3A4/P-gp induction; P-gp competition	SmPC, Ref. ¹⁴⁸	SmPC	SmPC	SmPC
Pregabalin	No relevant interaction known/assumed				
Topiramate	CYP3A4 induction; CYP3A4 competition				
Valproic acid	CYP3A4/P-gp induction				Ref. ¹⁴⁹
Zonisamide	CYP3A4 competition; No relevant interaction known/assumed				

Anticipated effects of common antiepileptic drugs on NOACs plasma levels.^{147,150}

The hatched colour coding indicates no clinical or PK data available, and recommendations are based on the respective NOAC SmPC, where available, or expert opinion. Some of the colour codes will likely require adaptation as more data become available over time.

White: No relevant drug–drug interaction anticipated.

Brown (dark): Contraindicated due to reduced NOAC plasma levels.

Brown (light): Use with caution or avoid—either the label for the respective NOAC mentions that co-administration is possible despite a decreased plasma level, which are deemed not clinically relevant (nevertheless, since not tested prospectively, such concomitant use should be used with caution, and avoided when possible) or expert opinion.

Where no data or SmPC instructions were available, expert opinion was based on the following principles:

- Strong CYP3A4 and/or P-gp inducer—should not be used (dark brown).
- Moderate CYP3A4 or P-gp inducer—use with caution or avoid (light brown).
- Strong CYP3A4 and/or inhibitor—should not be used (red).
- Moderate CYP3A4 or P-gp inhibitor—use with caution, consider dose reduction or different NOAC (orange).
- Mild CYP3A4 and/or P-gp inducers or inhibitors—caution is needed with polypharmacy or in the presence of ≥2 bleeding risk factors (yellow).

intervention demonstrated that concomitant intake of verapamil, dronedarone, or amiodarone was significantly associated with higher pre-operative plasma levels.¹⁶⁸

Other drugs

Table 3 also lists the potential interaction mechanisms for other drugs and their possible clinical relevance. Since some drugs are inhibitors of both CYP3A4 and P-gp, they may have an effect on NOAC plasma levels although the P-gp and/or CYP3A4 effect in itself is less pronounced. In general, although NOACs are substrates of CYP

enzymes or P-gp/breast cancer resistance protein (BCRP), they do not inhibit or induce any of them.

Co-administration of NOACs with other substrates of CYP3A4 (e.g. midazolam), P-gp (e.g. digoxin), or both (e.g. atorvastatin) does not significantly alter plasma levels of these drugs.

The platelet inhibitor ticagrelor is a P-gp inhibitor. Concomitant administration of ticagrelor 180 mg loading dose with dabigatran 110 mg increased dabigatran C_{max} by 65% (AUC +49%), compared with dabigatran given alone. When a loading dose of 180 mg ticagrelor was given 2 h after 110 mg dabigatran etexilate, the increase of




Figure 3 NOAC selection based on drug–drug interactions and/or risk of bleeding. Use of plasma level measurements to guide dosing is generally discouraged and should only be used in rare cases of potentially substantial interactions or special situations, and only in centres with great experience in the performance and interpretation of such assays as well as the care of NOAC-treated patients.

dabigatran C_{\max} and AUC was reduced to +23% and +27%, respectively, compared with dabigatran given alone. As per the dabigatran SmPC, this staggered intake is the recommended administration strategy for starting with the loading dose of ticagrelor. Concomitant administration of 90 mg ticagrelor BID (maintenance dose) with 110 mg dabigatran increased the adjusted dabigatran AUC and C_{\max} by 26% and 29%, respectively, compared with dabigatran given alone. These data are based on a Phase I study; the use of ticagrelor and dabigatran post-percutaneous coronary intervention (PCI) as studied in the RE-DUAL PCI study is discussed in detail later (see **chapter 14**).¹⁴¹

Of note, ‘herbal’ medicines are frequently underestimated regarding their potential for interaction, including the potent CYP3A4 and P-gp inducer St. John’s wort, although relevant interactions have been published (also outside the anticoagulation field).¹⁶⁹ Due to the relevant decrease in NOAC levels, the concomitant use of St. John’s wort is not recommended.

Pharmacodynamic interactions

Apart from the pharmacokinetic interactions, co-administration of NOACs with other anticoagulants, platelet inhibitors (e.g. aspirin, clopidogrel, ticlopidine, prasugrel, ticagrelor, others), and non-steroidal anti-inflammatory drugs increases the risk of bleeding.^{170–172} Therefore, such combinations should be carefully balanced against the potential benefit in each clinical situation. Co-administration of NOACs with dual antiplatelet drugs requires active measures to reduce time on triple therapy (see **chapter 14**).

Polypharmacy

Polypharmacy is a well-established risk factor for adverse events resulting from drug–drug interactions.^{173–175} In ROCKET-AF and ARISTOTLE, patients concomitantly taking several (≥ 5 or ≥ 9) medications experienced similar outcomes and consistent treatment effects of either NOAC relative to warfarin.^{174,175} Although reassuring, these findings are derived from *post hoc* analyses with many limitations. In addition, concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) or inducers (e.g. phenytoin, rifampicin) was not allowed. Conversely, event rates with warfarin also increase in patients with polypharmacy, likely not only due to interactions but also due to the higher baseline risk of these patients. While polypharmacy in itself is not a contraindication for the use of NOACs, special care needs to be taken when treating these vulnerable patients (Tables 3–5; Figure 3).

6. Non-vitamin K antagonist oral anticoagulants in patients with chronic kidney disease or advanced liver disease

Kidney and liver function both play an important role in the metabolism and elimination of NOACs.

Oral anticoagulation in chronic kidney disease

There is a bidirectional interaction between AF and chronic kidney disease (CKD): AF facilitates the development or progression of CKD, and the prevalence and incidence of AF increases with decreasing renal function.^{176–179} Patients with AF and CKD have an increased morbidity and mortality due to their excessive risk for both thromboembolic and severe bleeding events, making risk stratification and treatment challenging.^{180,181} In addition, all four NOACs are at least partly eliminated by the kidneys. Dabigatran has the greatest extent of renal elimination (80%), whereas 50%, 35%, and 27% of edoxaban, rivaroxaban, and apixaban, respectively, are cleared via the kidneys as unchanged drug (Table 6).

Clinical decisions on how to treat an AF patient with CKD who needs OAC requires the assessment of renal function. Basic information on the diagnosis/staging of CKD and assessment of renal function is provided in Table 7. Several equations are available to gauge a patient's renal function, all with inherent strengths and limitations. The CKD-EPI equation estimating the glomerular filtration rate is recommended by the *National Kidney Foundation* because it has been shown to be reliable across the range of CKD stages.¹⁸⁷ However, in the context of NOAC treatment, renal function should preferably be estimated by calculating the CrCl using the Cockcroft–Gault method, which was used in most NOAC trials and therefore also in this *Practical Guide*. Importantly, CKD can only be diagnosed and assessed in stable situations and must not be confused with acute renal failure. In the latter case, serum creatinine levels and calculated CrCl may indicate mildly reduced (or even normal) renal function when in reality it is severely impaired. In situations with acute renal failure, any NOAC therapy needs to be discontinued and parenteral anticoagulation initiated (after careful risk-benefit analysis).

In patients on NOACs, renal function needs to be monitored diligently, at least yearly, to detect changes in renal function and adapt the dose accordingly. If renal function is impaired (i.e. CrCl ≤ 60 mL/min), a more frequent evaluation is recommended (e.g. by dividing CrCl by 10 to obtain the minimum frequency of renal function testing in months; Table 2). In patients with additional risk factors (e.g. older age, frail, multiple co-morbidities etc.), it may be evaluated even more frequently, especially if on dabigatran. Intercurrent acute illness (like infections, acute heart failure, etc.) may transiently affect renal function and should also trigger re-evaluation; importantly, patients need to be alerted that in such situations they should seek contact with their healthcare provider. This guidance is also presented in the updated NOAC Card.

On the other side of the spectrum, a possibly decreased efficacy of edoxaban 60 mg OD compared with warfarin was observed in patients with a CrCl of >95 mL/min.³¹ Interestingly, as a result of these findings, further *post hoc* analyses revealed a similar effect also for Rivaroxaban¹⁸⁸ and Apixaban.¹⁸⁹ In 2015 the FDA issued a warning about the use of edoxaban in individuals with such a high-normal CrCl, and recommended the use of other oral anticoagulants in these patients. Also the EMA advised that 'edoxaban should only be used in patients with high CrCl after a careful evaluation of the individual thromboembolic and bleeding risk'. A *post hoc* analysis of the ENGAGE AF data showed that despite the trend towards a decrease in relative efficacy of edoxaban 60 mg

OD in the upper range of CrCl in an exploratory (not pre-defined) subgroup analysis, the safety and net clinical benefit of edoxaban compared with warfarin were consistent across the spectrum of renal function.¹⁹⁰

Oral anticoagulant therapy in patients with mild or moderate CKD (CrCl ≥ 30 mL/min)

The benefit of VKAs in terms of reduced stroke and mortality is well established in AF patients with *mild to moderate* CKD.^{191–194} Compared with warfarin, all four NOACs showed consistent efficacy and safety in patients with *mild to moderate* CKD compared with non-CKD patients in the respective Subgroup analyses of pivotal NOAC trials.^{190,195–199} In addition, the ARISTOTLE trial data analysis suggests that the bleeding benefit with apixaban compared with warfarin becomes significantly more prominent at lower CrCl values, while the stroke reduction benefit is maintained.^{181,197} In contrast, the bleeding benefit of 110 mg dabigatran over warfarin is lost in patients with CrCl <50 mL/min while maintaining a similar stroke risk reduction compared with VKA.¹⁹⁵

A *post hoc* analysis of the RE-LY trial data showed a significantly faster rate of decline in renal function during the trial in patients on warfarin (especially at lower TTRs) compared with those on dabigatran²⁰⁰ suggesting that it may delay the decline in renal function compared with warfarin. Moreover, it has been suggested that warfarin use may be associated with increased vascular calcification and/or the development of acute warfarin-related nephropathy with or without clinically overt haematuria.²⁰¹

Appropriate dosing is an essential issue to be addressed when using NOACs in patients with CKD (Figure 4). While rivaroxaban, apixaban, and edoxaban doses were reduced according to renal function in their respective randomized clinical trials (RCTs), patients in the RE-LY trial were randomized to dabigatran 150 mg BID or 110 mg BID without dose reduction for renal insufficiency. Per SmPc, a recommendation for the use of dabigatran 110 mg BID is made in patients with CrCl <50 mL/min at high risk of bleeding. With the availability of three FXa inhibitors with less pronounced renal clearance, the use of the latter may be preferred in this patient population. The use of NOAC doses inconsistent with drug labelling has been associated with worse outcome; for example, underdosing of apixaban in patients with normal or only mildly reduced renal function has been associated with less effectiveness (i.e. higher stroke rates) and no additional safety benefit in a large 'real-world' AF cohort.²⁰²

Oral anticoagulant therapy in patients with a CrCl of 15–29 mL/min

There are no RCT data on the use of NOACs for stroke prevention in AF patients with severe CKD or on renal replacement therapy (RRT) since all landmark NOACs trials essentially excluded patients with a CrCl of <30 mL/min (except for a few patients on apixaban with CrCl 25–30 mL/min). However, VKA have also never been prospectively assessed in a RCT in this patient population.

Rivaroxaban, apixaban, and edoxaban (but not dabigatran) are approved in Europe for the use in patients with severe CKD (Stage 4, i.e. a CrCl of 15–29 mL/min), with the reduced dose regimen (see chapter 15 and Figure 4). In view of the individual NOACs' pharmacokinetics, dose-reduction criteria and available evidence from RCTs,

Table 6 Absorption and metabolism of the different NOACs

	Dabigatran ^{158,182}	Apixaban ¹⁸³	Edoxaban ¹⁸⁴	Rivaroxaban ^{185,186}
Bioavailability	3–7%	50%	62%	15 mg/20 mg: 66% without food, 80–100% with food
Prodrug	Yes	No	No	No
Clearance non-renal/renal of absorbed dose	20%/80%	73%/27%	50%/50%	65%/35%
Plasma protein binding	35%	87%	55%	95%
Dialysability	50–60% (in part dialysable)	14% (in part dialysable)	n.a. (in part dialysable)	n.a. (in part dialysable)
Liver metabolism: CYP3A4 involved	No	Yes [elimination, moderate contribution ($\approx 25\%$) ^a]	Minimal (<4% of elimination)	Yes (hepatic elimination $\approx 18\%$) ¹³¹
Absorption with food	No effect	No effect	6–22% more; minimal effect on exposure	+39% more (see above)
Absorption with H2B/PPI	-12% to 30% (not clinically relevant)	No effect	No effect	No effect
Asian ethnicity	+25% ¹⁶⁶	No effect	No effect	No effect
Elimination half-life	12–17 h	12 h	10–14 h	5–9 h (young)
				11–13 h (elderly)
Other	Dyspepsia (5–10%)			Intake of 15 mg/20 mg with food mandatory

^aHepatic metabolism in total of $\approx 25\%$, mostly via CYP3A4, with minor contributions of CYP1A2, 2J2, 2C8, 2C9, and 2C19.

the use of either apixaban or edoxaban may be preferable in these patients. Apixaban is least renally cleared (27%), and the dose is reduced by 50% in rather stringent conditions according to its dose reduction algorithm; furthermore the relative safety of apixaban vs. warfarin has been demonstrated to increase with decreasing renal function.¹⁹⁷ Edoxaban is 50% renally cleared, but its dose reduction to 50% is applied more rapidly and was tested in a large subgroup. Rivaroxaban has an intermediate renal clearance (33%), and its dose is reduced less (by 25%) under similar conditions as edoxaban. In the US (but not in Europe), a low dose dabigatran 75 mg BID regimen has been approved for patients with severe CKD (a CrCl of 15–29 mL/min), based on pharmacokinetic simulations. Further randomized trial data are urgently required for these difficult to treat patients.

Oral anticoagulant therapy in patients with a CrCl of ≤ 15 mL/min and on dialysis

Numerous observational studies yielded conflicting results for VKA regarding efficacy without a clear consistent benefit of VKA in patients with severe renal dysfunction.^{192–194,203} Most studies confirmed a significantly lower incidence of stroke and embolism under warfarin, but also a markedly increased bleeding risk.^{192–194} The only registry that

assessed the net benefit found no changes in overall-mortality for warfarin in dialysis-dependent patients.¹⁹³ Of note, the use of warfarin in patients with end-stage renal failure may in some cases result in calciphylaxis, a painful and often lethal condition caused by calcification and occlusion of cutaneous arteries and arterioles.^{204–208}

The efficacy and safety of NOACs in patients with end-stage renal dysfunction and on dialysis is unclear and subject to ongoing studies. Registry data have shown a higher incidence of hospitalization or death from bleeding in dialysis-dependent patients started on off-label dabigatran or rivaroxaban compared with VKA.²⁰⁹ In the US (but not in Europe) apixaban 5 mg BID is currently approved in chronic, stable dialysis-dependent patients. However, plasma levels with apixaban 5 mg BID were recently shown to be supra-therapeutic.²¹⁰ Levels similar to those in patients with normal renal function on the respective NOACs were found for apixaban 2.5 mg BID in a small number of patients on dialysis,²¹⁰ for edoxaban 15 mg OD (in Japanese patients with severe renal insufficiency)²¹¹ and rivaroxaban 10 mg OD in end-stage renal disease patients.²¹² It needs to be kept in mind, however, that plasma levels are a surrogate endpoint. In the absence of hard endpoint studies (which are currently ongoing, e.g. NCT02942407, NCT02933697), the routine use of NOACs in patient with severe

Table 7 Criteria for diagnosing chronic kidney disease; estimation of renal function and categories of renal dysfunction

Decreased GFR ^a	GFR <60 mL/min/1.73 m ²		
Markers of kidney damage (≥1)	<ul style="list-style-type: none">Excessive albuminuria (AER ≥30 mg/24 h; ACR ≥30 mg/g or ≥3 mg/mmol)Urine sediment abnormalitiesElectrolyte or other abnormality caused by tubular disordersAbnormal histologyStructural abnormalities detected by kidney imagingHistory of kidney transplantation		
GFR category	CKD stage	GFR ^a	Descriptions
G1	1	≥90	Normal or high
G2	2	60–89	Mildly decreased
G3a	3	45–59	Mildly to moderately decreased
G3b		30–44	Moderately to severely decreased
G4	4	15–29	Severely decreased
G5	5	<15	Kidney failure (requires renal replacement therapy – dialysis or kidney transplantation)

Estimation of renal function in NOAC patients best by Creatinine Clearance (Cockcroft–Gault):

$$\text{CrCl [mg/dl]} = \frac{(140 - \text{age}) \times \text{weight (in kg)} \times [0.85 \text{ if female}]}{72 \times \text{serum creatinine (in mg/dL)}}$$

Online calculators available at (e.g.): www.kidney.org/professionals/kdoqi/gfr_calculator; www.nephron.com/cgi-bin/CGSI.cgi; www.mdcalc.com/creatinine-clearance-cockcroft-gault-equation; <https://reference.medscape.com/calculator/creatinine-clearance-cockcroft-gault>. Popular Apps are NephroCalc, MedMath, MedCalc, Calculate by QxMD, and Archimedes. CKD, chronic kidney disease; GFR, glomerular filtration rate; AER, albumin excretion rate; ACR, albumin-to-creatinine ratio; CrCl, creatinine clearance. ^amL/min/1.73 m².

renal dysfunction (CrCl <15 mL/min) as well as in patients on dialysis is best avoided. In fact, given the lack of strong evidence also for VKA in this patient population, the decision to anticoagulate remains a very individualized one requiring a multidisciplinary approach considering and respecting patients’ preferences.^{180,208,213}

There are no data on the use of NOACs in AF patients after kidney transplantation. If NOACs are used in such patients, the dosing regimen should be selected according to the estimated renal function, and caution is needed with respect to possible drug–drug interactions between the NOAC and concomitant immunosuppressive therapies (see **chapter 5**).

Non-vitamin K antagonist oral anticoagulants in liver disease

Advanced liver disease is associated with increased bleeding risk, but is also a prothrombotic disorder.²¹⁴ In addition, significant liver disease can profoundly affect hepatic clearance and drug metabolism, and altered functionality of the liver enzymes and transporters may alter drug response and facilitate drug-induced liver injury.²¹⁵

The use of VKAs in patients with advanced liver disease and coagulopathy (*Table 8*) is challenging due to intrinsically elevated INR

values and difficulties in selecting appropriate VKA dosing.²¹⁶ Patients with significant active liver disease including cirrhosis, or those with persistent (as confirmed by repeated assessment ≥1 week apart) elevation of the liver enzymes or bilirubin [e.g. alanine transaminase or aspartate transaminase ≥2(–3) times the upper limit of normal (ULN) or total bilirubin ≥1.5 times the ULN] were excluded from the landmark NOAC trials in AF.^{28–31} Consequently, all four NOACs are contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including Child-Turcotte-Pugh C cirrhosis (*Table 8*). Rivaroxaban should also not be used in AF patients with Child B liver cirrhosis due to a >two-fold increase in drug exposure in these patients.²¹⁷ Dabigatran, apixaban and edoxaban may be used with caution in patients with Child B cirrhosis (*Table 8*).^{218,219} Initiation and follow-up at a specialised centre in a multidisciplinary team (including a hepatologist and a haematologist) is recommended.

Due to the withdrawal/non-approval of the direct thrombin inhibitor ximelagatran from the market in 2006 as a result of its hepatotoxic side effects,²²⁰ there had been some concern about the potential of NOACs to cause drug-induced liver injury. However, no signal for increased hepatotoxicity has been observed in any of the NOAC trials.²²¹ In fact, the risk of liver injury may even be lower than with VKA.^{222–224}




Figure 4 Use of non-vitamin K antagonist oral anticoagulants according to renal function. * 2×110 mg in patients at high risk of bleeding (per SmPc). #Other dose reduction criteria may apply (weight ≤ 60 kg, concomitant potent P-Gp inhibitor therapy). \$ 2×2.5 mg only if at least two out of three fulfilled: age ≥ 80 years, body weight ≤ 60 kg, creatinine ≥ 1.5 mg/dL (133 $\mu\text{mol/L}$). Orange arrows indicate cautionary use (dabigatran in moderate renal insufficiency, FXa inhibitors in severe renal insufficiency, edoxaban in 'supranormal' renal function); see text for details.

Table 8 Calculation of the Child-Turcotte-Pugh score and use of NOACs in hepatic insufficiency

Parameters	1 point	2 points	3 points
Encephalopathy	No	Grade 1–2 (suppressed with medication)	Grade 3–4 (refractory/chronic)
Ascites	No	Mild (diuretic-responsive)	Moderate–severe (diuretic-refractory)
Bilirubin	<2 mg/dL	2–3 mg/dL	>3 mg/dL
	<34 μmol/L	34–50 μmol/L	>50 μmol/L
Albumin	>3.5 g/dL	2.8–3.5 g/dL	<2.8 g/dL
	>35 g/L	28–35 g/L	<28 g/dL
INR	<1.7	1.71–2.30	>2.30

Child–Pugh category	Dabigatran	Apixaban	Edoxaban	Rivaroxaban
A (5–6 points)	No dose reduction	No dose reduction	No dose reduction	No dose reduction
B (7–9 points)	Use with caution	Use cautiously	Use cautiously	Do not use
C (10–15 points)	Do not use	Do not use	Do not use	Do not use

7. How to measure the anticoagulant effect of non-vitamin K antagonist oral anticoagulants?

Routine coagulation tests [prothrombin time (PT) and activated partial thromboplastin time (aPTT)] generally do not provide an accurate assessment of NOAC anticoagulant effects. In contrast, the latter can be measured via specific coagulation assays developed for the quantification of NOAC plasma levels.^{225–227} Most routine coagulometers are capable of measuring NOAC plasma levels within ≤30 min. Institutions are recommended to consider 24/7 availability of these tests for emergency situations. In contrast, point-of-care tests are not yet available for patients on NOACs.²²⁸

Anti-FXa chromogenic assays are available to measure plasma concentrations of the FXa inhibitors using validated calibrators. Low and high plasma levels can be measured with acceptable inter-laboratory precision. The absence of anti-Xa activity with these assays excludes clinically relevant drug levels. Conversely, the diluted thrombin time (dTT) test as well as the ecarin chromogenic assay (ECA) display a direct linear relationship with dabigatran concentration and are suitable for the quantitative assessment of dabigatran concentrations.

The use of appropriate calibrators allows for the determination of plasma concentrations of all NOACs. Even though levels in clinical trials were measured using HPLC/MS, drug measurement and monitoring can be closely approximated using a calibrated dTT/ECA assay for dabigatran or chromogenic anti-FXa assay for FXa-inhibitors. It is recommended to primarily use plasma concentrations rather than anti-FXa activity or dTT to quantitatively assess the concentration of a NOAC. An overview of the expected peak and trough levels in patients on NOACs can be found in Table 9. When interpreting a

coagulation assay in a patient treated with a NOAC, it is important to know when the NOAC was administered relative to the time of blood sampling. The maximum effect of the NOAC on the clotting test will occur at its maximal plasma concentration, which is approximately (1-)2–3 h after intake for each of these drugs (Table 9).

Of note, NOACs affect routine coagulation test (PT and aPTT), and also more specialized assays (such as lupus anticoagulant assays and coagulation factors) can be altered.

Specific considerations

Dabigatran

For dabigatran, the aPTT may provide a qualitative assessment of dabigatran level and anticoagulant activity. The relationship between dabigatran and the aPTT is curvilinear.²²⁹ An aPTT in the normal range does not exclude dabigatran levels in the ‘on therapy’ range, but excludes drug levels above the ‘on therapy’ range when a sensitive assay is used.

Dabigatran has little effect on the PT and INR at clinically relevant plasma concentrations, which are therefore unsuitable for the assessment of the anticoagulant activity of dabigatran.²²⁸

The thrombin time (TT) is very sensitive to the presence of dabigatran and a normal TT excludes even very low levels of dabigatran. The TT is not suited for the quantitative assessment of dabigatran plasma concentrations in the range expected with clinical use. In contrast, dTT tests and the ECA allow for the measurement of dabigatran levels in the range that is clinically relevant.

Factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban)

The different factor Xa-inhibitors affect the PT and the aPTT to a varying extent. The aPTT cannot be used for any meaningful

Table 9 Plasma levels and coagulation assays in patients treated with non-vitamin K antagonist oral anticoagulants

	Dabigatran ^{229,230}	Apixaban ²³¹ , SmPc	Edoxaban ^{184,232}	Rivaroxaban ^{131,186}
Expected plasma levels of NOACs in patients treated for AF (based on dTT/ECA for dabigatran and anti-FXa activity for Xa inhibitors)				
Expected range of plasma levels at peak for standard dose (ng/mL) ^a	64–443	69–321	91–321	184–343
Expected range of plasma levels at trough for standard dose (ng/mL) ^a	31–225	34–230	31–230	12–137
Expected impact of NOACs on routine coagulation tests				
PT	↑	(↑)	↑(↑)	↑↑ (↑)
aPTT	↑↑(↑)	(↑)	↑	↑
ACT	↑(↑)	↑	↑	↑
TT	↑↑↑↑	—	—	—

Ranges indicate the P5/95 percentiles for dabigatran, rivaroxaban, and apixaban, and the interquartile ranges for edoxaban. The reagents influence the sensitivity of the PT for FXa inhibitors and of the aPTT for dabigatran. When a sensitive assay is used, normal aPTT excludes above on-therapy levels in dabigatran-treated patients, and normal PT excludes above on-therapy levels in rivaroxaban and edoxaban, but not apixaban treated patients. Point-of-care INR devices developed to monitor vitamin K antagonists do not accurately reflect the anticoagulant status of NOAC treated patients. ACT, activated clotting time; aPTT, activated partial thromboplastin time; dTT, diluted thrombin time; ECA, ecarin clotting assay; INR, international normalized ratio; PT, prothrombin time.

evaluation of FXa inhibitory effect because of the limited prolongation, variability of assays, and paradoxical response at low concentrations.²³³ Although Factor Xa-inhibitors demonstrate a concentration-dependent prolongation of the PT, the effect depends both on the assay and on the FXa inhibitor. Furthermore, PT is not specific and can be influenced by many other factors (e.g. hepatic impairment, vitamin K deficiency).²³³ For apixaban, the PT cannot be used for assessing the anticoagulant effect. For rivaroxaban and to a lesser extent edoxaban, the PT may provide some quantitative information, even though the sensitivity of the different PT reagents varies importantly and may be insensitive for the anti-FXa effect.²²⁶ Assessment of the sensitivity of the employed PT reagent for the Xa-inhibitors is strongly recommended.

Importantly, conversion of PT to INR does not correct for the variation and even increases the variability. The INR (especially a point-of-care determined INR) is unreliable for the evaluation of FXa inhibitory activity. Furthermore, the prolongation of the PT/INR by NOACs can be misleading during the transition of a NOAC to a VKA. Therefore, switching needs to be executed diligently, as discussed in **chapter 4**.

Impact of non-vitamin K antagonist oral anticoagulants on other coagulation assays

NOACs also interfere with thrombophilia tests and the measurement of coagulation factors. Therefore, a time window of at least 24 h is recommended between the last intake of a NOAC and blood sampling to confidently assess coagulation parameters. This time window may be even longer for lupus anticoagulant measurements (≥ 48 h).

The activated clotting time (ACT) test is used as a point-of-care test in settings where high heparin doses are administered and where the aPTT is too sensitive (e.g. bypass surgery, coronary interventions, ablation procedures, etc.). It is a test on whole blood, based on contact activation. Dabigatran increases the ACT in a curvilinear fashion, consistent with the effects on aPTT.²²⁹ The ACT has not been investigated to gauge dabigatran anticoagulant activity in clinical practice. There is a small dose-dependent effect of apixaban, edoxaban, and rivaroxaban on the ACT.^{234,235} It seems reasonable to use the same target ACT levels for heparin titration in NOAC-treated patients undergoing interventions. However, since ACT is a non-standardized test, ACT target levels require centre validation. The ACT cannot be used to gauge FXa anticoagulant activity.

8. Non-vitamin K antagonist oral anticoagulant plasma level measurement: rare indications, precautions and potential pitfalls

Non-vitamin K antagonist oral anticoagulants do not require monitoring of coagulation: neither the dose nor the dosing intervals need to be altered in response to changes in coagulation parameters for the currently registered indications. However, laboratory assessment of drug exposure and anticoagulant effect may help clinicians in

emergencies as well as in special situations. Laboratory monitoring to guide long-term use can also be considered in exceptional patients with special characteristics. This, however, should only be done under the guidance of a coagulation expert and in the knowledge that hard clinical outcome data do not exist for such a strategy.

Measurement in emergencies

In emergencies such as bleeding (**chapter 11**), urgent procedures (**chapter 13**), or an acute stroke (**chapter 17**), routine coagulation tests are rapidly available and may quickly inform the clinician on recent exposure; specific assays may provide accurate assessment of plasma levels (**chapter 7**).

In case of serious bleeding, coagulation tests may help the clinician to support haemostasis (**chapter 11**). Coagulation tests may also uncover associated bleeding disorders. In case of urgent surgery as well as in exceptional cases of planned surgery with high-bleeding risk, coagulation tests may help the clinician define the timing of surgery (see **chapters 12 and 13**).

Information on drug exposure may also guide treatment in patients who present with acute thrombotic events, particularly in patients with acute ischaemic stroke for whom thrombolysis is considered (**chapter 17**). Other emergency situations where assessment of anticoagulant activity may be valuable include suspected overdosing or intoxication.

Measurement before elective procedures

In general, routine measurement of the anticoagulant activity is not recommended prior to elective procedures (**chapter 12**). When the timing since last intake is unknown or uncertain, or when there are concerns on the clearance of the drug because of special patient characteristics (potential drug–drug interactions, change in renal or hepatic function), it is reasonable to check the absence of clinically relevant plasma concentrations when specific assays are available.¹⁶⁸ Importantly, however, there are currently no prospectively validated data with hard clinical endpoints on cut-off values of any coagulation test to guide the timing of elective or urgent surgery.²³⁶

Monitoring during long-term exposure

The expected drug levels while on therapy, as observed in clinical trials, are shown in *Table 9*. Importantly, no studies have investigated if measurement of drug levels and dose adjustment based on laboratory coagulation parameters reduces the risk for bleeding or thromboembolic complications, e.g. by dose reduction in case of higher than expected levels or by dose increase in case of lower than expected levels, during chronic treatment. As such, routine monitoring of plasma levels and subsequent dose adaptation is generally discouraged. For the (rare) patients with multiple factors that interfere with the pharmacokinetics of a given NOAC (e.g. the very obese; uncontrolled cancer patients receiving therapy for malignancies; treatment with anti-cancer drugs with unclear/unknown pharmacokinetic interactions), a reasonable strategy could be to verify that plasma levels are within the ‘on treatment’ range, taken into account the different ‘on therapy’ range for samples taken at peak or at trough levels (*Table 9*). However, this should only be performed in the hands of a coagulation expert with sufficient experience in the performance and interpretation of these assays as well as the care of these patients.

Alternatively, reverting to VKA therapy in these very special situations may be an option.

Over- and underweight patients

Patients at the extremes of the weight spectrum (i.e. <50 kg and >120 kg) have been underrepresented in the clinical trials, and NOAC use may be a challenge in these individuals (**chapter 18**). If NOAC treatment is decided on in such a patient, assessment of plasma trough levels may be considered.

9. How to deal with dosing errors?

Questions relating to dosing errors are very common in daily practice, and patients need to be informed on what to do in such cases. To avoid dosing errors as described below, patients on NOACs should be encouraged to make use of well-labelled weekly containers, with separate spaces for each dose timing. Importantly, however, dabigatran must not be taken out of its original bottle until immediately before intake. In order to provide a more uniform and simple practical advice some of the below recommendations do not fully align with all SmPCs. Also, patients' individual risk of stroke and bleeding need to be taken into consideration.

Missed dose

A forgotten dose may be taken until 50% of the dosing interval has passed. Hence, for NOACs with a BID dosing regimen (i.e. every 12 h), a forgotten dose can be taken up until 6 h after the scheduled intake. For patients with a high stroke risk and low bleeding risk, this may be extended up until the next scheduled dose.

For NOACs with an OD dosing regimen, a forgotten dose can be taken up until 12 h after the scheduled intake. After this time point, the dose should be skipped and the next scheduled dose should be taken. The 12 h interval may be extended in patients with a high stroke risk.

Double dose

For NOACs with a BID dosing regimen, the next planned dose (i.e. after 12 h) may be left out, with BID intake restarted 24 h after the double dose intake.

For NOACs with an OD dosing regimen, the patient should continue the normal dosing regimen, i.e. without skipping the next daily dose.

Uncertainty about dose intake

For NOACs with a BID dosing regimen, it is generally advisable to not take another tablet/capsule, but to simply continue with the regular dose regimen, i.e. starting with the next dose at the 12 h interval.

For NOACs with an OD dosing regimen, when thrombotic risk is high ($\text{CHA}_2\text{DS}_2\text{-VASc} \geq 3$), it may generally be advisable to take another tablet and then continue the planned dose regimen. In case the thrombotic risk is low ($\text{CHA}_2\text{DS}_2\text{-VASc} \leq 2$), it is recommended to wait until the next scheduled dose.

10. What to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a potential risk of bleeding?

Excessive NOAC plasma concentrations potentially expose the patient to an increased risk of bleeding. This may occur when the patient has (intentionally) taken an overdose. Also intercurrent events such as acute renal failure (especially with dabigatran) or administration of drugs with known drug–drug interactions (see **chapter 5**) may increase NOAC plasma concentrations to supra-therapeutic levels. In terms of management, it is important to distinguish between an overdose with bleeding complications (**chapter 11**) and without.

In case of a suspected overdose, coagulation tests can help to determine its degree and possible bleeding risk (see **chapter 7**). A normal aPTT excludes high levels of dabigatran; similarly a normal PT excludes very high levels of rivaroxaban and edoxaban. However, these routine coagulation tests are not appropriate for a quantitative assessment of high levels of these drugs.

Given the relatively short plasma half-life of the NOACs, a 'wait-and-see' strategy can be used in most cases without active bleeding. The elimination half-life can be estimated taking into account age and renal function. As a result of limited absorption, a ceiling effect with little to no further increase in plasma exposure is seen at supra-therapeutic doses of ≥ 50 mg rivaroxaban.²³⁷ There are no data in this respect concerning the other FXa inhibitors or dabigatran.

In the case of recent acute ingestion of an overdose (especially when ≤ 2 h ago), the use of activated charcoal to reduce absorption may be considered for any NOAC (with a standard dosing scheme for adults of 30–50 g) although clinical data on its effectiveness are lacking.^{238–240}

If a more aggressive normalization of plasma levels is deemed necessary, or rapid normalization is not expected (e.g. major renal insufficiency) the steps outlined below (**chapter 11**) may need to be considered, including the use of a specific reversal agent.²⁴¹ Only in exceptional cases, strategies to non-specifically support haemostasis awaiting clearance of the drugs may be considered, although clearly in these situations balancing the benefit of normalizing coagulation in a non-bleeding patient needs to be carefully weighed against a possibly strong prothrombotic effect.

11. Management of bleeding under non-vitamin K antagonist oral anticoagulant therapy

The Phase III NOAC studies have consistently shown that NOACs cause less intracranial and less life-threatening bleedings than warfarin, despite the absence of reversal strategies in these trials. Not only was there similar or even a reduced bleeding incidence, but patients experiencing a major (particularly extracranial) bleeding under NOACs were also shown to have a more favourable outcome than for bleeding under VKA treatment.^{240,242–245,378,379} Overall, a

reduction in all-cause mortality was observed with NOACs vs. warfarin for stroke prevention in AF.²⁴⁶

Nevertheless, as more patients are being treated with NOACs, the absolute number of NOAC-related bleeding events will increase. Importantly, any bleeding is an opportunity to review the correct choice and dosing of the NOAC (see **chapters 2, 5, 6, 15** and others) and to evaluate modifiable bleeding risk factors including suboptimally treated hypertension, labile INR (if on VKA) or erratic dosing, excessive alcohol intake and concomitant antiplatelet therapy, NSAIDs, glucocorticoids etc. (see also **chapter 14**).³

We recommend a hospital-wide policy concerning bleeding management under NOAC, developed in an interdisciplinary manner among cardiologists, haemostasis experts, emergency physicians/intensivists and others. This protocol should describe the availability and indications of specific coagulation tests as well as of specific and nonspecific reversal agents. Such a policy needs to be communicated well and be easily accessible (e.g. on an Intranet site, in the emergency room, in pocket-sized leaflets etc.).

Strategies to manage bleeding complications in patients treated with NOACs rely on a precise analysis of the clinical situation.

- (1) The type of bleeding: nuisance/minor, major non-life threatening, or life-threatening.
- (2) The patient and his/her treatment: The exact time of last NOAC intake, prescribed dosing regimen, renal function, other factors influencing plasma concentrations (incl. co-medication, see also *Table 3*), and other factors influencing haemostasis (such as concomitant use of antiplatelet drugs).

Both routine coagulation tests and assays that specifically measure plasma levels of NOACs are important pillars in the assessment of NOAC related bleeding. Normal results of dTT/ecarin clotting time (for dabigatran) and anti-Xa activity (for anti-FXa treated patients) likely exclude relevant levels of the anticoagulant. Specific assays allow for the quantification of plasma levels of the anticoagulant (**chapter 7**).²⁴⁷ However, it needs to be kept in mind that restoration of coagulation does not necessarily result in improved clinical outcome. Conversely, conventional coagulation tests may be abnormal not only due to the effect of the NOAC itself, but for a variety of other reasons, particularly in the setting of severe bleeding.

Depending on the clinical scenario, the anticoagulant effects in a NOAC-treated patient who presents with bleeding can be addressed with the following strategies:

- (1) *Waiting* until the anticoagulant activity of the NOAC effect wanes as a result of spontaneous clearance of the drug (*Table 6*), facilitated by maintaining (and potentially by stimulating) diuresis.
- (2) *Specific reversal*: A specific reversal agent is available for dabigatran (idarucizumab, a humanized antibody fragment that specifically binds dabigatran).²⁴⁸ Specific agents for FXa inhibitors are undergoing clinical testing, including andexanet alfa (a recombinant human FXa analogue that competes with FXa to bind FXa inhibitors)²⁴⁹ and ciraparantag (PER 977), a small synthetic molecule that seems to have more generalized antagonistic effects.²⁵⁰
- (3) *Non-specific support of haemostasis* using coagulation factors concentrates. There is increasing information about the effects of (activated) prothrombin complex concentrates in cohorts of NOAC-treated patients with bleeding.²⁵¹ In contrast, the use of fresh frozen

plasma is not considered a useful reversal strategy, primarily due to the plasma abundance of NOACs which will inhibit newly administered coagulation factors upon activation and the resulting large volume that would need to be administered.²⁴⁷ Vitamin K and protamine administration have no role in the management of a bleeding under NOACs, but are useful in the management of bleeding under NOACs when vitamin K deficiency is suspected or in case of concomitant treatment with heparin, respectively.

Nuisance and minor bleeding

The clinical relevance of both nuisance and minor bleedings under NOAC therapy should not be underestimated as they are a frequent cause of treatment interruptions. Patients need to be made aware of the signs and symptoms of such bleedings and instructed to alert their healthcare provider in case of such an event (see **chapter 2**). Cessation or temporary interruption without consultation needs to be discouraged due to the subsequently increased thromboembolic risk.

Nuisance bleeds can usually be managed by delaying intake or withholding the NOAC for a maximum of one dose. Minor bleedings may require more aggressive therapy with a focus aimed at treating the cause of the bleeding (e.g. PPI for gastric ulcers, antibiotics for urinary tract infection, etc.). Epistaxis and gum bleeds can be treated with local anti-fibrinolytics.

In case of recurrent minor bleeding events without causal therapeutic options, an alternative NOAC with a potentially different bleeding profile should be considered while maintaining effective stroke prevention (see **chapter 5**).

A suspected or documented occult bleeding should trigger a work-up to uncover the underlying cause and the treatment thereof whenever possible.

Non-life-threatening major bleeding

Causal therapy to stop the bleeding and standard supportive measures (such as mechanical compression, endoscopic or surgical haemostasis, fluid replacement, transfusion, and other haemodynamic support) are the main pillars in the management of non-life-threatening major bleeding. With increasing time a waning of the anticoagulant activity can be anticipated in view of the relatively short elimination half-lives of all NOACs (see *Tables 6, 10* and *Figure 5*).²⁵²

Adequate diuresis is recommended for all NOACs, but particularly in case of dabigatran (given the large degree of renal elimination of the drug). In addition, dialysis may be an option for non-life-threatening, severe bleeding with dabigatran in cases of severe renal failure if idarucizumab is not available.^{253,254} In contrast, dialysis has no significant impact in patients treated with any of the FXa inhibitors due to their high degree of protein plasma binding.^{255,256}

The use of antifibrinolytics (e.g. tranexamic acid, 1 g i.v., repeated every 6 h if needed) or desmopressin 0.3 µg/kg i.v. infusion (with a maximal dosing of 20 µg) – especially in special situations with associated coagulopathy or thrombopathy – may be considered. Tranexamic acid has proven efficacy to support haemostasis, particularly in trauma-induced bleeding, with a favourable safety profile.^{257,258} Even when not yet supported by clinical data its use can therefore be considered for bleeding under NOACs, especially in situations of severe bleeding where frequently many factors of the coagulation cascade are deficient.

Table 10 Possible measures to take in case of bleeding

	Direct thrombin inhibitors (dabigatran)	FXa inhibitors (apixaban, edoxaban, rivaroxaban)
Non life-threatening major bleeding	<ul style="list-style-type: none"> • Inquire about last intake + dosing regimen • Local haemostatic measures • Fluid replacement • RBC substitution, if necessary • Platelet substitution (in case of thrombocytopenia $\leq 60 \times 10^9/L$ or thrombopathy) • Fresh frozen plasma not as reversal agent (may be considered as plasma expander) • Tranexamic acid can be considered as adjuvant (1 g i.v., repeat every 6 h, if necessary) • Desmopressin can be considered in special cases such as coagulopathy or thrombopathy; 0.3 $\mu g/kg$ i.v. infusion (max dose 20 μg) 	
	<ul style="list-style-type: none"> • Estimate normalization of plasma levels: <ul style="list-style-type: none"> • Normal renal function: 12–24 h • CrCl 50–80 mL/min: 24–36 h • CrCl 30–50 mL/min: 36–48 h • CrCl <30 mL/min: ≥ 48 h • Maintain diuresis • Consider idarucizumab (see below) 	<ul style="list-style-type: none"> • Normalization of plasma levels: 12–24 h
Life-threatening bleeding	<ul style="list-style-type: none"> • All of the above • Direct reversal: Idarucizumab 5 g i.v. in two doses a 2.5 g i.v. no more than 15 min apart 	<ul style="list-style-type: none"> • All of the above • Direct reversal: Andexanet alpha (if available and approved)^a <ul style="list-style-type: none"> • Bolus over 15–30 min, followed by 2-h infusion • Rivaroxaban (last intake >7 h before) or apixaban: 400 mg bolus, 480 mg infusion @ 4 mg/min • Rivaroxaban (last intake <7 h before or unknown) or enoxaparin or edoxaban: 800 mg bolus, 960 mg infusion @ 8 mg/min
	<ul style="list-style-type: none"> • Prothrombin complex concentrate (PCC) 50 U/kg (with additional 25 U/kg if clinically needed) • Activated PCC 50 U/kg; max 200 U/kg/day): no strong data about additional benefit over PCC. Can be considered before PCC, if available 	

RBC, red blood cells; CrCl, creatinine clearance; PCC, prothrombin complex concentrate.

^aAndexanet alpha is currently neither approved nor available and final results of the ANNEXA-4 study are pending.

Life-threatening bleeding

Patients with life-threatening bleeding while treated with NOACs may benefit from its reversal in addition to the standard measures outlined above.

Importantly, even after direct reversal, significant NOAC concentrations may reappear in some patients and contribute to recurrent or continued bleeding (particularly after andexanet alpha, less after idarucizumab administration),^{249,259} underlining the necessity for continued clinical and laboratory monitoring.

Idarucizumab


In the REVERSE-AD study, idarucizumab was successfully used in patients on dabigatran presenting with major or life-threatening bleeding, or with the necessity of emergency surgery. Idarucizumab completely reversed the anticoagulant activity of dabigatran within

minutes in almost all patients.²⁴⁸ It is hence recommended as first-line therapy in such situations. A total of 5 g idarucizumab is administered intravenously in two bolus doses of 2.5 g no more than 15 min apart (Figure 6). Continued clinical and laboratory monitoring is recommended, since a 5 g dose of idarucizumab may not completely neutralize an exceptional high level of dabigatran (e.g. in case of overdose or renal insufficiency). Also, low levels of dabigatran may reappear after 12–24 h.

After 24 h, dabigatran can be re-started if clinically indicated and feasible, with normal kinetics.

Direct reversal of apixaban, edoxaban, or rivaroxaban (FXa-inhibitors)

Based on the ongoing ANNEXA-4 study (which, in contrast to REVERSE-AD only includes patients with major/life-threatening



bleeding),²⁴⁹ andexanet alpha may become the first choice of therapy in life-threatening bleeding under FXa-inhibitor therapy (pending its regulatory approval and availability). In the ANNEXA-4 study, the drug is administered as a bolus over 15–30 min, followed by a 2-h infusion. The dosing depends on the NOAC and on the timing since last intake: For rivaroxaban (with the last intake >7 h before reversal) or apixaban, a 400 mg bolus is administered followed by a 480 mg infusion (4 mg/min). For rivaroxaban (with the last intake <7 h before reversal or unknown recent intake), edoxaban or enoxaparin, a 800 mg bolus followed by a 960 mg infusion (8 mg/min) is given (Figure 6). Importantly, reappearance of anticoagulant activity may occur after stopping the infusion. Therefore, it is currently less clear at what point in time and with which anticoagulant effect FXa inhibitors or heparin can be re-administered following andexanet alpha administration.

Coagulation factors


Clinical trials and registry data with NOACs have shown that administration of coagulation factors is rarely needed.^{251,260} Indeed, any NOAC-antagonizing effect has to be balanced carefully against the potential prothrombotic effect. Animal experiments as well as studies in healthy volunteers have indicated the potential usefulness of PCCs and activated PCCs (aPCC) for the normalization of coagulation parameters under NOAC treatment as a surrogate for haemostatic support.^{261–267} As indicated above, data from the large Phase III trials demonstrated that outcomes of bleedings under NOACs were similar (if not better) than in the VKA arm with similar treatment used

(including PCC/aPCC).^{240,242–243} The efficacy on clinical outcomes of PCCs or aPCCs in patients taking NOACs who are actively bleeding has not been firmly established in a RCT. However, several observational studies in patients with major bleeding have been published (with some inherent limitations including the retrospective, non-controlled setting as well as absence of a control group) indicating that (a)PCCs appeared to be efficacious in supporting haemostasis.^{268,269}

The administration of PCCs or aPCCs can be considered in a patient with life-threatening bleeding if immediate haemostatic support is required, especially in situations where a specific reversal agent is not available (Table 10). The choice between PCC and aPCC may depend on their availability and the experience of the treatment centre. Particularly aPCC induces a strong pro-coagulant effect and should only be used by physicians experienced in their use. PCC and aPCC are preferred over recombinant activated factor VIIIa (NovoSeven, 90 µg/kg) given the absence of any outcome data and the latter's pronounced pro-coagulant effect.^{247,270}

Anticoagulation post-extracranial bleeding

In most cases of nuisance or minor bleeding anticoagulation can be re-started, sometimes simply by delaying or skipping a single dose. All other bleedings, particularly life-threatening bleeding episodes, require a careful re-assessment of the risks and benefits of re-initiating anticoagulation. In most cases of bleedings due to secondary (e.g. bleeding post-trauma) or reversible causes (e.g. genito-urinary




bleed due to cancer) anticoagulation can be resumed once the cause of the bleed has been eliminated. As exemplified for GI bleedings, i.e. one of the most frequently encountered bleeds, many additional factors need to be taken into consideration (Figure 7). Particularly for severe and life-threatening bleedings without a clear secondary or reversible/treatable cause the risks of re-initiating anticoagulation may outweigh the benefits. In such cases, implantation of a left atrial appendage (LAA) occluder or surgical LAA occlusion may be considered as a potential substitute for long-term anticoagulation.³ However, RCT evidence for LAA occlusion after bleeding under OAC is missing, which is why, ideally, treatment should occur wherever possible in the framework of a randomized trial to contribute to evidence for this difficult to treat population.

The approach post-intracerebral, intracranial, subdural, and epidural bleeding is outlined below (chapter 17).

12. Patients undergoing a planned invasive procedure, surgery or ablation

When to stop non-vitamin K antagonist oral anticoagulants?

About one quarter of anticoagulated patients require temporary cessation for a planned intervention within 2 years.²⁶⁰ Awaiting the results of the ongoing Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE; NCT02228798) study, few prospective data on the management of NOACs are available.²⁷¹ Various societies have issued separate guidelines on the timing of NOAC



interruption prior to surgery or interventions. It is impossible to summarize all recommendations, and healthcare providers are recommended to check this guide's recommendations against the relevant recommendations of their country/healthcare setting and professional society. The EHRA practical guide intends to provide a unified approach, which is as simplified as possible to allow its broad implementation.

Patient characteristics (including age, history of bleeding complications, concomitant medication, and kidney function) as well as surgical factors (Table 11) need to be taken into account to determine when to discontinue and restart a NOAC. While invasive surgical interventions require temporary discontinuation of a NOAC, many less invasive procedures carry a relatively low bleeding risk and do not necessarily require discontinuation (Table 12; Figure 8). All patients undergoing a planned intervention as well as caregivers (primary care physician etc.) should receive a written note indicating the anticipated date and time of their intervention as well as the date and time of the last intake of their NOAC (and any other medication).

Minor bleeding risk

It is recommended not to interrupt oral anticoagulation for most minor surgical procedures and those procedures where bleeding is easily controllable (Figure 8). In general, these procedures can be performed 12–24 h after the last NOAC intake. It may be practical to have the intervention scheduled 18–24 h after the last NOAC intake, and then restart 6 h later (skipping one dose of dabigatran or apixaban or no dose of edoxaban or rivaroxaban). The patient may only leave the ambulatory practice/outpatient clinic/hospital, if any peri-interventional bleeding has completely stopped. Moreover, the

Table 11 Timing of last non-vitamin K antagonist oral anticoagulant intake before start of an elective intervention

	Dabigatran		Apixaban – Edoxaban – Rivaroxaban	
	No important bleeding risk and/or adequate local haemostasis possible: perform at trough level (i.e. 12 h or 24 h after last intake)			
	Low risk	High risk	Low risk	High risk
CrCl ≥80 mL/min	≥24 h	≥48 h	≥24 h	≥48 h
CrCl 50–79 mL/min	≥36 h	≥72 h	≥24 h	≥48 h
CrCl 30–49 mL/min	≥48 h	≥96 h	≥24 h	≥48 h
CrCl 15–29 mL/min	Not indicated	Not indicated	≥36 h	≥48 h
CrCl <15 mL/min	No official indication for use			
No bridging with LMWH/UFH				
Resume full dose of NOAC ≥24 h post-low bleeding risk interventions and 48 (–72) h post-high-bleeding risk interventions (see also <i>Figure 8</i>)				
Patients undergoing a planned intervention should receive a written note indicating the anticipated date and time of their intervention, and the date and time of the last intake of their NOAC (and any other medication)				

Low risk: with a low frequency of bleeding and/or minor impact of a bleeding; high risk: with a high frequency of bleeding and/or important clinical impact. See also Table 12. CrCl, creatinine clearance; LMWH, low molecular weight heparin; UFH, unfractionated heparin.

patient has to be instructed about the normal post-procedural course and the measures to be taken in case of bleeding. The physician/dentist (or an informed colleague) has to be accessible in such a case.

Low bleeding risk

For invasive procedures with a low bleeding risk (i.e. low frequency of bleeding and/or minor impact of bleeding; Table 11), it is recommended to take the last dose of a NOAC 24 h before the elective procedure in patients with normal kidney function (Table 12, Figure 8). For patients on dabigatran and a CrCl < 80 mL/min a graded interruption should be considered. For patients taking a FXa inhibitor and with a CrCl of 15–29 mL/min the last NOAC should be taken 36 h or more before surgery (Table 12). In patients taking concomitant dronedarone, amiodarone or verapamil, it may be advisable to add an extra 24 h of interruption, especially if the thromboembolic risk is not very high ($\text{CHA}_2\text{DS}_2\text{-VASc} \leq 3$).¹⁶⁸ Conversely, for some procedures (e.g. cardiac device implantations, see below) a shorter interruption may be warranted, including intake of the last dose the morning of the day before the procedure. The PAUSE trial will provide more information on the relation between last intake, preprocedural plasma level and, most importantly, clinical outcome.²⁷¹

High bleeding risk

In case of invasive procedures that carry a high risk for major bleeding (i.e. with a high frequency of bleeding and/or important clinical impact), it is recommended to take the last NOAC dose 48 h or longer before surgery. Again, the decision to halt therapy for longer should take into account the patient's thromboembolic vs. bleeding risk as well as concomitant therapy with antiarrhythmic drugs as described above. Moreover, in patients with impaired renal function

longer interruption of the NOAC intake is required, especially for dabigatran (Table 11, Figure 8). In cases with combined factors that make prediction of NOAC clearance unclear, measurement of NOAC plasma levels may be considered, and only go ahead with the planned surgical intervention when the level is considered low enough (chapter 7, Table 9). However, it needs to be clearly stated that such an approach is without evidence base, including the determination of 'safe' NOAC levels in this setting as well as waiting for levels to drop into that range whilst accepting the inherent risk of thromboembolism during that time.

Bridging

Preoperative bridging with LMWH or heparin is *not* recommended in NOAC-treated patients since the predictable waning of the anticoagulation effect allows properly timed short-term cessation of NOAC therapy before surgery. On the contrary, the mixing of two anticoagulants (although with similar pharmacodynamics and -kinetics) has been associated with an increased bleeding risk.²⁷² As demonstrated in the BRIDGE trial for VKA, bridging with heparin/LMWH was associated with a significantly higher risk of major bleeding during cessation of oral anticoagulation but did not reduce cardiovascular events.²⁷³

Dental surgery

Dental surgery is generally considered a procedure with minor bleeding risk and with the possibility for adequate local haemostasis. Most professional statements on dental surgery advise not to suspend NOAC treatment and avoid the use of NSAIDs.²⁷⁴ However, recommendations are often based on a low quality of evidence and mainly rely on available pharmacological information.²⁷⁵ Dental extractions can generally be performed safely in an outpatient facility by applying

Table 12 Classification of elective surgical interventions according to bleeding risk

Interventions with minor bleeding risk
Dental interventions
Extraction of 1–3 teeth
Paradental surgery
Incision of abscess
Implant positioning
Cataract or glaucoma intervention
Endoscopy without biopsy or resection
Superficial surgery (e.g. abscess incision; small dermatologic excisions; . . .)
Interventions with low bleeding risk (i.e. infrequent or with low clinical impact)
Endoscopy with biopsy
Prostate or bladder biopsy
Electrophysiological study or catheter ablation (except complex procedures, see below)
Non-coronary angiography (for coronary angiography and ACS: see Patients undergoing a planned invasive procedure, surgery or ablation section)
Pacemaker or ICD implantation (unless complex anatomical setting, e.g. congenital heart disease)
Interventions with high bleeding risk (i.e. frequent and/or with high impact)
Complex endoscopy (e.g. polypectomy, ERCP with sphincterotomy etc.)
Spinal or epidural anaesthesia; lumbar diagnostic puncture
Thoracic surgery
Abdominal surgery
Major orthopaedic surgery
Liver biopsy
Transurethral prostate resection
Kidney biopsy
Extracorporeal shockwave lithotripsy (ESWL)
Interventions with high bleeding risk AND increased thromboembolic risk
Complex left-sided ablation (pulmonary vein isolation; some VT ablations)

For each patient, individual factors relating to bleeding and thromboembolic risk need to be taken into account, and be discussed with the operating physician.

local haemostatic measures, without interrupting anticoagulation or by just skipping the morning dose of the NOAC.^{276–279} Periprocedural management includes specific haemostatic techniques including the use of oxidized cellulose or absorbable gelatin sponge, sutures, tranexamic acid mouthwashes, or compressive gauze soaked in tranexamic acid.

Device implantation procedures

Device implantations are generally considered procedures with a low bleeding risk. For patients undergoing device implantation, prospective, and randomized data in VKA-treated patients have indicated lower thromboembolic and bleeding rates if the VKA is continued in an uninterrupted fashion.²⁸⁰ For NOAC-treated patients, the recently presented BRUISE-CONTROL 2 trial demonstrated similar bleeding and embolic rates in patients with a last intake 48 h before the implantation for rivaroxaban/apixaban (and based on glomerular filtration rate for dabigatran) vs. continued NOAC until the morning of the procedure (Birnie et al., presented at AHA 2017). Therefore, a standard strategy as for ‘low bleeding risk’ procedures with intake of the last dose in the morning of the day before the procedure can be recommended in most cases, followed by restarting one day afterwards (Table 12 and Figure 8). An overview of data and recommendations can be found in the recent EHRA/HRS/APHRS consensus document.²⁸¹

Regional anaesthesia and pain medicine

Invasive procedures such as spinal anaesthesia, epidural anaesthesia, and lumbar puncture require complete haemostatic function, and fall under the ‘high bleeding risk’ category. European as well as North American guidelines do not recommend neuraxial anaesthesia or deep blocks in the presence of uninterrupted NOAC use and recommend interruption of NOACs for up to five half-lives (corresponding to an interruption of 3 days in FXa-inhibitors and 4–5 days for dabigatran).^{282,283} NOAC therapy can usually be resumed 24 h after the intervention. On the other hand, ‘low risk’ procedures (such as peripheral nerve blocks or peripheral joint and musculoskeletal injections) do not necessarily require NOAC interruption and if so for only a short period (e.g. two half-lives).²⁸⁴

Lab testing before surgery or invasive procedures

Specific coagulation measurements (see chapter 7) prior to surgery or invasive procedures provide a direct assessment of the (residual) drug concentration²⁸⁵ and may be useful in high-risk interventions and/or patients at risk for relevant residual drug concentrations such as older age, renal impairment, or certain concomitant medication (see chapter 5).¹⁶⁸ However, as indicated, such an approach is without evidence base, including the determination of ‘safe’ NOAC levels. For the majority of patients and procedures, a ‘time-based’ interruption as outlined above appears safe.

When to restart a non-vitamin K antagonist oral anticoagulant after an invasive procedure?

After a procedure with immediate and complete haemostasis, NOACs can generally be resumed 6–8 h after the end of the

		Day -4	Day -3	Day -2	Day -1	Day of surgery	Day +1	Day +2
Minor bleeding risk	Dabi					No bridging Yellow star Restart ≥ 6h post surgery		
	Apix							
	Edo / Riva (AM intake)							
	Edo / Riva (PM intake)							
Low bleeding risk	Dabi		 (if CrCl ≥ 30)	 (if CrCl ≥ 50) (if CrCl ≥ 80)		No bridging Yellow star		
	Apix							
	Edo / Riva (AM intake)							
	Edo / Riva (PM intake)							
High bleeding risk	Dabi	 (if CrCl ≥ 30)	 (if CrCl ≥ 50) (if CrCl ≥ 80)	No bridging (heparin / LMWH) Consider plasma level measurements (in special situations *)		No bridging Yellow star	Consider postoperative thromboprophylaxis per hospital protocol	
	Apix							
	Edo / Riva (AM intake)							
	Edo / Riva (PM intake)							
							Restart ≥ 48h (~72h) post surgery	

Figure 8 Stopping and re-initiation of non-vitamin K antagonist oral anticoagulant therapy in elective surgery. Yellow star, time point of the intervention/operation. Consider +24 h of interruption in situations likely resulting in increased plasma levels [e.g. patients taking verapamil, body weight <50 kg, significant interactions (see **chapter 5**)]. *Consider measurement of plasma levels (see **chapter 7**) in very special situations, e.g. highest risk neurosurgery/cardiac surgery, severe renal insufficiency, and combination of factors predisposing to higher non-vitamin K antagonist oral anticoagulant levels (see **chapter 5**). Rivaroxaban needs to be taken with food for stroke prevention in atrial fibrillation, which needs to be looked after (also) in the post-operative setting. Apix, apixaban; CrCl, creatinine clearance; Dabi, dabigatran; Edo, edoxaban; LMWH, low molecular weight heparin; Riva, rivaroxaban.

intervention. However, there are some surgical interventions in which resuming full dose anticoagulation within the first 48–72 h after the procedure carries a bleeding risk that may outweigh the risk of AF-related embolism. In such cases, initiation of post-operative thromboprophylaxis 6–8 h after surgery and restarting the NOAC 48–72 hours postoperatively (but as soon as possible) can be considered. There are, however, no data on the safety and efficacy of the post-operative use of a reduced dose of the NOACs (such as used for the prevention of venous thromboembolism (VTE) after hip/knee replacement) in patients with AF undergoing a surgical procedure.

It is strongly recommended to develop and implement institutional guidelines and a hospital-wide policies concerning perioperative anticoagulation management in different surgical settings, which are widely communicated and readily available.

Special considerations for atrial fibrillation ablation procedures

Left atrial catheter ablation constitutes an intervention with a risk of serious bleeding secondary to trans-septal puncture or extensive manipulation and ablation in the left atrium, although the incidence has been decreasing.²⁸⁶ Major bleeds in the groin are not uncommon. On the other hand, left atrial catheter ablation implies a pro-thrombotic setting, increasing the risk of thromboembolic complications.^{286,287} Recent international consensus statements and guidelines recommend performing left atrial catheter ablation under uninterrupted anticoagulant treatment (target INR 2–2.5),^{3,286} since such a strategy was associated with less thromboembolic events and less bleeding.²⁸⁸ The randomized RE-CIRCUIT (comparing dabigatran to warfarin in addition to peri-interventional heparin)²⁸⁹ as well as the

VENTURE AF trial (comparing rivaroxaban to warfarin in addition to peri-interventional heparin)²⁹⁰ showed a similar risk of embolism in the uninterrupted NOAC vs. VKA arms, although both studies by themselves were underpowered to detect statistically significant differences in endpoints. While in VENTURE-AF, patients preferentially received their last dose rivaroxaban in the evening before the procedure, dabigatran was routinely administered even in the morning before ablation in RE-CIRCUIT. As a result, approximately 80% of patients received their last dose <8 h before the procedure and 41% underwent ablation within 4 h of the last dabigatran dose. While a similar risk of major bleedings between rivaroxaban and warfarin was observed in VENTURE-AF, a large reduction in major bleeding was seen in RE-CIRCUIT with dabigatran compared with warfarin. Similar trials for apixaban (AXAFA-AFNET 5)²⁹¹ as well as edoxaban (ELIMINATE-AF) are ongoing. Registry data as well as a subanalysis of the ENGAGE-AF trial (with varying protocols and timings of NOAC interruption) did not indicate an increased risk of stroke or bleeding for apixaban or edoxaban in the setting of AF ablation.^{292–294}

An institutional protocol for NOAC patients undergoing AF ablation should be developed to ensure a uniform approach. Whether opting to administer the last NOAC dose shortly before the procedure (i.e. 'truly uninterrupted') or to go for a short cessation period (last NOAC dose on the day before the procedure), depends on a number of factors including renal function, CHA₂DS₂-VASc score, experience of the operator, and routine practice of heparin administration prior to (first) trans-septal puncture.^{2,281,286} It is reasonable to administer a last dose of NOAC 12 h before the start of the intervention, especially if trans-septal puncture is performed without periprocedural imaging (as is mostly the case in Europe). Especially, when adherence is uncertain over the weeks prior to the intervention, left atrial thrombus should be ruled out prior to ablation. A similar approach may be advisable if the last NOAC dose is taken ≥36 h before the intervention as the patient would be without adequate anticoagulation for a prolonged period of time as well as in patients at high risk for thromboembolism. During the ablation, intravenous heparin should be administered to achieve an ACT of 300–350 s.²⁹⁵ It seems reasonable to use the same target ACT levels for heparin titration in NOAC-treated patients as in patients on (uninterrupted) VKA. It has been noted that the total need for heparin and the time to target ACT was higher in some NOAC treated patients.^{290,296,297} This likely reflects a difference in whole blood coagulability when NOACs are stopped some time before the procedure, rather than a direct interaction between NOACs and the ACT test.

NOAC intake can be resumed 3–5 h after sheath removal if adequate haemostasis is established and pericardial effusion has been ruled out.²⁸¹

13. Patients requiring an urgent surgical intervention

If an emergency intervention is required, the NOAC should be discontinued immediately. Specific management will then depend on the level or urgency (immediate, urgent, or expedite; Figure 9).²⁹⁸

- (1) *Immediate procedures* (Immediate life-, limb- or organ-saving intervention, typically cardiac, vascular, and neurosurgical emergency procedures) need to be performed within minutes of the decision to operate and cannot be delayed. In these cases, reversal with idarucizumab (for dabigatran)²⁴⁸ should be considered, especially in moderate- to high-haemorrhagic risk procedures.²⁹⁹ While the REVERSE-AD trial with idarucizumab enrolled both bleeding patients as well as those requiring urgent surgery, the prospective open-label Phase III trial with andexanet alfa, a reversal agent for FXa inhibitors, only enrolls patients experiencing an acute major bleed under therapy but not patients requiring urgent surgical interventions (Clinicaltrials.gov NCT02329327).²⁴⁹ After publication of the full dataset and approval of the drug (expected by the end of 2018) its usefulness in this setting needs to be re-evaluated. If specific reversal agents are not available, PCCs or aPCCs should be considered despite the lack of evidence for efficacy and safety (see also **chapter 11** section).^{269,272,283} Especially, if no specific reversal agent is available it may be advisable to perform immediate (and urgent) procedures under general rather than spinal anaesthesia in order to reduce the risk of epidural haematoma.
- (2) *Urgent procedures* (e.g. intervention for acute onset or clinical deterioration of potentially life-threatening conditions, conditions that may threaten the survival of limb or organ, fixation of fractures, relief of pain, or other distressing symptoms) need to be performed within hours of the decision to operate. In these situations, surgery or intervention should be deferred, if possible, until at least 12 h and ideally 24 h after the last dose. Also, coagulation test results (see below) can be awaited in this situation to gauge the necessity for reversal or application of (a)PCCs.
- (3) *Expedite procedures* (patients requiring early treatment where the condition is not an immediate threat to life, limb, or organ survival) should be performed within days of decision to operate. In these situations, interruption of NOACs should follow the proposed rules for elective surgery (see **chapter 12**).

In all such situations, particularly prior to the application of any haemostatic agents, a full panel of coagulation assays (including PT, aPTT, anti-FXa, or dTT/ECA etc.) should be obtained in order to assess the coagulation status of the patient. Even if in the emergency situation application of pro-haemostatic agents will not be postponed, results of these initial tests may have implications for further treatment during the ensuing hours. Importantly, a normal aPTT in case of dabigatran intake and a normal PT in case of rivaroxaban intake (and to a lesser extent edoxaban) may rule out high plasma levels of the respective drugs; conversely, however, normal routine coagulation tests do not exclude drug levels as expected while on therapy for all of the NOACs (see **chapter 7**). Specific coagulation tests (dTT or ECA for dabigatran; anti-FXa chromogenic assays for FXa inhibitors) and assessment of plasma levels may help in interpreting the current anticoagulant status as well as the waning of any anticoagulant effect, particularly in situations with potentially increased anticoagulant levels [e.g. in older age (see **chapter 18.1**), renal insufficiency (see **chapter 6**), and/or certain co-medications (see **chapter 5**)].




Figure 9 Non-vitamin K antagonist oral anticoagulant management in the setting of unplanned surgery.

14. Patient with atrial fibrillation and coronary artery disease

Scope of the problem and randomized clinical trial evidence

The combination of AF and coronary artery disease (CAD) is not only a common and complex clinical setting to deal with regarding anticoagulation and antiplatelet therapy, it is also associated with significantly higher morbidity and mortality.^{300,301} The practice of adding aspirin or a P2Y₁₂ inhibitor to a (N)OAC is referred to as 'dual therapy', while adding both aspirin and a P2Y₁₂ inhibitor to a (N)OAC is called 'triple therapy'. Dual antiplatelet therapy is referred to as 'DAPT'. Stacking antithrombotic agents, i.e. by adding one or two antiplatelet(s) to NOACs, inevitably increases the risk of bleeding significantly,^{170,171,302,303} leading to a clear need to avoid long-term triple therapy in daily clinical practice.^{304–306}

The current understanding is that DAPT is necessary to prevent stent thrombosis but not sufficient for stroke prevention,³⁰⁷ and vice versa, that (N)OAC are essential for stroke prevention but on their own not suitable for preventing new coronary events, especially in the acute/subacute setting.³ A combination of at least one antiplatelet agent in addition to (N)OAC is recommended for up to 12 months after an ACS event and/or stenting procedure according to the most recent ESC guidelines on AF,³ ST-elevation myocardial infarction (STEMI),³³ and the use of antiplatelet agents.³²

To date, there are a handful of prospective trials addressing the issue of oral anticoagulation after PCI, including two RCTs comparing NOACs to VKA, in a variety of combinations with antiplatelet

agents.^{141,308} In essence, these trials focus on bleeding as the primary endpoint, and are underpowered to address relatively rare ischaemic/thromboembolic events including stroke, re-infarction and stent thrombosis. A meta-analysis combining WOEST, PIONEER AF-PCI, and RE-DUAL PCI suggests that the likelihood of an excess of thromboembolic events during dual therapy vs. triple therapy is low.³⁰⁹ The two ongoing NOAC in AF trials, AUGUSTUS (NCT02415400) and ENTRUST-AF PCI (NCT02866175)³¹⁰ will add further information on how and how long (if at all) triple anticoagulation should be administered.

Randomized clinical trial evidence for non-vitamin K antagonist oral anticoagulants post-percutaneous coronary intervention

In PIONEER AF-PCI, two different rivaroxaban regimens were compared with 'standard' triple therapy with VKA and DAPT in 2124 AF patients undergoing PCI: a low-dose of rivaroxaban 15 mg (10 mg in patients with CrCl 30–50 mL/min) with a P2Y₁₂ inhibitor and a very low dose of rivaroxaban 2.5 mg twice daily combined with aspirin and a P2Y₁₂ inhibitor.³¹¹ The trial design was complex: One year fixed treatment of 15 mg rivaroxaban plus P2Y₁₂ inhibitor was compared to triple anticoagulation with very-low dose rivaroxaban (2 × 2.5 mg) or VKA. The P2Y₁₂ inhibitor was clopidogrel in the vast majority of patients, and DAPT durations of 1, 6, and 12 months were pre-specified for the latter two arms. PIONEER AF-PCI showed that both rivaroxaban arms reduced the risk of clinically significant bleeding complications at 1 year when compared with standard triple therapy with a VKA targeted to an INR between 2 and 3 and with

varying DAPT durations.³⁰⁸ While there were numerically similar rates of cardiovascular death, myocardial infarction, or stroke in all three arms, the trial was underpowered for efficacy. However, neither of the rivaroxaban doses in PIONEER AF-PCI (15 mg/10 mg OD or 2.5 mg BID) have been investigated for stroke prevention in AF [with the exception of the 15 mg dose in a relatively underpowered trial conducted in an exclusively Japanese population with normal renal function (J-ROCKET)].¹⁵⁶

In RE-DUAL PCI, the safety of two doses of dabigatran (110 or 150 mg BID) in combination with clopidogrel or ticagrelor (i.e. dual therapy, without aspirin) were compared with standard triple therapy (for 1 or 3 months depending on the type of stent) with VKA, aspirin, and either clopidogrel or ticagrelor in 2725 patients with AF undergoing PCI.¹⁴¹ The composite of major or clinical relevant non-major bleeding events and major bleeding events alone were significantly reduced in the 110- and 150-mg dabigatran dual therapy arms compared to the standard VKA triple therapy arm. This trial was also underpowered for individual efficacy endpoints; however, it was powered to show non-inferiority of the combined dual-therapy arms vs. the triple therapy in a composite efficacy endpoint of death, thromboembolic events and unplanned revascularization. Stent thrombosis was observed in 15 (1.5%) patients in the 110-mg dual therapy group vs. 8 (0.8%) patients in the triple-therapy group ($P=0.15$) and in 7 (0.9%) patients in the 150-mg dual-therapy group.¹⁴¹ Both dabigatran doses in RE-DUAL PCI have been shown non-inferior (110 mg) or superior (150 mg) to VKA for stroke prevention in AF.²⁸

Key 'scientific' data on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and acute coronary syndrome, percutaneous coronary intervention, or stable coronary artery disease

What is known:

- (1) Adding aspirin and/or a P2Y₁₂ inhibitor to oral anticoagulants substantially increases bleeding risk across different clinical scenarios and should thus be avoided in AF patients without clear indication for antiplatelet therapy, including CAD patients beyond 12 months after an ACS.^{170,300,312} However, in general the bleeding risk seems to be lower with a NOAC plus antiplatelet combination than with a VKA plus antiplatelet combination.^{170,302,313}
- (2) ESC guidelines clearly state that the length of DAPT does not depend (anymore) on the type of stent (i.e. DES or BMS) but on the clinical presentation of the patient.^{3,32} As contemporary DES are more efficient and as safe (or safer) as BMS regarding the risk for stent thrombosis, it does not make sense to opt for a BMS as a strategy to reduce the duration of P2Y₁₂ inhibitor therapy in patients on a NOAC. The use of a contemporary DES will also minimize the risk of avoidable repeat interventions due to restenosis thereby reducing the need for additional periods of dual or triple therapy.
- (3) Clinical trials with contemporary DES suggest that (very) short dual antiplatelet regimens (i.e. 1 month after elective stenting or 6

months in case of ACS) are safe and efficacious in patients perceived to have a high bleeding risk and/or the elderly.^{314,315} Patients receiving (N)OAC in combination with dual antiplatelet agents are considered to be at high bleeding risk.

- (4) Rivaroxaban 15 mg or dabigatran 110/150 mg BID in dual therapy with P2Y₁₂ inhibitor, mainly clopidogrel (but without aspirin) is safer in terms of bleeding risk than triple therapy with VKA, clopidogrel, and low-dose aspirin (PIONEER AF-PCI / RE-DUAL PCI).^{141,308}
- (5) Rivaroxaban 2.5 mg BID in triple therapy with aspirin and clopidogrel is safer in terms of bleeding risk than triple therapy with dose-adjusted VKA, clopidogrel, and low-dose aspirin.
- (6) Measures to reduce the bleeding risk in patients with ACS should be retained: low doses of aspirin (75–100 mg), especially when combined with a P2Y₁₂ inhibitor; new-generation drug-eluting stents (DES) to minimize the duration of dual/triple therapy; and a radial approach for interventional procedures (reducing at least the risk of access site bleeding).^{33,316}
- (7) Prolonged antiplatelet therapy beyond 1 year after ACS or DES implantation has been suggested in non-(N)OAC treated patients based on large-scale RCTs.^{317–319} In the DAPT trial, patients were randomized 12 months after a PCI with DES to aspirin plus clopidogrel or aspirin alone, up to 30 months after the PCI. In the PEGASUS TIMI 54 trial, patients were randomized 1–3 years after an myocardial infarction to aspirin plus ticagrelor or aspirin alone, and followed for a median of 33 months. Since patients in need of long-term OAC therapy were excluded from these studies, the results are of less relevance for treatment of AF patients.

What is unknown

- (1) It is unknown whether the doses of rivaroxaban used in PIONEER AF-PCI (i.e. 2.5 mg BID or 15 mg OD) are sufficient for stroke prevention, at least compared with standard dose-adjusted VKA or compared with the 20 mg OD rivaroxaban dose in patients with a normal renal clearance.²⁹
- (2) It remains unknown whether dual therapy strategies combining a NOAC with clopidogrel are safer in terms of bleeding risk than a dual therapy with a VKA and clopidogrel. This is currently being addressed in the AUGUSTUS study with apixaban.
- (3) It remains unknown whether dual therapy (i.e. rivaroxaban 15 mg OD or dabigatran 110/150 mg BID in combination with a P2Y₁₂ inhibitor) sufficiently protects against stent thrombosis or myocardial infarction, due to underpowered clinical trials.^{141,308}
- (4) It remains unknown whether dual therapy with NOAC and aspirin could be an alternative to NOAC and a P2Y₁₂ inhibitor, as there is no randomized study evaluating aspirin vs. a P2Y₁₂ inhibitor as part of dual therapy with NOAC or VKA.
- (5) There were insufficient numbers of patients on ticagrelor or prasugrel in both PIONEER AF-PCI and RE-DUAL PCI to conclusively assess the safety of combining these more powerful P2Y₁₂ inhibitors in dual or triple therapy regimens.
- (6) In VKA-treated patients, a PCI seems safe without bridging and without additional periprocedural heparin.³²⁰ It is unknown if this applies also to NOACs, since most clinical studies have suggested interruption of NOAC therapy at PCI. A small pilot study in 50 stable patients undergoing planned PCI and on DAPT suggests that pre-procedural dabigatran provides insufficient anticoagulation during PCI.³²¹

A similar study with rivaroxaban, however, showed suppressed coagulation activation after elective PCI, without increased bleeding.³²²

The safety of performing a PCI in patients on a NOAC, with or without additional periprocedural intravenous anticoagulation still needs to be prospectively studied in larger clinical trials.

Scenario 1: coronary interventions in patients with known atrial fibrillation already on non-vitamin K antagonist oral anticoagulant

Whereas guidelines recommend maintaining VKA patients uninterrupted on their treatment, both during elective or urgent PCI, NOACs should preferably be temporarily discontinued for elective interventions and upon presentation with non-ST-elevation ACS where early coronary angiogram is anticipated, as has been done during the pivotal NOAC vs. VKA AF trials. NOACs should be continued in non-invasively-managed ACS patients. Performing a PCI (scheduled or not) under NOAC is different than under VKA for many reasons: last dose and adherence needs to be carefully scrutinized; uncertainty about the extent of anticoagulation in the absence of mainstream/point of care tests, and hence uncertainty about stacking of additional periprocedural anticoagulants; variability in renal function (especially when unknown in an acute setting); singular anti-factor II or Xa blockade vs. multifactor antagonism with VKA, etc. Temporary discontinuation of the short-acting NOACs allows safe initiation of antiplatelet therapy and standard local anticoagulation practices periprocedurally.

In the 2016 ESC AF guideline and 2017 DAPT focused update, the use of ticagrelor or prasugrel as part of a triple therapy regimen is discouraged (Class III, level of evidence C), but no comments are made on dual therapy with combination of ticagrelor or prasugrel and a NOAC as possible alternative for triple therapy with aspirin, clopidogrel and a NOAC.^{3,32} It leaves the opportunity to use one of these newer P2Y₁₂ inhibitors with a (N)OAC under certain circumstances such as perceived high thrombotic risk, ACS, or prior stent thrombosis. In a subset of the RE-DUAL PCI study the use of ticagrelor appeared safe and effective in the setting of dual therapy (Oldgren *et al.*, presented at AHA 2017). Triple anticoagulation with any of the new P2Y₁₂ inhibitors, on the other hand, is clearly discouraged beyond the first day(s) post-PCI. A signal for a relevant role of 'clopidogrel resistance' has so far not surfaced clinically in the large outcome trials but experience in earlier DAPT studies may provide a rationale for further studies on the use of newer P2Y₁₂ inhibitors in the setting of dual anticoagulation.

In-hospital management

A general flow diagram indicating possible scenarios is provided in Figure 10.

Elective coronary intervention (stable coronary artery disease)

Contemporary DES are preferred to shorten exposure to dual or triple therapy after the procedure (see below) but also to avoid the need for repeat interventions. There is no reason anymore to opt for a BMS as a strategy to reduce DAPT duration.^{32,314} Sole balloon angioplasty or bypass surgery should be considered as an alternative

in patients in need for chronic anticoagulation due to the reduced need for long-term dual or triple therapy.

There is no rationale for switching a NOAC to VKA after (or just prior) to elective PCI, since this may be associated with an increased bleeding and thromboembolic risk compared with restarting the NOAC.

NOAC therapy should be discontinued before patients are taken to the cath lab and the procedure be performed at least (12–)24 h after last intake (see **chapter 12**). Periprocedural anticoagulation should be used per local practice. Unfractionated heparin (70 IU/kg) or bivalirudin rather than enoxaparin is preferred.³²³ Unfractionated heparin should be administered to target ACT or aPTT levels per standard clinical practice. Bivalirudin may be an alternative because of its very short therapeutic half-life.

Acute coronary syndrome

In the absence of contraindications, all NOAC patients developing an ACS should receive low-dose aspirin immediately at admission (150–300 mg loading dose) as well as a P2Y₁₂ inhibitor. Since clopidogrel as well as the newer P2Y₁₂ inhibitors take considerable time to achieve their maximal antiplatelet effect in unstable patients, P2Y₁₂ inhibition without aspirin cannot be recommended in the acute setting. In frail patients at high bleeding risk, aspirin only might be a safer initial therapy awaiting invasive management, when indicated.

ST-elevation myocardial infarction. In case of a STEMI, primary PCI via a radial approach is strongly recommended over fibrinolysis.³²⁴ It is recommended to use additional parenteral anticoagulation (i.e. UFH, enoxaparin, or bivalirudin, but not fondaparinux), regardless of the timing of the last dose of NOAC. Unless used for bail-out situations, routine glycoprotein IIb/IIIa inhibitors should be avoided.

If fibrinolysis is the only available reperfusion therapy, it may be considered if the NOAC-treated patient presents with normal dTT, ECT, aPTT (for dabigatran), PT (for FXa inhibitors), and importantly, plasma levels below the reference range (*Table 9*). Also, additional UFH or enoxaparin in addition to fibrinolysis should be avoided until the NOAC effect has decreased (12 h or longer after last intake).

Non-ST-elevation myocardial infarction. After discontinuing the NOAC and awaiting the waning of its effect (12 h or longer after last intake; **chapter 12**), fondaparinux or enoxaparin can be initiated. The use of upstream glycoprotein IIb/IIIa inhibitors should be avoided in this setting. Unfractionated heparin or bivalirudin is only recommended in bail-out situations, awaiting an intervention (Class IIb C).³²⁵ To reduce the risk of access site bleeding, a radial approach is preferred.³²⁴

In more urgent situations, the same approach as in primary PCI STEMI patients should be followed, as described above.

Post-procedural resumption of anticoagulation

In stabilized patients (i.e. no recurrent ischaemia or need for other invasive treatments), anticoagulation can be restarted as soon as parenteral anticoagulation has been stopped. There are no data to recommend switching to VKA (which may even be associated with higher bleeding and thromboembolic risks, especially in VKA-naïve patients in whom the correct VKA dose is unknown). The same applies for AF patients after coronary bypass grafting.




Figure 10 Acute management of elective percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulant.

The initial combination of antiplatelet agent(s) and NOAC as well as the subsequent duration of aspirin or P2Y₁₂ inhibitor treatment need to be individualized, based on a careful assessment of ischaemic vs. bleeding risk (Figure 11). Based on PIONEER AF-PCI and REDUAL PCI, triple treatment should be kept as short as possible (see chronic phase below). An alternative is to opt for dual therapy with only a NOAC and a P2Y₁₂ inhibitor within 1–7 days after the acute phase.

While awaiting the results of trials with apixaban and edoxaban the 150 mg dabigatran dual therapy appears to be the preferred choice over triple therapy for the majority of patients based on both the results from RE-LY²⁸ and REDUAL PCI¹⁴¹; dual therapy using 110 mg dabigatran or rivaroxaban 15 mg (10 mg in renal insufficiency) appears as a viable alternative for patients with estimated high bleeding risk—provided that dabigatran or rivaroxaban *per se* appear as a good choice for this individual patient based on age (see chapter 18.1), comorbidities (e.g. renal insufficiency; see chapter 6), interactions (see chapter 5), and others.

Management from discharge to 1 year post-acute coronary syndrome/percutaneous coronary intervention

Combining one or two antiplatelet agents with chronic anticoagulation (NOAC or VKA) significantly increases bleeding risk, regardless

of the large varieties of possible combinations.^{141,170,300,302,308,326} Despite two recent studies on dual or triple therapy with NOAC (and two more underway), there is no one combination fitting every patient. The type and level of anticoagulation as well as one or two antiplatelet agents and its duration need to be highly individualized, based on atherothrombotic risk, cardioembolic risk, and bleeding risk.^{3,32,33} It is highly recommended to formally assess stroke and ischaemic event risk using validated tools such as the CHA₂DS₂-VASc and GRACE scores.³² Estimating the bleeding risk should lead to efforts to correct or reduce reversible bleeding risk factors.³ Reducing the time exposed to triple or even dual therapy needs to drive the physician's choice between the myriad of possible combinations for long-term therapy. Proton pump inhibitors should be encouraged in all patients with a combination of antiplatelets and anticoagulants, particularly in the setting of triple anticoagulation.

In patients at high ischaemic risk (e.g. after an ACS), a default time of triple therapy of 1 month up to 6 months is proposed, thereafter stepping down to dual therapy (with NOAC and either aspirin or clopidogrel) until 1 year.³² Triple therapy beyond 6 months after PCI is not recommended, and (much) shorter regimens will likely suffice for most patients. Factors that weigh in to shorten triple therapy with earlier switch to dual therapy are an estimated low atherothrombotic




Figure 11 Long-term treatment of patients on non-vitamin K antagonist oral anticoagulant therapy after elective percutaneous coronary intervention or acute coronary syndrome. There are innumerable possible variations on this global theme, as discussed in the text. Patient characteristics and institutional practices should be taken into account to *individualize the approach* to each and every single patient. This figure wants to create a 'backbone' as guidance for such tailored approaches. A: aspirin 75–100 mg OD; C: clopidogrel 75 mg OD; Tica: Ticagrelor 90 mg BID. *If triple therapy needs to be continued after discharge clopidogrel is preferred over ticagrelor (due to lack of data).

risk or a high (uncorrectable) bleeding risk. Conversely, procedural and/or anatomical factors may drive longer triple therapy regimens. Beyond those patients at very high ischaemic risk, early dual therapy may well become the default strategy for most patients based on PIONEER AF-PCI and RE-DUAL PCI (while awaiting results from AUGUSTUS and ENTRUST-AF PCI).^{32,310}

In a small subset of patients with a low stroke risk (CHA₂DS₂-VASc of 0–1 in males or 1–2 in females, i.e. only ACS) and elevated bleeding risk, one could opt to treat with DAPT only, without anticoagulants, from the onset.³⁰⁷

Chronic coronary artery disease setting (≥ 1 year post-acute coronary syndrome/percutaneous coronary intervention)

The 2017 ESC DAPT and 2016 AF guidelines recommend discontinuing any antiplatelet agent at 12 months after a PCI or ACS episode (see following paragraphs) and to only consider keeping one antiplatelet plus a (N)OAC beyond 12 months in patients at very high risk of coronary events.^{3,32} Switching to NOAC monotherapy at an earlier stage (e.g. at 6 months) could represent an alternative for patients at low ischaemic- and high bleeding risk after a PCI for stable angina.

Independent of the chosen anticoagulation regimen and timing, the patient needs to be discharged with a pre-specified planned downgrade schedule of antithrombotic/antiplatelet agents to reduce the longer-term risk of bleeding while protecting against coronary events. Such a schedule should be prominently delineated in the discharge letter, and reviewed at every following patient visit.

Scenario 2: management of the patient with a recent acute coronary syndrome (<1 year) who develops new-onset atrial fibrillation

Current ACS guidelines recommend DAPT for up to 1 year after the acute event in patients without indication for OAC, while high-risk patients might require an even longer DAPT duration.^{318,319} They do, however, also allow for shorter DAPT durations (3–6 months) in high bleeding risk ACS patients.^{32,33,327} If AF develops during the first year after an ACS and there is an indication for thromboembolic prevention with anticoagulation, (N)OAC should be started and the need for continuing DAPT carefully weighed against the increased bleeding risk. Following a scheme as outlined above (Management from discharge to 1 year post-ACS/PCI) appears reasonable in this setting.

Scenario 3: a stable coronary artery disease patient (acute coronary syndrome ≥ 1 year ago) develops atrial fibrillation

Stable CAD patients developing AF should receive anticoagulation, depending on their CHA₂DS₂-VASc score. Based on studies showing that VKAs alone are superior to aspirin post-ACS, and VKAs plus aspirin may not be more protective but associated with excess bleeding, anticoagulation only without additional antiplatelet agents is considered sufficient for most AF patients with stable CAD.^{32,316,328}

In the four Phase III NOAC AF trials, about one third of the patients had CAD and 15–20% of patients had a prior MI.^{28–31} No interaction in terms of efficacy or safety was observed between patients with or without a prior MI, although it is unclear in how many patients antiplatelet therapy was maintained and for how long. It is likely that the advantages of NOACs (in monotherapy) over VKAs are preserved in CAD patients with AF. Also for dabigatran, the net clinical benefit was maintained and total myocardial ischaemic events were not increased, which was further supported by the very large registry follow-up in 134 000 older patients treated with dabigatran or VKA, which did not reveal any increased risk for MI.^{79,329} Since direct comparative data are lacking, there is no strong argument for choosing one NOAC over another in this setting based purely on the existence of stable coronary artery disease.

15. Avoiding confusion with non-vitamin K antagonist oral anticoagulant dosing across indications

In order to replicate the positive findings of the RCTs, using the correct dosing is critical, especially since all NOACs are also studied in other indications. With four NOACs available in different dosages for different indications and with different dose reduction criteria, identification of the correct dose has become more complicated and is one of the key challenges in the daily use and individualization of treatment.

Table 13 gives an overview of the currently available NOACs and their doses in the different populations and indications, including the relevant dose reduction criteria for each NOAC and indication.

16. Cardioversion in a non-vitamin K antagonist anticoagulant-treated patient

Based on current ESC guidelines,³ in patients with AF of ≥ 48 h (or unknown) duration undergoing electrical or pharmacological cardioversion, effective oral anticoagulation needs to be established for at least 3 weeks prior to cardioversion or transesophageal echocardiography (TOE) performed to rule out left atrial thrombi. After cardioversion, continuous oral anticoagulation is mandatory for at least another 4 weeks, irrespective of CHA₂DS₂-VASc score.^{3,348} Different scenarios have to be distinguished: electrical cardioversion

in a patient who is on chronic treatment with a NOAC and now requires cardioversion for a new bout of AF, and cardioversion in a patient newly diagnosed with AF and naïve to anticoagulation (Figure 12).

Cardioverting an atrial fibrillation patient treated for ≥ 3 weeks with non-vitamin K antagonist oral anticoagulant

Analyses from RE-LY (dabigatran), ROCKET-AF (rivaroxaban), and ARISTOTLE (apixaban) suggest that electrical cardioversion in patients treated with NOACs has a similar (and very low) thromboembolic risk as under warfarin.^{28–30} Later prospective trials with rivaroxaban (X-VerT),³⁴⁹ edoxaban (ENSURE-AF),³⁵⁰ and apixaban (EMANATE, Ezekowitz et al., presented at ESC 2017) have confirmed the low peri-cardioversion stroke risk in patients treated with a NOAC for ≥ 3 weeks compared with warfarin. These trials did not include sufficient patient numbers to demonstrate statistically sound non-inferiority. In congregate, however, these data indicated that a cardioversion without TOE seems reasonably safe under regular and continued NOAC intake, provided that adequate anticoagulation has been installed for 3 weeks before cardioversion.³ As there is no coagulation assay available for any NOAC that provides information on effective anticoagulation over the past 3 weeks, the patient needs to be inquired about adherence over the last weeks and his/her answer documented in their file. If in doubt about adherence, a TOE should be performed prior to cardioversion under a NOAC. Importantly, it has to be kept in mind that left atrial thrombi can also form in spite of adequate long lasting oral anticoagulation with a VKA or NOAC. Therefore, it remains an individual decision whether to perform a cardioversion with or without prior TOE. For this decision, the individual thromboembolic risk of a patient according to the CHADS₂ or CHA₂DS₂-VASc score can be considered: in 1.6–2.1% of therapeutically anticoagulated patients a TOE prior to AF ablation revealed thrombi or sludge in the left atrium, with the risk of thrombus correlating with the CHADS₂ score (thrombus incidence $\leq 0.3\%$ in CHADS₂ 0–1 patients, thrombus incidence 0.5% in CHADS₂ ≥ 2 patients).^{351–353}

Cardioverting atrial fibrillation of > 48 h in a patient not on non-vitamin K antagonist oral anticoagulant

For the scenario of cardioversion in an AF patient who is not on NOAC, the X-VerT,³⁴⁹ ENSURE-AF,³⁵⁰ and EMANATE (presented at ESC 2017)³⁵⁴ studies with rivaroxaban, edoxaban, and apixaban, respectively, offered important data since they included 57%, 27%, and 100% of OAC-naïve patients, respectively. The cardioversion strategy was either early (with TOE) or without TOE (delayed strategy, i.e. with 3–8 weeks anticoagulation before cardioversion). OAC-naïve patients tended to have slightly higher thromboembolic event rates (which was not statistically significant). Overall, there was no difference in ischaemic or bleeding events between NOAC and VKA groups (except for lower ischaemic events with apixaban in the EMANATE trial), nor between early and delayed groups, although neither of the trials were powered for non-inferiority. In EMANATE, about half of the patients received an initial loading dose of 10 mg (followed by 5 mg BID); also these patients did not show a higher

Table 13 NOACs and approved/studied doses across indications

Stroke prevention in atrial fibrillation (SPAF)		
	Standard dose	Comments/dose reduction
Apixaban ³⁰	2 × 5 mg	2 × 2.5 mg if two out of three: weight ≤60 kg, age ≥80 years, serum creatinine ≥133 μmol/(1.5 mg/dL) [or if CrCl 15–29 mL/min]
Dabigatran ²⁸	2 × 150 mg / 2 × 110 mg	No pre-specified dose-reduction criteria ^a
Edoxaban ³¹	1 × 60 mg	1 × 30 mg if: weight ≤60 kg, CrCl ≤50 mL/min, concomitant therapy with strong P-Gp inhibitor (see chapter 5)
Rivaroxaban ²⁹	1 × 20 mg	1 × 15 mg if CrCl ≤50 mL/min
Treatment of DVT/PE		
	Initial therapy	Remainder of treatment phase
Apixaban ³³⁰	2 × 10 mg, 7 days	2 × 5 mg, no dose reduction
Dabigatran ³³¹	Heparin/LMWH	No pre-specified dose-reduction criteria ^b
Edoxaban ³³²	Heparin/LMWH	1 × 60 mg, same dose reduction as for SPAF (see above)
Rivaroxaban ^{333,334}	2 × 15 mg, 21 days	1 × 20 mg, no dose reduction ^c
Long-term prevention of recurrent DVT/PE (i.e. after 6 months)		
	Standard dose	Comments/dose reduction
Apixaban ³³⁵	2 × 2.5 mg	
Dabigatran ³³⁶	2 × 150 mg	No pre-specified dose-reduction criteria ^d
Edoxaban	not specifically studied	
Rivaroxaban ³³⁷	1 × 10 mg	e
VTE prevention post-major orthopaedic surgery		
	Standard dose	Comments/dose reduction
Apixaban ³³⁸	2 × 2.5 mg	
Dabigatran ^{339,340}	1 × 220 mg	f
Edoxaban ^{341,342}	1 × 30 mg	Not approved in Europe (only studied in Asia)
Rivaroxaban ^{343–346}	1 × 10 mg	
Stroke prevention post-PCI (with concomitant atrial fibrillation) ^g		
	Standard dose	Comments/dose reduction
Apixaban	To be determined (pending results of AUGUSTUS trial)	
Dabigatran ¹⁴¹	150 mg BID or 110 mg BID	+Clopidogrel or Ticagrelor; no dose reduction
Edoxaban	To be determined (pending results of ENTRUST-AF PCI trial) ³¹⁰	
Rivaroxaban ³⁰⁸	15 mg OD (+Clopidogrel)	Dose reduction to 10 mg OD if CrCl 30–49 mL/min

Secondary prevention of atherothrombotic events post-ACS (without AF)		
	Standard dose	Comments/dose reduction
Rivaroxaban ¹⁷¹	2.5 mg BID	In addition to Aspirin ± P2Y ₁₂ inhibitor
Secondary prevention of atherothrombotic events in stable CAD (without AF) ^h		
	Standard dose	Comments/dose reduction
Rivaroxaban ³⁴⁷	2.5 mg BID	In addition to Aspirin ^h

ACS, acute coronary syndrome; CAD, coronary artery disease.
^aSmPC: 2 × 110 mg if age ≥80 years, concomitant verapamil, increased risk of GI bleeding.
^bSmPC: 2 × 110 mg if age ≥80 years, concomitant verapamil, increased risk of GI bleeding (based on PK/PD analyses; not studied in this setting).
^cSmPC: 15 mg if risk of bleeding outweighs risk for recurrent DVT and PE (based on PK/PD analyses; not studied in this setting).
^dSmPC: 2 × 110 mg if age ≥80 years, concomitant verapamil (both based on PK/PD analyses; not studied in this setting).
^eSmPC: 1 × 20 mg in patients. At high risk of recurrence.
^fSmPC: 1 × 150 mg if CrCl 30–50 mL/min; concomitant verapamil, amiodarone, quinidine; age >75 years.
^gAs outlined in detail in **chapter 14**, both PIONEER AF-PCI as well as RE-DUAL PCI were powered for safety and were underpowered to determine non-inferiority for individual efficacy endpoints.
^hAs studied in COMPASS; approval of this indication and regimen is pending.




Figure 12 Cardioversion work-flow in atrial fibrillation patients treated with NOACs, depending on the duration of the arrhythmia and prior anti-coagulation. TOE, transoesophageal echocardiography.

bleeding tendency. The 10 mg loading dose is not part of the official labelling (which may change in the near future). Taken together, a strategy with at least a single NOAC dose ≥4 h before cardioversion (≥2 h after apixaban loading dose) appears safe and effective in patients with AF of ≥ 48 h duration, provided that a TOE is performed prior to cardioversion. The alternative is starting anticoagulation with a NOAC for at least 3 weeks followed by cardioversion (without TOE unless high risk patient or deemed non-adherent).

Cardioverting atrial fibrillation of ≤ 48 h in an anticoagulation-naïve patient

Even in patients with recent onset AF of ≤ 48 h, different observational studies have shown a lower thromboembolic incidence rate with vs. without anticoagulation, especially in those with a $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$ and AF duration ≥ 12 h.^{355,356} Neither X-VerT nor ENSURE-AF provided information on whether intake of at least one dose of NOAC is a feasible strategy in patients with AF of ≤ 48 h duration, who are currently often cardioverted after a single dose of LMWH (with continuation of anticoagulation for ≥ 4 weeks). Some of such patients were included in EMANATE, but publication of the final results is still pending and subgroup results are unknown.

In the absence of data, adherence to current institutional practice with heparin/LMWH with or without TOE may be prudent in such patients. Given the consistent efficacy and safety of NOACs in patients with AF ≥ 48 h combined with the similar pharmacodynamic and -kinetic properties of NOACs and LMWH, the use of a single dose of NOAC (2)–4 h before cardioversion to replace LMWH may be justified in patients with AF < 48 h, without a TOE. Nevertheless in high risk patients (i.e. $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 4$) or those in whom there is any doubt about the onset of AF, a TOE strategy or a strategy with longer term anticoagulation (at least for 3 weeks before cardioversion) is recommended. It needs to be kept in mind that the 48 h cut-off is not binary and cardioversion in the setting of even shorter durations of AF have been associated with an increased risk of stroke, e.g. cardioversion after 12–48 h vs. < 12 h).^{356,357}

Duration of anticoagulation post-cardioversion

The long-term management of patients post-cardioversion depends on the individual patient's $\text{CHA}_2\text{DS}_2\text{-VASc}$ score. Men and women with a $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$ and ≥ 3 , respectively, require long-term anticoagulation independent of the 'success' of cardioversion according to current guidelines.³ This is also true for AF with a clear 'trigger' including pulmonary embolism, sepsis, or major surgery, since the trigger does not negate underlying structural or vascular factors associated with increased thromboembolic risk. For AF of > 48 h duration and a low $\text{CHA}_2\text{DS}_2\text{-VASc}$ score (0 in men, 1 in women) anticoagulation needs to be continued for 4 weeks post-cardioversion. In contrast, it is currently unknown how long (if at all) the latter patients should be anticoagulated if AF is of shorter duration (especially when < 12 h), since AF and/or cardioversion may contribute to atrial mechanical and/or endothelial dysfunction for hours to days.³⁵⁷

Management of a patient with documented left atrial appendage thrombus

Patients in whom TOE identifies a left atrial thrombus should not undergo cardioversion. Observational and prospective data have not shown a different thrombus incidence in patients treated with NOAC or VKA.^{349,358–360} There are no comprehensive hard clinical endpoint data on the best strategy how to treat a left atrial thrombus with either form of anticoagulant. Previously, standard therapy consisted of VKA therapy with rigorous follow-up and INR monitoring

until resolution of the thrombus (with heparin bridging if necessary). Recently, the prospective X-TRA study indicated a thrombus resolution rate of 41.5% (22/53 patients) with standard dose rivaroxaban (20 mg/d)³⁶¹ – comparable to the retrospective CLOT-AF registry in which left atrial thrombus resolution was observed in 60/96 patients (62.5%) in heparin/warfarin treated patients.³⁶¹ Similarly, in the EMANATE trial, thrombus resolution rate was similar in patients treated with apixaban (52%, 12/23) as with conventional therapy (56%, 10/18; Ezekowitz et al.,⁸ presented at ESC 2017). Individual case reports are equally available for the other NOACs; the RELATED AF study (with dabigatran; NCT02256683) is still ongoing. In congregate, these data indicate that using NOACs for left atrial thrombus resolution may be an option (best data available for rivaroxaban and apixaban), particularly in patients where a VKA is not well tolerated or adequate INR control cannot be obtained.

17. Atrial fibrillation patients presenting with acute stroke while on non-vitamin K antagonist oral anticoagulants

According to controlled clinical trials, the incidence of ischaemic stroke remains 1–2% per year in patients with AF despite anticoagulant treatment. Adherence to medication needs to be assessed in case of stroke in NOAC treated AF patients. The measurement of anticoagulant plasma level at the time of hospital admission may help to optimize secondary stroke prevention.³⁶² In addition, alternative causes of stroke should be assessed in any AF patient.

Management the acute phase of stroke in NOAC treated AF patients

Patients with acute ischaemic stroke

According to current guidelines and official labelling, thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is approved within 4.5 h of onset of stroke symptoms but should not be administered in patients on full anticoagulation (e.g. $\text{INR} \geq 1.7$ in VKA treated patients) (Figure 13).³⁶³ Thrombolytic therapy cannot be given within 24 h after the last intake of a NOAC due to their plasma half-lives (Table 6), which may even be prolonged in renal insufficiency (see chapter 6), the elderly (see chapter 18) and other situations. The case is different for dabigatran due to the availability of the rapid acting specific reversal agent, idarucizumab (see chapter 11). After reversal and assessment of coagulation status, intravenous thrombolysis within 4.5 h of onset of moderate to severe stroke seems feasible and safe according to case series.^{364,365} In the absence of randomized studies demonstrating the overall efficacy and safety of this approach, balancing the anticipated benefit of this approach vs. its risks is of paramount importance. It remains to be demonstrated whether the same approach will be safe and effective also for Xa-inhibitors once andexanet alpha becomes available.

Published case series suggest that rt-PA may also be safe in patients with low plasma concentrations of NOACs.^{366,367} Despite recent advances reliable and sensitive rapid (point-of-care) tests for the individual NOACs are not widely available yet.^{362,368,369} However, the use of rt-PA may be considered in selected patients on a NOAC in




Figure 13 Acute management of acute ischaemic stroke in a patient on non-vitamin K antagonist oral anticoagulant. *Currently only available for dabigatran (idarucizumab). #Perform systemic thrombolysis only if there are no (other) contraindications for intravenous application of recombinant tissue plasminogen activator according to its label. %Perform endovascular thrombectomy only if there is a target vessel occlusion and procedure is indicated and feasible according to present evidence. **According to expert consensus.³⁷⁰

cases in which a reliable and NOAC specific coagulation assessment (see **chapter 7**) is available without long delay and demonstrating a concentration <30 ng/mL for rivaroxaban, apixaban, or edoxaban (if measured more than 4 h after drug administration), a reference value which is based on expert consensus only.³⁷⁰ Since the efficacy and safety of this strategy needs to be further evaluated in clinical studies, we urge for the implementation of easy-to-use point-of-care testing for the emergency setting. In contrast, the use of thrombolysis in situations with uncertainty about the anticoagulation status (e.g. in AF patients with aphasia, unknown time of last NOAC dose, and lack of availability of rapid assessment of plasma levels) cannot be recommended.

There is a proven benefit of endovascular thrombectomy up to 7.3 h after stroke onset in selected non-anticoagulated patients with a distal occlusion of the internal carotid artery or the proximal middle cerebral artery.³⁷¹ Interestingly, endovascular thrombectomy also seems to be beneficial in highly selected stroke patients with a distal occlusion of the internal carotid artery or the proximal middle cerebral artery and favourable perfusion mismatch (according to the DEFUSE or DAWN study) within 6 to up to 24 h of last seen normal.^{372,373} The European Stroke Organization recommendations now mention the use of endovascular thrombectomy as ‘first-line treatment’ in patients with contraindication for intravenous thrombolysis, while the AHA’s guidelines provide no specific recommendation in this regard.^{363,374} Although the trials underlying these recommendations either excluded or contained just a few patients on VKA or NOAC, the small amount of data available suggests that

endovascular thrombectomy may be safe also in these individuals. Of note, the potential impact of present anticoagulation on reperfusion-related bleeding risk has to be taken into account and a comparably high rate of asymptomatic haemorrhagic transformation was observed in a prospective registry including 28 NOAC patients undergoing mechanical recanalization.³⁷⁵ Further prospective data are urgently needed.

Patients with acute intracranial bleeding

About two thirds of all NOAC-related intracranial bleedings (ICBs) are intracerebral and about one third of all ICBs are subdural bleedings.^{376,377} According to a meta-analysis of retro- as well as prospective studies, patients with intracerebral bleeds on NOAC (without using idarucizumab as a specific reversal agent of dabigatran) had the same poor prognosis as patients on VKA,³⁷⁸ while a more recent and much larger retrospective analysis of the Get With the Guidelines-Stroke program found a more favourable outcome with NOACs compared with VKA.³⁷⁹ A neurologist/stroke physician should examine all patients presenting with ICB on a NOAC, and neurosurgical consult should be solicited.

Recommendations for the treatment of ICB under oral anticoagulants are published, but the available level of evidence is low for NOAC-related ICB. In analogy to patients with acute ICB being treated with warfarin, discontinuation of the drug, urgent blood pressure management and rapid correction of the coagulation status (see also **chapter 11**) is needed to limit haematoma enlargement in patients under NOAC.^{376,380,381} Whether the use of PCC is helpful

in NOAC-related ICB is a matter of debate since a retrospective multicentre analysis did not prove a significant benefit on haematoma enlargement.³⁸² For dabigatran related ICB reversal is possible via infusion of idarucizumab (see **chapter 11**). According to a reported case series,³⁶⁵ haematoma growth was observed in two out of twelve ICB patients treated with dabigatran receiving idarucizumab on hospital admission. Despite present recommendations, the efficacy of this reversal strategy is unclear and needs to be further evaluated in clinical studies.

Management in the post-acute phase

Atrial fibrillation patients post-ischaemic stroke

There is no evidence from RCTs to prefer one NOAC over the other or to switch from one NOAC to another in patients with a history of ischaemic stroke under NOAC therapy (*Figure 14*). Appropriate dosing as well as patient specific issues need to be assessed.^{41,93,202} Substantial study data regarding timing of reinstitution of oral anticoagulation by using a NOAC after transient ischaemic attack (TIA) or stroke in AF patients are missing,³⁸³ as Phase III trials excluded patients within 7–30 days after stroke.

Therefore, present recommendations are based on consensus opinion, and NOACs should be (re-) initiated in analogy to clinical practice with VKAs. Recommendations on (re-) starting of oral anticoagulation after ischaemic stroke must outweigh (recurrent) stroke risk vs. secondary haemorrhagic transformation (*Figure 14*).^{3,383} As stated in the current ESC guidelines,³ oral anticoagulation using a NOAC may be continued (according to prescription and label) or started one day after a transient ischaemic attack (TIA) and exclusion of ICB by imaging. If stroke size is not expected to substantially increase the risk of secondary haemorrhagic transformation in patients with mild stroke, oral anticoagulation may be initiated ≥ 3 days after an ischaemic stroke. In patients with moderate stroke, anticoagulation may be started ≥ 6 –8 days and in patients with severe stroke at ≥ 12 –14 days, after excluding secondary haemorrhagic transformation by repeating brain imaging [using computed tomography (CT) or magnetic resonance imaging (MRI)].^{383–385}

Due to the rapid onset of action of NOACs as well as an associated risk of bleeding, ‘bridging’ with heparin (LMWH or UFH) is not recommended. Moreover, a meta-analysis revealed that administration of parental anticoagulants within 7–14 days after ischaemic stroke is associated with a significant increase in symptomatic ICB.³⁸⁶

Atrial fibrillation patients with ischaemic stroke and concomitant atherosclerosis

Besides a (well-tolerated) statin therapy, temporally limited addition of aspirin to a NOAC may be considered in selected patients if underlying large-vessel disease is suspected and bleeding risk is considered to be comparably low. However, evidence for both approaches is lacking and further studies are required. Patients with AF and known carotid atherosclerosis with an asymptomatic stenosis of the internal carotid artery should be treated with a statin and an oral anticoagulant, without the need for additional antiplatelet therapy, similar to the situation in stable coronary heart disease (see **chapter 14**). Acute stroke patients with AF and ‘symptomatic’ high-grade carotid stenosis should preferably undergo carotid endarterectomy,³⁸⁷ as carotid stenting would result in the need for dual

antiplatelet therapy in addition to anticoagulation therapy with a subsequently higher risk of major bleeding. In patients undergoing endarterectomy, aspirin is recommended prior to and for some days after surgery. Aspirin should be stopped after (re-) starting oral anticoagulation.

Patients post intracranial bleeding

Apart from its immediate prognosis, an ICB in the setting of AF is also associated with later ischaemic stroke and mortality, partly due to the cessation of anticoagulation after ICB (*Figure 15*).^{388–390} Evidence-based guidelines regarding the use of NOACs in AF patients after ICB are not available. A history of a spontaneous ICB constitutes a contraindication against anticoagulation according to labelling of VKAs and NOACs, unless the cause of the bleeding (like uncontrolled hypertension, aneurysm or arteriovenous malformation, or medical ‘triple’ therapy) has been reversed.³ A recent meta-analysis of observational studies demonstrates that restarting VKA (but not antiplatelet agents) is associated with a significantly lower rate of ischaemic stroke without significantly increasing the risk of recurrent ICB.³⁸⁹ However, publication bias as well as selection bias have to be taken into account. In the absence of RCTs, a case-by-case consideration is needed whether or not to reintroduce anticoagulation of any type in patients who have experienced an anticoagulation-related ICB (*Figure 15*).³ Adequate blood pressure control is of paramount importance in all patients post ICB.³⁸⁰ Left atrial appendage occlusion may be considered as potential substitute for long-term anticoagulation in AF patients post-ICB.³ However, this strategy requires a period of antiplatelet treatment post-deployment, which also carries a risk of ICB. The safety and effectiveness of shorter duration antiplatelet therapy (or foregoing anticoagulation altogether) is not known. Overall, RCT evidence for LAA occlusion after OAC-related ICB under OAC is missing, which is why, ideally, treatment should occur in the framework of a randomized trial to contribute to evidence.

Patients post intracerebral bleeding

In analogy to the management of VKA-related intracerebral bleeding, administration of NOACs may be restarted 4–8 weeks after intracerebral bleeding if the individual risk of cardioembolic stroke is estimated to be high and the risk of recurrent ICB is estimated to be lower.³⁹¹ In practice, however, the same risk factors (including old age, hypertension, and previous stroke) are predictive for ischaemic stroke as well as recurrent intracerebral bleeding.³⁸¹

Arguments for not resuming or initiating anticoagulation in intracerebral bleeding patients with AF should be assessed on an individual basis (*Figure 15*).^{3,380} Patients with (probable) cerebral amyloid angiopathy have a very high risk of recurrent ICB and should not be anticoagulated.³⁹⁰ Whether long-term anticoagulation should be avoided after a lobar bleed, as currently recommended by the AHA guidelines, is a matter of debate, since a recent meta-analysis of three retrospective studies indicate decreased mortality and favourable functional outcome after resumption of oral anticoagulation after intracerebral bleeding, irrespective of haematoma localization.³⁹¹

Patients post subarachnoid haemorrhage

There is little evidence to guide the resumption of OAC treatment in patients with AF following subarachnoid haemorrhage. A thorough




Figure 14 (Re-) initiation of anticoagulation after transient ischaemic attack/stroke. (Re-) start only in the absence of contraindications and if stroke size is not expected to substantially increase the risk of secondary haemorrhagic transformation. *Consider shorter delays to (re-) start a non-vitamin K antagonist oral anticoagulant if there is a very high risk of stroke recurrence (e.g. left atrial appendage thrombus) and no haemorrhagic transformation on follow-up brain imaging (using computed tomography or magnetic resonance imaging). Consider longer delays to (re-)start a non-vitamin K antagonist oral anticoagulant according to the recommendations made in the European Society of Cardiology Atrial Fibrillation Guidelines 2016. #Without proven evidence; consider inclusion of patient in an ongoing trial.




Figure 15 (Re-) initiation of anticoagulation post intracranial bleeding. #Without evidence; ideally include the patient in an ongoing trial. *Brain imaging (CT/MRI) should be considered before (re-)initiation of (non)-vitamin K antagonist oral anticoagulant.

angiographic evaluation and treatment of underlying aneurysm or arteriovenous malformation is needed. Moreover, neurological/neurosurgical evaluation regarding future risk of re-bleeding is key to balance the risk vs. benefit of OAC resumption in such cases. When

subarachnoid haemorrhage occurs in AF patients taking a NOAC in the absence of a remediable aetiology it seems prudent not to re-initiate OAC treatment. Despite the absence of data, LAA closure should be considered, ideally in the framework of a randomized trial.

Patients post epidural or subdural haematoma

Although there are no specific data, it appears to be safe to start or reinstitute anticoagulation about 4 weeks after (surgical removal of) traumatic epidural or subdural haematoma, if ongoing (chronic) alcohol abuse or a substantial risk of falling is not present (see **chapter 18**). Adequately dosed NOAC or no anticoagulation at the time of non-traumatic epidural or subdural haematoma does not support (re-) initiation of oral anticoagulation.³ According to clinical presentation and haematoma extension, brain imaging (using CT or MRI) is recommended before (re-) starting OAC.

18. NOACs in special situations

18.1. Non-vitamin K antagonist oral anticoagulants in the frail and older patients

The ≥75-year-old patient

The incidence of AF rises steadily with each decade.^{392,393} Stroke prevention in older AF patients is important as stroke risk rises dramatically with age.³⁹⁴ However, OAC remains underutilized in older age groups.³⁹⁵ Older people with AF do better on OAC than not and on NOACs rather than VKA.^{396–398}

All trials of NOAC treatment in AF included significant populations of older people (defined as ≥75 years) ranging from 31% to 43% in the individual trials, comprising over 27 000 older patients in whom

NOACs have been studied. Meta-analyses of NOAC trial data suggest no interaction of age for safety and efficacy.²⁴⁶ Importantly, the higher absolute risk resulted in a larger absolute risk reduction by using NOACs instead of VKA in these older patients, resulting in a lower number needed to treat compared to younger patients.³⁹⁹ Older patients had more bleeding but the overall pattern of bleeding observed (reduced intracranial and increased GI bleeding) showed no difference between NOACs and VKA.²⁴⁶ While ICB remains lower with all NOACs compared with VKA, individual trial results showed heterogeneity on the interaction between age and bleeding outcomes. There was a significant interaction between age and increased extracranial major bleeding with both doses of dabigatran.¹⁵⁵ Conversely, no significant age interaction on rates of extracranial major bleeding was seen with apixaban, edoxaban, or rivaroxaban compared with overall trial results.^{399–401} Importantly, certain comorbidities (renal insufficiency in particular, see **chapter 6**) are more common in the older patient, and the individual choice of the NOAC needs to take this into consideration. One interesting study investigating low-dose edoxaban in the management of elderly Japanese patients with atrial fibrillation who are ineligible for standard oral anticoagulant therapies (ELDERCARE-AF study) is currently ongoing.⁴⁰²

Frailty and falls

Frailty and pre-frail states are common with age and raise specific considerations with regard to the risk-benefit ratio of OAC. Frailty is commonly defined as a rules-based distinct phenotype or by clinical judgement of deficits in function in a frailty scale (see **Table 14**).^{403–405}

Among others, frailty is a risk for rapid deterioration of renal function (see **chapter 6**) and risk of falling. Community dwelling individuals over 65 years have a 1–2% risk of falling per year; only 5% of falls, however, result in fracture and hospitalization.⁴⁰⁶ Falls and risk of subdural haemorrhage in particular are often considered by physicians as a contraindication to OAC.⁴⁰⁷ While in states of severe frailty with poor physical functioning and limited life expectancy there may be limited benefit to OAC, a Markov decision analytic model has demonstrated that with VKA a patient would have to fall 295 times in order for the risk of a subdural haematoma to outweigh the benefit of anticoagulation.⁴⁰⁸ Given the even lower risk of subdural bleeding compared with VKA, this 'number needed to fall' would be even higher with the use of NOACs.

The risk of falling can be estimated using simple or more sophisticated tools (**Table 15**). The effect of NOACs vs VKA in patients at risk of falling was specifically analysed in two NOAC trials (prospectively defined in ENGAGE-AF TIMI 48, retrospectively in ARISTOTLE).^{52,409} The treatment effect of the respective NOAC was consistent in patients at increased vs. not at increased risk of falling. However, the larger absolute risk of events of patients at increased risk of falling resulted in a larger absolute risk reduction vs. VKA and, consequently, a lower number needed to treat compared to those not at an increased risk of falling.

In summary, frailty *per se* should not be an exclusion criterion to anticoagulate since frail and older patients are at an increased risk of stroke and have been shown to benefit from OAC. The benefit of NOACs over VKA has best been demonstrated for edoxaban and apixaban in this patient population. To improve things further, all

falling patients on OAC should be referred to a falls service for multidisciplinary assessment of diagnosis, risk and to address remediable pathology and/or prescribe interventions (e.g. exercise programs; home environmental assessment etc.) that reduce risk of further falls.^{411–413}

Dementia and anticoagulation

Dementia is common in older age groups. A stroke is a very significant event for patients with dementia with a greater risk of cognitive and functional decline, loss of independence and institutionalization compared to non-dementia patients.⁴¹⁴ Indeed, atrial fibrillation is itself a risk factor for dementia and there is encouraging evidence that use of OAC may reduce the risk of dementia in AF patients.^{415,416}

Dementia does pose unique considerations, however, when considering anticoagulation and in particular around patient capacity in decision making, choice of treatment and managing drug adherence safely. Importantly dementia should not be viewed as a general contraindication to anticoagulation, especially if well managed from a logistical point of view (see below). All patients with dementia should have a careful assessment of their ability to understand and make a treatment decision regarding OAC in AF, with indicative risks of stroke and bleeding provided. Where capacity is lacking, it may be reasonable for the physician to recommend treatment on the basis of the 'best medical interest' principle, ideally including next of kin assent.

Adherence to OAC intake is a significant consideration in dementia. Once daily medications, weekly tablet boxes, reminders or blister packing may be helpful. Paradoxically, the fact that others take care of providing medication to dementia patients may guarantee higher adherence. The possible advantages of electronic monitoring, or even telemonitoring, in this population should further be explored.⁵¹

18.2. Obesity and low body weight

Obesity

The WHO defines overweight and obesity as a body mass index (BMI) of greater than 25 and 30 kg/m², respectively. The incidence of obesity has tripled since 1975. In 2016, 650 million adults (13.1% worldwide population) were obese.⁴¹⁷ Among many other things, obesity also increases the risk of atrial fibrillation and recurrences of atrial fibrillation after successful ablation.^{418–420} As such, weight loss is an integral part in the multidisciplinary treatment of patients with AF and obesity.⁴²¹

Obesity affects the pharmacokinetics of drugs, including the volume of distribution (of lipophilic drugs in particular) as well as drug clearance. Indeed, renal blood flow and CrCl have been shown to be increased in obesity and could increase elimination of OACs.⁴²² A number of studies of VKA have indicated that obese patients require greater doses and longer lead-in periods for achieving therapeutic INR values.⁴²³

Studies of dabigatran reported no effect of weight on pharmacokinetic variables although analysis in older healthy individuals did not include very obese patients.^{159,166,182} Pharmacokinetic data on both rivaroxaban and apixaban initially reported weight-dependent changes on volume distribution and half-life across a range of weights; however, these were felt unlikely to be clinically significant.^{185,424,425} Data with edoxaban suggests low body weight may be a factor in

Table 14 The ‘Canadian Study of Health and Aging’ (CHSA) Clinical Frailty Scale

From <http://www.csha.ca> and Ref.⁴⁰⁴

(1)	Very fit – People who are robust, active, energetic, and motivated. These people commonly exercise regularly. They are among the fittest for their age.
(2)	Well – People who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally, e.g. seasonally.
(3)	Managing well – People whose medical problems are well controlled, but are not regularly active beyond routine walking.
(4)	Vulnerable – While not dependent on others for daily help, often symptoms limit activities. A common complaint is being ‘slowed up’, and/or being tired during the day.
(5)	Mildly frail – These people often have more evident slowing, and need help in high order IADLs (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation and housework.
(6)	Moderately frail – People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressing.
(7)	Severely frail – Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~6 months).
(8)	Very severely frail – Completely dependent, approaching the end of life. Typically, they could not recover even from a minor illness.
(9)	Terminally ill – Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise evidently frail.

IADL, instrumental activities of daily living.

reduced clearance of the drug,⁴²⁶ and a converse situation would seem plausible.

Concerns have been expressed about the reliability of the anticoagulant effect of NOACS in obese patients.^{427,428} Weight was not an exclusion criterion in any of the NOAC trials in AF or VTE. However, case reports of treatment failure with low serum levels of dabigatran have been reported in cases of severe obesity (BMI ≥40 kg/m²).^{429,430}

Apixaban demonstrated no difference in efficacy and safety in patients <60 kg vs. >60 kg,³⁰ but patients with a BMI ≥30 kg/m² had a trend towards a better outcome compared to the remainder of the study (independent of treatment).⁴³¹ This was in contrast to the reduced bleeding seen in the obese patient group in the AMPLIFY study of apixaban in the treatment of VTE.³³⁰ Similarly in ROCKET-AF, obese patients (BMI ≥35 kg/m²) had a reduced stroke risk compared with the remainder of the cohort, and there was no interaction for the efficacy and safety of rivaroxaban vs. warfarin depending on BMI.⁴³² ENGAGE-AF did not (yet) report a sub-analysis of efficacy and safety with edoxaban according to weight criteria.³¹ Clinical trial data from use of edoxaban in acute VTE, included 611 (14.1%) patients >100 kg and sub analysis by weight showed no difference in safety or efficacy.³³²

Because of limited data in extreme obesity, the use of VKA in patients with a BMI ≥40 kg/m² or weight >120 kg should be considered (in line with recommendations from the International Society on Thrombosis and Haemostasis).⁴²⁷ In rare case when a NOAC is needed in such circumstances, specific measurements of drug trough levels should be considered. This, however, should only be done under the guidance of a haematologist and in the knowledge that hard clinical outcome data do not exist for such an approach.

Low body weight

There is no unifying definition of low body weight and future criteria may need to be race specific as Asian populations tend to be smaller and leaner. Low body weight may increase exposure to any NOAC and as such increase the risk of bleeding.⁴³³ Importantly, patients with low body weight frequently present with other conditions and co-morbidities which may increase the risk of stroke as well as bleeding, including old age, frailty, cancer, and renal insufficiency. Of note, renal function may be overestimated in underweight patients due to their reduced muscle mass (especially when calculated with the MDRD formula; see **chapter 6**). As such, special care is needed when anticoagulating these patients.

Body weight ≤60 kg was a dose-reduction criterion for apixaban (if also age ≥80 years and/or creatinine ≥1.5 mg/dL, see **chapter 15**) as well as for edoxaban. For these drugs, efficacy and safety compared to warfarin was consistent in the (few) underweight patients when compared with the remainder of the study cohort.^{30,31} As such, both drugs may be a preferred choice for patients <60 kg.

Dabigatran was studied *post hoc* in patients with low body weight (<50 kg) with consistent efficacy and safety compared with the remainder of the study cohort.²⁸ However, observational studies have suggested that low BMI (<23.9 kg/m²) can be an independent predictor of bleeding events with dabigatran.⁴³⁴ In addition, frequently co-existing renal insufficiency may make dabigatran a less preferably option for the underweight patients. Also rivaroxaban showed similar efficacy and safety in an exploratory analysis of lower body weight, but only patients <70 kg were compared with those >70 kg.²⁹ No outcome data are available for patients with <60 kg or <50 kg in patients on the full AF dose of rivaroxaban.

Table 15 Examples of falls risk tools

(A) High risk of falls (from ENGAGE-AF TIMI 48) ⁵²				
Presence of one or more of				
<ul style="list-style-type: none">● Prior history of falls● Lower extremity weakness● Poor balance● Cognitive impairment● Orthostatic hypotension● Use of psychotropic drugs● Severe arthritis● Dizziness				

(B) Probability falls assessment ⁴¹⁰				
1 point for each 'Yes'				
Previous falls		Yes/No		
Medications				
>4		Yes/No		
Psychotropics		Yes/No		
Low visual acuity		Yes/No		
Diminished sensation		Yes/No		
Near tandem stand 10 s		Yes/No		
Alternate step test 10 s		Yes/No		
Sit to stand 12 s		Yes/No		

Score	0–1	2–3	4–5	6+
Probability of fall per year	7%	13%	27%	49%

Severely underweight patients (<50 kg) were clearly underrepresented in the large outcome trials. As such, even for NOACs that were dose-reduced based on body weight (apixaban and edoxaban), data are limited for these patients. Of note, bleeding may also be increased with VKA therapy in underweight patients.⁴³¹ If therapy with a NOAC is warranted in these individuals, measurement of trough levels may be considered to check for accumulation of the drug.⁴³⁵ However, no evidence-based recommendations can be given regarding (further) dose reduction in such cases.

18.3. Women of reproductive age

All OAC use should be considered with caution in women of child-bearing age and an appropriate test to rule out pregnancy and contraceptive counselling advice arranged before initiation of any agent. Abnormal uterine bleeding (AUB; formerly called *menorrhagia*), occurs in 9–14% of the general female population of reproductive age,⁴³⁶ which may be exacerbated by oral anticoagulants.⁴³⁷

In a recent case series of NOAC use in the treatment of acute VTE in women of reproductive age, rivaroxaban was associated with prolonged (>8 days) menstrual bleeding (27% vs. 8.3%, $P=0.017$), increased need for menorrhagia-related medical or surgical intervention (25% vs. 7.7%, $P=0.032$), and more adaptations of anticoagulant therapy (15% vs. 1.9%, $P=0.031$) compared with VKA.⁴³⁸ A similar trend towards increased AUB with rivaroxaban compared to enoxaparin has also been reported.⁴³⁹ Registry data report a 32% incidence of AUB in women of reproductive age ($n=178$) on factor Xa inhibitor.⁴⁴⁰ Most cases were managed successfully with change of hormonal or anticoagulation therapy, including temporary discontinuation or cessation of factor Xa inhibitor medication. Some authors have expressed concern about the lack of robust data for NOAC use in this population with AF.⁴⁴¹ In any case, women should be counselled about the risk of increased menstrual bleeding while on NOAC and monitored carefully especially during the first cycles after NOAC initiation.⁴⁴²

All cases of AUB on OAC need to have gynaecological assessment for underlying structural problems and possibility of local hormonal treatments and/or surgical procedure to reduce risk of recurrence of AUB. Importantly, NOACs are contraindicated in pregnancy as well as during breastfeeding.

18.4. Non-vitamin K antagonist oral anticoagulants in Athletes

AF is the most common arrhythmia in athletes and endurance athletes are known to be more prone to AF.^{443–446} Additional risk factors for stroke may be uncommon in this population; however, older individuals are increasingly engaged in competitive and/or vigorous sports activities.⁴⁴⁷

If the CHA₂DS₂-VASc score is ≥ 1 in men and ≥ 2 in women, the use of anticoagulation may be warranted in such settings according to current guidelines.³ Traditional advice to athletes on OAC for VTE has been to avoid contact sports while on treatment and there is little published evidence on the use of NOACs in AF in such populations. The use of a OD agent may be preferable with intake in the evening to avoid high levels of the drugs during the actual exercise, but no outcome data are available to support this. All athletes presenting with AF should have a full cardiological assessment.

18.5. Epilepsy

A risk of seizures has been reported in >5% of overall post-stroke patients.^{448,449} Following an unprovoked seizure after stroke, the risk of subsequent unprovoked seizures is about 65% within 10 years.⁴⁵⁰

OAC poses a special risk for patients with epilepsy due to the risk of injury during a seizure (with or without falling). Most seizures in older people or post-stroke patients are focal in onset. However, patients who do suffer rare generalized atonic seizures are particularly vulnerable to head trauma while tongue biting is a risk in the tonic component of generalized seizures.

Anticoagulation is affected by antiepileptic drugs via various potential interactions (Table 5).¹⁴⁷ A number of antiepileptic drugs can in addition cause thrombocytopenia or platelet dysfunction.¹⁴⁷ The significance of these drug–drug interactions is still largely unknown with only occasional case reports available. In

some situations of severe, relevant interactions NOACs may not be the preferred choice.

19. Anticoagulation in atrial fibrillation patients with a malignancy

The scope of the problem

Cancers are not infrequent in older patients, similar to AF. One study found a prevalence of 2.4% of pre-existing AF and 1.8% new AF among cancer patients.⁴⁵¹ Cancer and cancer therapy may in turn precipitate AF, while both age and malignancy are independent risk factors for thrombosis and bleeding.

The greater incidence and prevalence of AF in patients with malignancy may result from the presence of comorbid conditions (e.g. hypertension, heart failure), a direct tumour effect (including dehydration, altered sympathetic tone due to anxiety or pain, systemic inflammation, etc.) or as a complication of cancer therapy (e.g. after lung cancer surgery or as a side effect of specific targeted therapies such as tyrosine kinase inhibitor ibrutinib).^{452–455} The increasing survival of cancer patients may additionally increase the incidence of AF among patients with active and past malignancies.

The risk of VTE is increased in the presence of cancer through a host of possible mechanisms.⁴⁵⁶ Brain, pancreatic, ovarian, lung, or haematological malignancies, as well as many cancer treatments (e.g. cisplatin, gemcitabine, 5-fluorouracil, erythropoietin, granulocyte colony stimulating factors) are associated with particularly increased thromboembolic risk.⁴⁵⁷

Conversely, cancers may cause infiltrative liver failure resulting in thrombocytopenia or coagulopathy and increased risk of bleeding. Tumours may erode into blood vessels directly, and many GI and solid tumours such as intracranial tumours, renal cell carcinoma, or metastatic melanoma are very vascular and prone to bleeding. Haematologic malignancies may cause coagulation defects thus increasing the risk of bleeding further. In addition, every form of cancer therapy, be it surgery, radiation, or chemotherapy, may induce bleeding through local wounds (surgery), tissue damage (radiation), or systemic antiproliferative effects reducing platelet count and function (e.g. chemotherapy, some forms of irradiation).

Anticoagulant therapy in atrial fibrillation patients with malignancy

So far, the only published RCT specifically targeting cancer patients stems from the HOKUSAI-VTE Cancer trial comparing edoxaban with LMWH in patients with VTE (but not AF).⁴⁵⁸ Edoxaban proved to be non-inferior regarding the primary endpoint of recurrent VTE and major bleeding; while recurrent VTE trended to be lower with edoxaban, major bleeding was higher (driven by an increased risk of upper GI bleeding in patients with gastrointestinal cancer). In line with these findings, several meta-analyses of the small subgroup of cancer patients in VTE trials reported similar or better efficacy of NOACs in comparison to VKA or LMWH for VTE prevention, although major bleeding rates were higher.^{459,460} Most of these cancer patients may have been clinically stable, in contrast to those requiring active therapy or in a palliative setting.

Table 16 Atrial fibrillation and malignancy

Interdisciplinary teamwork	
(1)	Estimate individual patient risk profile <ul style="list-style-type: none">● AF-related risk factors (CHA₂DS₂-VASc, bleeding risk)● Cancer-related risk factors (type, liver metastases, coagulopathy, renal/hepatic function etc.)● Treatment-related risk factors (thrombocytopenia, surgery, radiation, central lines etc.)
(2)	Choose anticoagulant <ul style="list-style-type: none">● Current standard of care: VKA/(LMWH)^a● NOACs: Available data scarce, but encouraging● Consider patient preference (VKA vs. NOAC)
(3)	Protect the patient <ul style="list-style-type: none">● Gastric protection (PPI/H2 blockers)● Beware of drug–drug interactions (Table 4)● Dose reduction/treatment interruption (if platelets <50k, renal dysfunction, bleeding, ...)
Beware <ul style="list-style-type: none">● Risk of thromboembolism ↑● Risk of bleeding ↑	

^aIf oral therapy is not possible reversion to LMWH is reasonable.

Moreover, in how far these findings apply to AF patients with cancer requires further data. In cancer patients who develop incident AF, VKAs, or LMWH have been traditionally preferred over NOACs, based on greater clinical experience with these drugs, possibility for closer monitoring and availability of ‘reversal’ options. However, evidence for stroke prevention with LMWH in AF is lacking and LMWH is contraindicated in secondary prevention in the setting of acute stroke.³⁸⁶ Active malignancy was an exclusion criterion in most NOAC AF trials, and although there were a few patients with cancer in the Phase III AF trials, the absence of information on the type and stage of cancer precluded any relevant subgroup analysis. An exploratory analysis of AF patients with active cancer (*n* = 157) or a history of malignancy (*n* = 1079) in the ARISTOTLE trial showed consistently superior efficacy and safety of apixaban vs. warfarin in patients with and without cancer.⁴⁶¹ A large registry using prescription based analysis for AF patients on VKA or NOAC with and without cancer recently reported equivalence for bleeding and thromboembolic risk and cancer status, although the rates of both were lower in the NOAC population.⁴⁶² However, much is still unknown about drug–drug interactions between NOACs and specific chemotherapeutic agents, urging further caution (Table 4).¹⁴⁴

Overall, antithrombotic therapy in patients with AF suffering from a malignancy needs a dedicated interdisciplinary team approach (Table 16).⁴⁶³ Especially, when myelosuppressive chemotherapy or radiation therapy is planned, temporary dose reduction or cessation of NOAC therapy needs to be evaluated, taking into account full blood counts including platelets, renal/liver function, and physical signs of bleeding. Gastric protection with PPI or H2 blockers should be considered in all such patients.

20. Optimizing dose adjustments of vitamin-K antagonists

In spite of the preferred use of NOACs for stroke prevention in eligible patients with AF,³ some situations still require the use of VKA, including patients with mechanical heart valves as well as those with AF in the setting of rheumatic mitral stenosis. As such, mastering VKA therapy and dosing to keep patients in the therapeutic range remains an important skillset.

Beyond the standard target INR of 2.0–3.0 much of the optimal management of VKA therapy in AF is experience - rather than evidence-based. As such, various algorithms exist for the management of different VKA^{464,465} and experience in the past decades has led to different clinical routines (e.g. anticoagulation clinics, self-measurement via point-of-care devices etc.). One aspect, however, is key to success in VKA treated patients: Maintenance of a high time in therapeutic range (TTR) has been shown to reduce the risk of ischaemic and bleeding events and should be the primary goal in the treatment of these patients independent of the type management approach. Conversely, a change in the approach to these patients needs to be considered if a low TTR is consistently observed.

Dosing during initiation of therapy

Automated dosing calculators are available that help in the determination of the 'optimal' starting regimen (e.g. <http://www.warfarindos.org>). One randomized trial comparing a 10 mg and 5-mg Warfarin Initiation Nomograms for the outpatient treatment of acute VTE suggested the 10 mg scheme to be superior with patients reaching a therapeutic INR faster.⁴⁶⁶ However, a meta-analysis found no evidence of superiority of either starting regimen.⁴⁶⁷ Moreover, the situation is different in patients with AF as they are generally older and more frail than VTE patients. Furthermore, AF patients are usually not initiated in the setting of an acute thrombotic event. Indeed, various factors may play in favour of using a low (or even lower, i.e. 2 mg qd) starting dose, including older age, frailty, and renal insufficiency. As such, no strong recommendation can be made for routinely using either strategy, and individualizing the approach based on patient characteristics is recommended. In view of the lack of evidence supporting genotype-based dosing the latter is not recommended on a general basis.^{465,468}

In many parts of Europe, anticoagulation with phenprocoumon is frequently started with a loading dose in order to shorten the time to therapeutic INR levels owing to the long half-life of the drug,⁴⁶⁹ whereas the situation for warfarin and acenocoumarol is less clear.⁴⁷⁰ In order to prevent a possible transient prothrombotic effect due to a reduction of the equally vitamin K dependent, anticoagulant protein C (and S), the first phase of anticoagulation (particularly with phenprocoumon) is frequently paralleled by a parenteral anticoagulant, but evidence for the superiority of routinely using this approach is missing.

Dosing during maintenance therapy

Interpatient variability of optimal warfarin dose is enormous. Even in (formerly) 'stable' patients, intercurrent illness, change in dietary habits, changes in co-medication etc. may have a substantial impact on INR values. Despite the large variation of warfarin dosing habits amongst different centres, data have emerged indicating the

Table 17 Maintenance Warfarin dosing for out-of-therapeutic-range international normalized ratio

INR	Dose adjustment per week
≤1.5	↑ by 15%/week
1.6–1.9	↑ by 10%/week
2–2.9	Unchanged
3–3.9	↓ by 10%/week
4–4.9	Hold 1 dose, then restart with dose ↓ by 10%/week
≥5	Hold until INR is 2–3, then restart with dose ↓ by 15%/week

Suggested dose adjustment in case of out-of-therapeutic-range INR.⁴⁷² Importantly, dosing is optimized not using daily dose adjustments but adjustments based on the weekly intake in warfarin.

usefulness of using dosing algorithms to optimize VKA dosing and, ultimately, the time in therapeutic range (TTR).^{471–473} One such algorithm is presented in Table 17, derived from the warfarin arm of the RE-LY trial. Importantly from a conceptual point of view dosing is optimized not using daily dose adjustments but adjustments based on the weekly intake in warfarin. Obtaining INR measurements at least every 4 weeks and at least weekly in case of out-of-range values is an important prerequisite. A similar dosing scheme may be used for phenprocoumon given its even longer half-life, whereas for acenocoumarol more short-term based adjustment may be feasible given its shorter half-life.

In patients with repeated out-of-range INR values, supplemental measures may be required including (re-)educating patients on the risk and benefits of VKA intake, the importance of strict adherence as well as food- and drug–drug interactions etc. Receiving care at a dedicated anticoagulation clinic^{474,475} as well as self-monitoring and self-management⁴⁷⁶ has been shown to improve INR control. However, patient selection is a critical component, particularly for the latter, and not every patient may be suitable.

In summary, every effort needs to be made in VKA treated patients to optimize the individual patient's TTR. At the same time, however, it needs to be kept in mind that even being within the therapeutic range does not protect from bleeding events. Recent studies indicate that although the risk of ICB increases at an INR >3 (and clearly >4–5), the vast majority of events in absolute numbers occurs at a therapeutic INR level.³⁷⁷ Keeping the patient in the therapeutic range (2.0–3.0) hence primarily confers relative, but not absolute efficacy and safety.

Acknowledgements

The authors thank EHRA Scientific Documents committee: Gregory Y.H. Lip, Laurent Fauchier, David Arnar, Carina Blomstrom-Lundqvist, Zbigniew Kalarus, Gulmira Kudaiberdieva, Georges H. Mairesse, Tatjana Potpara, Irina Savelieva, Jesper Hastrup Svendsen, Vassil B. Traykov.

Funding

This article and derived educational materials (slide set, website, booklet, and NOAC card) were produced by and under the sole responsibility of the European Heart Rhythm Association, and supported by Bayer Pharma AG, Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer Alliance and Daiichi-Sankyo Europe GmbH in the form of an Unrestricted Educational Grant.

The EHRA writing committee collaborated with medical advisors from the different companies to assure data accuracy and completeness.

Conflict of interest: J. S. has received consultant and/or speaker fees from Amgen, Astra-Zeneca, Atricure, Bayer, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cook Medical, Daiichi Sankyo, Medtronic, Novartis, Pfizer, Sanofi-Aventis, Sorin, St. Jude Medical/Abbott, and Zoll. He reports ownership of CorXL. J.S. has received grant support through his institution from Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, Medtronic, and St. Jude Medical/Abbott. P. V. reports grants and personal fees from Bayer, Boehringer Ingelheim, BMS, Leo Pharma, Daiichi-Sankyo; and personal fees from Pfizer, Medtronic, and Portola. T.S. P. has received speaker fees from Pfizer and Bayer. P. A. reports personal fees from Boehringer Ingelheim, personal fees and non-financial support from Bayer and Portola, and grants, personal fees and non-financial support from Pfizer-BMS and Csl-Behring. M. A. reports personal fees from Bayer, Boehringer Ingelheim, Daiichi Sankyo, personal fees from Pfizer, Sanofi Aventis, Medtronic, Biosense Webster, Novartis, Abbott, and Biotronik. L.D. has no conflict of interest to disclose. K.G. H. reports personal fees from Bayer, Boehringer-Ingelheim, Pfizer, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Edwards Lifesciences, Sanofi, EIP Pharma, non-financial support from Getemed AG, and grants from Bayer. J. O. reports fees to his institution from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. H. R. reports personal fees from BMS, MedUpdate, NephroUpdate, Pfizer, and Pluristem; and grants from the German Federal Ministry for Education and Research (BMBF), Bard, Bayer, and Biotronik. V. R. has received consultant and/or speaker fees from Bayer Healthcare, Boehringer-Ingelheim, Bristol-Myers Squibb, Leo Pharma, Pfizer, and Rovi. N. R. reports personal fees from BMS, Pfizer, Daiichi-Sankyo, Bayer and Boehringer Ingelheim. P. S. reports grants from Daiichi Sankyo and Astra Zeneca, and institutional fees from BMS, Pfizer, and Boehringer. R. C. reports personal fees from Daiichi Sankyo, Pfizer, Bayer and Boehringer Ingelheim. A. J.C. has received institutional research grants and personal fees for advice and for speaking from Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer/BMS. H. H. reports personal fees (before June 2017) from Abbott, Pfizer/BMS, Daiichi-Sankyo, Boehringer-Ingelheim, Cardiome; he received no personal fees after June 2017; he received research grants from Bayer, Bracco Imaging Europe, Medtronic, and St. Jude Medical through the University of Hasselt or Antwerp.

References

- Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. *Europace* 2013;**15**:625–651.
- Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. *Europace* 2015;**17**:1467–1507.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deffereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorennek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savellieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;**37**:2893–2962.
- Barnes GD, Agno W, Ansell J, Kaatz S; Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis. Recommendation on the Nomenclature for Oral Anticoagulants: communication from the SSC of the ISTH. *J Thromb Haemost* 2015;**13**:1154–1156.
- Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Jung B, Lancellotti P, Lansac E, Muñoz DR, Rosenhek R, Sjogren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017;**38**:2739–2791.
- Lip GYH, Collet JP, Caterina R, Fauchier L, Lane DA, Larsen TB, Marin F, Morais J, Narasimhan C, Olshansky B, Pierard L, Potpara T, Sarrafzadegan N, Sliwa K, Varela G, Vilahur G, Weiss T, Boriani G, Rocca B; ESC Intervention Document Group. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). *Europace* 2017;**19**:1757–1758.
- Avezum A, Lopes RD, Schulte PJ, Lanus F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *Circulation* 2015;**132**:624–632.
- Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). *Circulation* 2016;**134**:589–598.
- Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. *Eur Heart J* 2014;**35**:3377–3385.
- De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 Trial. *J Am Coll Cardiol* 2017;**69**:1372–1382.
- Pan KL, Singer DE, Oviagele B, Wu YL, Ahmed MA, Lee M. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. *J Am Heart Assoc* 2017;**6**:e005835.
- Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. *J Am Coll Cardiol* 2017;**69**:1363–1371.
- Noseworthy PA, Yao X, Shah ND, Gersh BJ. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. *Int J Cardiol* 2016;**209**:181–183.
- Noseworthy PA, Yao X, Shah ND, Gersh BJ. Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation. *J Am Coll Cardiol* 2016;**67**:3020–3021.
- Dominguez F, Climent V, Zorio E, Ripoll-Vera T, Salazar-Mendiguchía J, García-Pinilla JM, Urbano-Moral JA, Fernández-Fernández X, Lopez-Cuenca D, Ajo-Ferrer R, Sanz-Sanchez J, Gomez-Perez Y, López-Garrido MA, Barriales-Villa R, Gimeno JR, García-Pavia P. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. *Int J Cardiol* 2017;**248**:232–238.
- van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. *Circ Heart Fail* 2013;**6**:740–747.
- McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, Bartunek J, Commerford P, Oh BH, Harjola VP, Al-Khatib SM, Hanna M,

- Alexander JH, Lopes RD, Wojdyla DM, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Circ Heart Fail* 2013;**6**: 451–460.
18. Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, Moccetti T, Mitrovic V, Shi M, Mercuri M, Antman EM, Braunwald E. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. *Eur J Heart Fail* 2016;**18**:1153–1161.
 19. Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills MT, Hylek EM, LaHaye SA, Lip GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS, Pisters R, Stewart S, Wood K, Potpara TS, Document R, Gorenek B, Conti JB, Keegan R, Power S, Hendriks J, Ritter P, Calkins H, Violi F, Hurwitz J. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). *Europace* 2015;**17**:1747–1769.
 20. Heidbuchel H, Berti D, Campos M, Desteghe L, Freixo A, Nunes A, Roldán V, Toschi V, Lassila R. Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. *Thromb J* 2015;**13**:22.
 21. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAME-TT(2)R(2) score. *Chest* 2013;**144**:1555–1563.
 22. Ruiz-Ortiz M, Bertomeu V, Cequier Á, Marín F, Anguita M. Validation of the SAME-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. *Thromb Haemost* 2015;**114**:695–701.
 23. Roldán V, Cancio S, Galvez J, Valdes M, Vicente V, Marín F, Lip GY. The SAME-TTR score predicts poor anticoagulation control in AF patients: a prospective 'Real-World' inception cohort study. *Am J Med* 2015;**128**:1237–1243.
 24. Esteve-Pastor MA, Roldán V, Valdés M, Lip GYH, Marín F. The SAME-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. *Expert Rev Cardiovasc Ther* 2016;**14**:177–187.
 25. Lobos-Bejarano JM, Barrios V, Polo-García J, Escobar C, Vargas-Ortega D, Marín-Montañés N, Prieto-Valiente L, Fuentes S, Prieto MA, García-Ortiz L. Evaluation of SAME-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain. *Curr Med Res Opin* 2016;**32**:1201–1207.
 26. Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, Lopez-Lopez A, Redondo-Dieguez A, Alvarez-Iglesias D, Rodriguez-Manero M, Pena-Gil C, Gonzalez-Juanatey JR. Evaluation of SAME-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. *Europace* 2015;**17**:711–717.
 27. Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAME-TT2R2 score. *Eur Heart J Cardiovasc Pharmacother* 2015;**1**:150–152.
 28. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;**361**:1139–1151.
 29. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;**365**:883–891.
 30. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Gerdal M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;**365**:981–992.
 31. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinler J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013;**369**:2093–2104.
 32. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2018;**39**:123–260.
 33. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2018;**39**:119–177.
 34. Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. *BMC Med* 2016;**14**:179.
 35. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein CM. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. *Gastroenterology* 2016;**151**: 1105–1112.e10.
 36. Di Minno A, Spadarella G, Spadarella E, Tremoli E, Di Minno G. Gastrointestinal bleeding in patients receiving oral anticoagulation: current treatment and pharmacological perspectives. *Thromb Res* 2015;**136**:1074–1081.
 37. Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, Wong IC. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. *Gastroenterology* 2015;**149**:586–595.e3.
 38. Shields AM, Lip GY. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. *J Intern Med* 2015;**278**:1–18.
 39. Okumura K, Hori M, Tanahashi N, John Camm A. Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. *Clin Cardiol* 2017;**40**:126–131.
 40. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FWA, Veltkamp R, Lip GYH. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. *Eur Heart J* 2017;**38**:852–859.
 41. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FWA, Veltkamp R, Lip GYH. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. *Eur Heart J* 2017;**38**:860–868.
 42. Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient education. *Curr Pharm Des* 2015;**21**:533–543.
 43. Lane DA, Wood K. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation. *Circulation* 2015;**131**:e412–e415.
 44. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand J-P, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AGG, Verheugt FWA, Kakkar AK. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. *Heart* 2017;**103**:307–314.
 45. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener H-C, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GYH. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. *J Am Coll Cardiol* 2017;**69**:777–785.
 46. Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ, Hindricks G, Moons P, Heidbuchel H. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. *Eur Heart J* 2013;**34**:2725–2730.
 47. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA, Blaauw Y, Tieleman RG. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. *Eur Heart J* 2012;**33**:2692–2699.
 48. Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, Mahajan R, Lau DH, Sanders P, Hendriks JML. Integrated care in atrial fibrillation: a systematic review and meta-analysis. *Heart* 2017;**103**:1947–1953.
 49. Carter L, Gardner M, Magee K, Fearon A, Morgulis I, Doucette S, Sapp JL, Gray C, Abdelwahab A, Parkash R. An integrated management approach to atrial fibrillation. *J Am Heart Assoc* 2016;**5**:e002950.
 50. Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. *Lancet* 2017;**390**:1873–1887.
 51. Desteghe L, Vijgen J, Koopman P, Dilling-Boer D, Schurmans J, Dendale P, Heidbuchel H. Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. *Eur Heart J* 2018;**39**:1394–1403.
 52. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. *J Am Coll Cardiol* 2016;**68**:1169–1178.

53. Romero-Ortuno R, Walsh CD, Lawlor BA, Kenny RA. A frailty instrument for primary care: findings from the Survey of Health, Ageing and Retirement in Europe (SHARE). *BMC Geriatr* 2010;**10**:57.
54. Chao TF, Lip GYH, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Chen SA. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. *J Am Coll Cardiol* 2018;**71**:122–132.
55. Lip GYH, Skjoth F, Nielsen PB, Kjeldgaard JN, Larsen TB. The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants. *Am J Med* 2017; [Epub ahead of print].
56. Guo Y, Zhu H, Chen Y, Lip GYH. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. *Am J Med* 2018;**131**:185–192.
57. Esteve-Pastor M, Rivera-Caravaca J, Shantsila A, Roldán V, Lip G, Marín F. Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED Score. The AMADEUS Trial. *Thromb Haemost* 2017;**117**:2261–2266.
58. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Chen SA. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. *Int J Cardiol* 2018;**254**:157–161.
59. Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L. ARISTOTLE and RE-LY Investigators. *Lancet* 2016;**387**:2302–2311.
60. O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. *Eur Heart J* 2015;**36**:3258–3264.
61. Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. *J Thromb Haemost* 2016;**14**:1711–1714.
62. Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. *Thromb Haemost* 2016;**117**:209–218.
63. Montalescot G. Abstract 18842: adherence and persistence to apixaban treatment in patients with non valvular atrial fibrillation is high and similar with standard of care patient education or with an additional educational program: the randomized AEGEAN Study. *Circulation* 2016;**134**(Suppl 1): A18842–A18842.
64. Desteghe L, Engelhard L, Vijgen J, Koopman P, Dilling-Boer D, Schurmans J, Dendale P, Heidbuchel H. Effect of individualised education sessions on the knowledge level of patients with atrial fibrillation. *EP Europace* 2017;**19**:iii147. P817.
65. Labovitz DL, Shafner L, Reyes Gil M, Virmani D, Hanina A. Using artificial intelligence to reduce the risk of nonadherence in patients on anticoagulation therapy. *Stroke* 2017;**48**:1416–1419.
66. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, Gersh BJ, Shah ND, Noseworthy PA. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. *J Am Heart Assoc* 2016;**5**:e003074.
67. Beyer-Westendorf J, Ehken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. *Europace* 2016;**18**:1150–1157.
68. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, Bradley SM, Maddox TM, Grunwald GK, Baron AE, Rumsfeld JS, Varosy PD, Schneider PM, Marzec LN, Ho PM. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. *Am Heart J* 2014;**167**:810–817.
69. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. *J Thromb Haemost* 2015;**13**:495–504.
70. McHorney CA, Crivera C, Laliberte F, Nelson WW, Germain G, Bookhart B, Martin S, Schein J, Lefebvre P, Deitelzweig S. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. *Curr Med Res Opin* 2015;**31**:2167–2173.
71. Crivera C, Nelson WW, Bookhart B, Martin S, Germain G, Laliberte F, Schein J, Lefebvre P. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. *Curr Med Res Opin* 2015;**31**:1889–1895.
72. Coleman CI, Tangirala M, Evers T. Medication adherence to rivaroxaban and dabigatran for stroke prevention in non-valvular atrial fibrillation in the United States. *Int J Cardiol* 2016;**212**:171–173.
73. Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D, Schein JR, Coleman CI. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. *Int J Cardiol* 2016;**215**(Suppl C):11–13.
74. McHorney CA, Peterson ED, Laliberte F, Germain G, Nelson WW, Crivera C, Schein J, Lefebvre P. Comparison of adherence to rivaroxaban versus apixaban among patients with atrial fibrillation. *Clin Ther* 2016;**38**:2477–2488.
75. Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. *J Manag Care Spec Pharm* 2016;**22**:1319–1329.
76. Zhou M, Chang HY, Segal JB, Alexander GC, Singh S. Adherence to a novel oral anticoagulant among patients with atrial fibrillation. *J Manag Care Spec Pharm* 2015;**21**:1054–1062.
77. Manzoor BS, Lee TA, Sharp LK, Walton SM, Galanter WL, Nutescu EA. Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation. *Pharmacotherapy* 2017;**37**:1221–1230.
78. Cutler TW, Chuang A, Huynh TD, Witt RG, Branch J, Pon T, White R. A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center. *J Manag Care Spec Pharm* 2014;**20**:1028–1034.
79. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. *Circulation* 2015;**131**:157–164.
80. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in 'real-world' patients with atrial fibrillation: a prospective nationwide cohort study. *J Am Coll Cardiol* 2013;**61**:2264–2273.
81. Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. *Thromb Haemost* 2016;**116**:975–986.
82. Adeboyeje G, Sylwestrzak G, Barron JJ, White J, Rosenberg A, Abarca J, Crawford G, Redberg R. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. *J Manag Care Spec Pharm* 2017;**23**:968–978.
83. Bai Y, Deng H, Shantsila A, Lip GYH. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. *Stroke* 2017;**48**:970–976.
84. Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. *Am J Cardiol* 2017;**120**:1813–1819.
85. Bai Y, Shi X-B, Ma C-S, Lip GYH. Meta-analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban. *Am J Cardiol* 2017;**120**:1689–1695.
86. Staerk L, Fosbøl EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C, Ozenne B, Gerdts TA, Gislason GH, Olesen JB. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. *Europ Heart J* 2017;**38**:907–915.
87. Beyer-Westendorf J, Camm AJ, Coleman CI, Tamayo S. Rivaroxaban real-world evidence: validating safety and effectiveness in clinical practice. *Thromb Haemost* 2016;**116**:S13–S23.
88. Potpara TS, Lip GH. Postapproval observational studies of non-vitamin k antagonist oral anticoagulants in atrial fibrillation. *JAMA* 2017;**317**:1115–1116.
89. Friberg L, Oldgren J. Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. *Open Heart* 2017;**4**:e000682.
90. Ntaios G, Papavasileiou V, Makritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. *Stroke* 2017;**48**:2494–2503.
91. Larsen TB, Skjoth F, Nielsen PB, Kjeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. *BMJ* 2016;**353**:i3189.
92. Halvorsen S, Ghanima W, Fridtveit I, Hoxmark C, Falck P, Solli O, Jonasson C. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. *Eur Heart J Cardiovasc Pharmacother* 2017;**3**:28–36.
93. Nielsen PB, Skjoth F, Sogaard M, Kjeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. *BMJ* 2017;**356**, <https://www.ncbi.nlm.nih.gov/pubmed/28188243>.
94. Hohnloser SH, Basic E, Nabauer M. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. *Clin Res Cardiol* 2017;**106**:618–628.

95. Lamberts M, Staerk L, Olesen JB, Fosbol EL, Hansen ML, Harboe L, Lefevre C, Evans D, Gislason GH. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. *J Am Heart Assoc* 2017;**6**:e004517.
96. Coleman CI, Antz M. Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). *Intern Emerg Med* 2017;**12**:419–422.
97. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in 'real-world' clinical practice. A propensity-matched analysis of 76,940 patients. *Thromb Haemost* 2017;**117**:1072–1082.
98. Deitelzweig S, Farmer C, Luo X, Li X, Vo L, Mardekian J, Fahrbach K, Ashaye A. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. *Curr Med Res Opin* 2018;**34**:487–498.
99. Obamiro KO, Chalmers L, Bereznicki LR. A summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation. *Am J Cardiovasc Drugs* 2016;**16**:349–363.
100. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. *Thromb Haemost* 2016;**115**:31–39.
101. Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV, Schein JR. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. *Curr Med Res Opin* 2014;**30**:2461–2469.
102. Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. *Curr Med Res Opin* 2014;**30**:1317–1325.
103. Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H. Higher persistence in newly diagnosed non-valvular atrial fibrillation patients treated with dabigatran versus warfarin. *Circ Cardiovasc Qual Outcomes* 2013;**6**:567–574.
104. Beyer-Westendorf J, Forster K, Ebertz F, Gelbricht V, Schreier T, Gobelt M, Michalski F, Endig H, Sahin K, Tittl L, Weiss N. Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry. *Europace* 2015;**17**:530–538.
105. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persistence, and switching patterns of dabigatran etexilate. *Am J Manag Care* 2013;**19**:e325–e332.
106. Jackevicius CA, Tsadok MA, Essebag V, Atzema C, Eisenberg MJ, Tu JV, Lu L, Rahme E, Ho PM, Turakhia M, Humphries KH, Behloul H, Zhou L, Pilote L. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. *Heart* 2017;**103**:1331–1338.
107. Paquette M, Riou Franca L, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Huisman MV, Lip GYH, Nieuwlaar R. Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation. *J Am Coll Cardiol* 2017;**70**:1573–1583.
108. Lane DA, Wood KA. A patient's guide to taking the non-vitamin K antagonist oral anticoagulants (NOACs) for atrial fibrillation: lane; patient's guide to taking NOACs. *Circulation* 2015;**131**:e412–e415.
109. Desteghe L, Engelhard L, Raymaekers Z, Kluts K, Vijgen J, Dilling-Boer D, Koopman P, Schurmans J, Dendale P, Heidbuchel H. Knowledge gaps in patients with atrial fibrillation revealed by a new validated knowledge questionnaire. *Int J Cardiol* 2016;**223**:906–914.
110. Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, He W, Xian Y, Ciobanu AO, Kamath DY, Fox KA, Rao MP, Pokorney SD, Berwanger O, Tajer C, de Barros e Silva PGM, Roettig ML, Huo Y, Granger CB; IMPACT-AF investigators. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. *Lancet* 2017;**390**:1737–1746.
111. Camm AJ, Luscher TF, Serruys P. *The ESC Textbook of Cardiovascular Medicine*, 2nd ed. Oxford, NY: Oxford University Press; 2009.
112. Germeys J, Desteghe L, Vijgen J, Dilling-Boer D, Koopman P, Schurmans J, Dendale P, Heidbuchel H. The effect of online targeted education on procedure-specific knowledge of atrial fibrillation patients undergoing cardioversion or ablation. *Acta Cardiol* 2017;**72**:573.
113. Shore S, Ho PM, Lambert-Kerzner A, Gloriosio TJ, Carey EP, Cunningham F, Longo L, Jackevicius C, Rose A, Turakhia MP. Site-level variation in and practices associated with dabigatran adherence. *JAMA* 2015;**313**:1443–1450.
114. Guo Y, Chen Y, Lane DA, Liu L, Wang Y, Lip GYH. Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: MAF App Trial. *Am J Med* 2017;**130**:1388–1396.e6.
115. Santo K, Richtering SS, Chalmers J, Thiagalingam A, Chow CK, Redfern J. Mobile phone apps to improve medication adherence: a systematic stepwise process to identify high-quality apps. *JMIR Mhealth Uhealth* 2016;**4**:e132.
116. Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL, Tomlin ME. Adherence and dosing frequency of common medications for cardiovascular patients. *Am J Manag Care* 2012;**18**:139–146.
117. Weeda ER, Coleman CI, McHorney CA, Crivera C, Schein JR, Sobieraj DM. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis. *Int J Cardiol* 2016;**216**:104–109.
118. Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. *Adv Ther* 2012;**29**:675–690.
119. Sorensen R, Jamie Nielsen B, Langtved Pallisgaard J, Ji-Young Lee C, Torp-Pedersen C. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists. *Eur Heart J Cardiovasc Pharmacother* 2017;**3**:151–156.
120. Forslund T, Wettermark B, Hjendahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. *Eur J Clin Pharmacol* 2016;**72**:329–338.
121. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. *Chest* 2016;**150**:1302–1312.
122. Al-Khalili F, Lindström C, Benson L. The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. *Curr Med Res Opin* 2016;**32**:779–785.
123. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. *Europace* 2015;**17**:514–523.
124. Kreutz R, Persson PB, Kubitz D, Thelen K, Heitmeier S, Schwes S, Becka M, Hemmrich M. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. *J Thromb Haemost* 2017;**15**:2017–2028.
125. Ruff CT, Giugliano RP, Braunwald E, Mercuri M, Curt V, Betcher J, Grip L, Cange AL, Crompton AE, Murphy SA, Deenadayalu N, Antman EM. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. *J Am Coll Cardiol* 2014;**64**:576–584.
126. Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). *J Am Coll Cardiol* 2013;**61**:651–658.
127. Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L, Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Am Heart J* 2015;**169**:25–30.
128. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. *J Pharmacol Exp Ther* 2011;**338**:372–380.
129. Mueck W, Kubitz D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. *Br J Clin Pharmacol* 2013;**76**:455–466.
130. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CA, Maxwell BD, Chen S-y, He K, Goosen TC, Griffith WH, Grossman SJ. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. *Drug Metab Dispos* 2010;**38**:448–458.
131. Mueck W, Stampfuss J, Kubitz D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. *Clin Pharmacokinet* 2014;**53**:1–16.
132. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. *Thromb Haemost* 2012;**107**:925–936.
133. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, Camm AJ, Antman EM, Ruff CT. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. *Eur Heart J* 2015;**36**:2239–2245.
134. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. *Am J Cardiovasc Drugs* 2013;**13**:331–342.

135. Frost C, Song Y, Yu Z, Wang J, Lee LS, Schuster A, Pollack A, LaCreta F. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. *Clin Pharmacol* 2017;**9**:19–28.
136. Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, Zhang D, Yu Z, Dias C, Shenker A, LaCreta F. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. *Br J Clin Pharmacol* 2015;**79**:838–846.
137. Mendell J, Noveck R, Zahir H, Lee F, Petrushin V, Rubets I, Zhang G, Shi M, Chen S. The effect of quinidine and verapamil, P glycoprotein/CYP3A4/5 inhibitors, on edoxaban pharmacokinetics and pharmacodynamics. *Basic Clin Pharmacol Toxicol* 2010;**107**:2848. (Abstract).
138. Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, Yu Z, Dias C, Shenker A, LaCreta F. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. *Am J Cardiovasc Drugs* 2016;**16**:119–127.
139. Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J, Zhang D, Byon W, Boyd RA, LaCreta F. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. *Br J Clin Pharmacol* 2014;**78**:877–885.
140. Kubitz D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H₂ antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. *J Clin Pharmacol* 2006;**46**:549–558.
141. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med* 2017;**377**:1513–1524.
142. U.S. Food and Drug Administration. *Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers*. <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm> (8 February 2018).
143. Parasrampur DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. *Br J Clin Pharmacol* 2016;**82**:1591–1600.
144. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. *Oncologist* 2014;**19**:82–93.
145. Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. *Adv Drug Deliv Rev* 2012;**64**:930–942.
146. Schelleman H, Pollard JR, Newcomb C, Markowitz CE, Bilker WB, Leonard MB, Hennessy S. Exposure to CYP3A4-inducing and CYP3A4-non-inducing antiepileptic agents and the risk of fractures. *Pharmacoepidemiol Drug Saf* 2011;**20**:619–625.
147. Stollberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. *Epilepsy Res* 2016;**126**:98–101.
148. Wiggins BS, Northup A, Johnson D, Senfield J. Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. *Pharmacotherapy* 2016;**36**:e5–e7.
149. Stollberger C, Finsterer J. Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state. *Heart Lung* 2014;**43**:262–263.
150. Stollberger C. Drug interactions with new oral anticoagulants in elderly patients. *Expert Rev Clin Pharmacol* 2017;**10**:1191–1202.
151. LaHaye SA, Gibbens SL, Ball DG, Day AG, Olesen JB, Skanes AC. A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. *Eur Heart J* 2012;**33**:2163–2171.
152. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *J Am Coll Cardiol* 2014;**63**:321–328.
153. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet* 2015;**385**:2288–2295.
154. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. *Thromb Haemost* 2014;**111**:933–942.
155. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation* 2011;**123**:2363–2372.
156. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. *Circ J* 2012;**76**:2104–2111.
157. Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. *JAMA Cardiol* 2016;**1**:673–681.
158. Bleh S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. *Drug Metab Dispos* 2008;**36**:386–399.
159. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. *Clinical Pharmacokinetics* 2008;**47**:47–59.
160. Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. *J Clin Pharmacol* 2011;**51**:687–694.
161. Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, LaCreta F, Frost CE. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. *Clin Pharmacol* 2013;**5**:59–66.
162. Song Y, Chang M, Suzuki A, Frost RJ, Kelly A, LaCreta F, Frost C. Evaluation of crushed tablet for oral administration and the effect of food on apixaban pharmacokinetics in healthy adults. *Clin Ther* 2016;**38**:1674–1685.e1.
163. Duchin K, Duggal A, Atiee GJ, Kidokoro M, Takatani T, Shipitofsky NL, He L, Zhang G, Kakkur T. An open-label crossover study of the pharmacokinetics of the 60-mg edoxaban tablet crushed and administered either by a nasogastric tube or in apple puree in healthy adults. *Clin Pharmacokinet* 2018;**57**:221–228.
164. Moore KT, Krook MA, Vaidyanathan S, Sarich TC, Damaraju CV, Fields LE. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. *Clin Pharmacol Drug Dev* 2014;**3**:321–327.
165. Song Y, Wang X, Perlstein I, Wang J, Badawy S, Frost C, LaCreta F. Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects. *Clin Ther* 2015;**37**:1703–1712.
166. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. *J Thromb Haemost* 2011;**9**:2168–2175.
167. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoagulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). *Am Heart J* 2010;**160**:635–641.
168. Godier A, Dincq AS, Martin AC, Radu A, Leblanc I, Antona M, Vasse M, Golmard JL, Mullier F, Gouin-Thibault I. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. *Eur Heart J* 2017;**38**:2431–2439.
169. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. *Lancet* 2000;**355**:548–549.
170. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. *Circulation* 2013;**127**:634–640.
171. Mega JL, Braunwald E, Wiwiot SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med* 2012;**366**:9–19.
172. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRASE) trial. *Circulation* 2009;**119**:2877–2885.
173. Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. *Clin Res Cardiol* 2016;**105**:412–420.
174. Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. *Circulation* 2016;**133**:352–360.

175. Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanus F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. *Brmj* 2016;**353**:i2868.
176. Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, Katz R, Kestenbaum B, Mathew J, Robinson-Cohen C, Sarnak MJ, Shlipak MG, Sotoodehnia N, Young B, Heckbert SR. eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. *Clin J Am Soc Nephrol* 2017;**12**:1386–1398.
177. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. *Circulation* 2009;**119**:1363–1369.
178. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). *Am Heart J* 2010;**159**:1102–1107.
179. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. *Am Heart J* 2009;**158**:629–636.
180. Reinecke H, Brand E, Mesters R, Schabitz WR, Fisher M, Pavenstadt H, Breithardt G. Dilemmas in the management of atrial fibrillation in chronic kidney disease. *J Am Soc Nephrol* 2009;**20**:705–711.
181. Steffel J, Hindricks G. Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis. *Eur Heart J* 2012;**33**:2766–2768.
182. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. *Br J Clin Pharmacol* 2007;**64**:292–303.
183. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D. Apixaban metabolism and pharmacokinetics after oral administration to humans. *Drug Metab Dispos* 2009;**37**:74–81.
184. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. *J Clin Pharmacol* 2010;**50**:743–753.
185. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. *Clin Pharmacokinet* 2011;**50**:675–686.
186. Kubitz D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. *Clin Pharmacol Ther* 2005;**78**:412–421.
187. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI 3rd, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;**150**:604–612.
188. Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Becker RC, Fox KA, Patel MR, ROCKET AF Steering Committee and Investigators. Treatment consistency across levels of baseline renal function with rivaroxaban or warfarin: a ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. *Circulation* 2017;**135**:1001–1003.
189. Fanikos J, Burnett AE, Mahan CE, Dobesh PP. Renal function considerations for stroke prevention in atrial fibrillation. *Am J Med* 2017;**130**:1015–1023.
190. Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. *Circulation* 2016;**134**:24–36.
191. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. *Clin J Am Soc Nephrol* 2011;**6**:2599–2604.
192. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. *N Engl J Med* 2012;**367**:625–635.
193. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. *J Am Coll Cardiol* 2014;**64**:2471–2482.
194. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. *Eur Heart J* 2015;**36**:297–306.
195. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. *Circulation* 2014;**129**:961–970.
196. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. *Eur Heart J* 2011;**32**:2387–2394.
197. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanus F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Eur Heart J* 2012;**33**:2821–2830.
198. Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Granger CB, Wallentin L. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE Randomized Clinical Trial. *JAMA Cardiol* 2016;**1**:451–460.
199. Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. *Circulation* 2016;**134**:37–47.
200. Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY Trial. *J Am Coll Cardiol* 2015;**65**:2481–2493.
201. Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM, Bhatt UY, Hebert LA. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. *Kidney Int* 2011;**80**:181–189.
202. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. *J Am Coll Cardiol* 2017;**69**:2779–2790.
203. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behloul H, Guo H, Pilote L. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. *Circulation* 2014;**129**:1196–1203.
204. Galloway PA, El-Damanawi R, Bardsley V, Pritchard NR, Fry AC, Ojha SK, Hiemstra TF. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. *Nephron* 2015;**129**:197–201.
205. Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y; Japanese Calciphylaxis Study Group. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. *Nephrol Dial Transplant* 2012;**27**:1580–1584.
206. Han KH, O'Neill WC. Increased peripheral arterial calcification in patients receiving warfarin. *J Am Heart Assoc* 2016;**5**:e002665.
207. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. *Semin Dial* 2002;**15**:172–186.
208. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, Eckardt KU, Kasike BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). *Kidney Int* 2011;**80**:572–586.
209. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. *Circulation* 2015;**131**:972–979.
210. Mavranakas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. *J Am Soc Nephrol* 2017;**28**:2241–2248.
211. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment. *Circ J* 2015;**79**:1486–1495.
212. De Vriese AS, Caluwe R, Bailleul E, De Bacquer D, Borrey D, Van Vlem B, Vandecasteele SJ, Emmerechts J. Dose-finding study of rivaroxaban in hemodialysis patients. *Am J Kidney Dis* 2015;**66**:91–98.
213. Reinecke H, Engelbertz C, Schabitz WR. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. *Stroke* 2013;**44**:2935–2941.
214. Khoury T, Ayman AR, Cohen J, Daher S, Shmuel C, Mizrahi M. The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going. *Digestion* 2016;**93**:149–159.
215. Lauschke VM, Ingelman-Sundberg M. The importance of patient-specific factors for hepatic drug response and toxicity. *Int J Mol Sci* 2016;**17**:1714.
216. Efrid LM, Mishkin DS, Berlowitz DR, Ash AS, Hylek EM, Ozonoff A, Reisman JJ, Zhao S, Jasuja GK, Rose AJ. Stratifying the risks of oral anticoagulation in patients with liver disease. *Circ Cardiovasc Qual Outcomes* 2014;**7**:461–467.

217. Kubitz D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. *Br J Clin Pharmacol* 2013;**76**:89–98.
218. Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. *Dig Dis Sci* 2016;**61**:1721–1727.
219. Hum J, Shtatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. *Eur J Haematol* 2017;**98**:393–397.
220. Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. *Handb Exp Pharmacol* 2010;**196**:407–418.
221. Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, Costa J. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. *Heart* 2014;**100**:550–556.
222. Alonso A, MacLehose RF, Chen LY, Bengtson LG, Chamberlain AM, Norby FL, Lutsey PL. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. *Heart* 2017;**103**:834–839.
223. Potpara TS, Lip GY. Drug-induced liver injury with oral anticoagulants: a threat or not? *Heart* 2017;**103**:809–811.
224. Licata A, Puccia F, Lombardo V, Serruto A, Minissale MG, Morreale I, Giannitrapani L, Soresi M, Montalto G, Almasio PL. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. *Eur J Gastroenterol Hepatol* 2018;**30**:226–232.
225. Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, Digne JM, Mullier F. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. *J Thromb Haemost* 2018;**16**:209–219.
226. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Digne JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. *Thromb Res* 2012;**130**:956–966.
227. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Digne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. *Thromb Haemost* 2012;**107**:985–997.
228. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. *Am J Med* 2012;**125**:417–420.
229. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. *Thromb Haemost* 2010;**103**:1116–1127.
230. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). *Am J Cardiol* 2007;**100**:1419–1426.
231. Douxfils J, Chatelain C, Chatelain B, Digne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. *Thromb Haemost* 2013;**110**:283–294.
232. Cuker A, Husseinadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. *J Thromb Thrombolysis* 2015;**39**:288–294.
233. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. *Ther Drug Monit* 2010;**32**:673–679.
234. Mani H, Herth N, Kasper A, Wendt T, Schuetzfort G, Weil Y, Pfeilschifter W, Linnemann B, Herrmann E, Lindhoff-Last E. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. *Ther Drug Monit* 2014;**36**:624–631.
235. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, Grebmer C, Bourrier F, Buiatti A, Kolb C, Deisenhofer I, Hessling G. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. *Am J Cardiol* 2015;**115**:47–51.
236. Auer J, Huber K, Granger CB. Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough? *Eur Heart J* 2017;**38**:2440–2443.
237. Kubitz D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. *Curr Med Res Opin* 2008;**24**:2757–2765.
238. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. *Thromb Haemost* 2012;**107**:838–847.
239. Green R, Grierson R, Sitar DS, Tenenbein M. How long after drug ingestion is activated charcoal still effective? *J Toxicol Clin Toxicol* 2001;**39**:601–605.
240. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. *J Am Coll Cardiol* 2014;**63**:2141–2147.
241. Peetermans M, Pollack C Jr, Reilly P, Liesenborghs L, Jacquemin M, Levy JH, Weitz JI, Verhamme P. Idarucizumab for dabigatran overdose. *Clin Toxicol (Phila)* 2016;**54**:644–646.
242. Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Mahaffey KW, Singer DE, Califf RM, Fox KA; ROCKET AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. *Eur Heart J* 2014;**35**:1873–1880.
243. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. *Circulation* 2013;**128**:2325–2332.
244. Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, Shi M, Mercuri MF, Antman EM, Braunwald E. Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 Trial. *Am J Med* 2016;**129**:850–857.e2.
245. Kawabori M, Niiya Y, Iwasaki M, Mabuchi S, Ozaki H, Matsubara K, Houkin K. Characteristics of symptomatic intracerebral hemorrhage in patient receiving direct oral anticoagulants: comparison with warfarin. *J Stroke Cerebrovasc Dis* 2018; [Epub ahead of print].
246. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;**383**:955–962.
247. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messe SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegel D, Wiggins BS. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol* 2017;**70**:3042–3067.
248. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for dabigatran reversal—full cohort analysis. *N Engl J Med* 2017;**377**:431–441.
249. Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegel DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. *N Engl J Med* 2016;**375**:1131–1141.
250. Ansell JE, Bakhr S, Lalicich BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. *N Engl J Med* 2014;**371**:2141–2142.
251. Beyer-Westendorf J, Forster K, Pannach S, Ebert F, Gelbricht V, Thieme C, Michalski F, Kohler C, Werth S, Sahin K, Tittel L, Hansel U, Weiss N. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. *Blood* 2014;**124**:955–962.
252. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. *J Thromb Haemost* 2011;**9**:1705–1712.
253. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. *Clin Pharmacokinet* 2010;**49**:259–268.
254. Getta B, Muller N, Motum P, Hsu D, Zebeljan D, Rosenfeld D. Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. *Br J Haematol* 2015;**169**:603–604.
255. Parasarmpuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown KS. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. *Thromb Haemost* 2015;**113**:719–727.
256. Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. *J Clin Pharmacol* 2016;**56**:628–636.
257. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Ouldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakassumsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet* 2010;**376**:23–32.

258. Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. *BMJ* 2014;**349**:g4829.
259. Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. *Europace* 2016;**18**:955–964.
260. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Heidbuchle H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. *Circulation* 2012;**126**:343–348.
261. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. *Stroke* 2011;**42**:3594–3599.
262. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. *J Thromb Haemost* 2012;**10**:1841–1848.
263. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. *Anesthesiology* 2012;**116**:94–102.
264. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. *Circulation* 2015;**131**:82–90.
265. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. *Circulation* 2011;**124**:1573–1579.
266. Song Y, Wang Z, Perlstein I, Wang J, LaCreta F, Frost RJA, Frost C. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study. *J Thromb Haemost* 2017;**15**:2125–2137.
267. Levi M, Moore KT, Castillejos CF, Kubitz D, Berkowitz SD, Goldhaber SZ, Raghoobar M, Patel MR, Weitz JI, Levy JH. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. *J Thromb Haemost* 2014;**12**:1428–1436.
268. Albaladejo P, Samama C-M, Sié P, Kauffmann S, Mémier V, Suchon P, Viallon A, David JS, Gruel Y, Bellamy L, de Maistre E, Romegoux P, Thoret S, Pernod G, Bosson J-L; GIHP-NACO Study Group. Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis. *Anesthesiology* 2017;**127**:111–120.
269. Majeed A, Agren A, Holmstrom M, Bruzelius M, Chairati R, Odeberg J, Hempel EL, Magnusson M, Frisk T, Schulman S. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. *Blood* 2017;**130**:1706–1712.
270. Warkentin TE, Margets P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. *Blood* 2012;**119**:2172–2174.
271. Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassir J, Kowalski S, Lee AY, Le Gal G, Le Templeur G, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale. *Thromb Haemost* 2017;**117**:2415–2424.
272. Beyer-Westendorf J, Gelbricht V, Forster K, Ebert F, Kohler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. *Eur Heart J* 2014;**35**:1888–1896.
273. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL. Perioperative bridging anticoagulation in patients with atrial fibrillation. *N Engl J Med* 2015;**373**:823–833.
274. Sivoella S, De Biagi M, Brunello G, Berengo M, Pengo V. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. *Odontology* 2015;**103**:258–263.
275. Johnston S. An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. *Int J Oral Maxillofac Surg* 2016;**45**:618–630.
276. Mauprivez C, Khonsari RH, Razouk O, Goudot P, Lesclous P, Descroix V. Management of dental extraction in patients undergoing anticoagulant oral direct treatment: a pilot study. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2016;**122**:e146–e155.
277. Patel JP, Woolcombe SA, Patel RK, Obisesan O, Roberts LN, Bryant C, Arya R. Managing direct oral anticoagulants in patients undergoing dentoalveolar surgery. *Br Dent J* 2017;**222**:245–249.
278. Yagyu T, Kawakami M, Ueyama Y, Imada M, Kurihara M, Matsusue Y, Imai Y, Yamamoto K, Kiritani T. Risks of postextraction bleeding after receiving direct oral anticoagulants or warfarin: a retrospective cohort study. *BMJ Open* 2017;**7**:e015952.
279. Miclotte I, Vanhaverbeke M, Agbaje JO, Legrand P, Vanassche T, Verhamme P, Politis C. Pragmatic approach to manage new oral anticoagulants in patients undergoing dental extractions: a prospective case-control study. *Clin Oral Investig* 2017;**21**:2183–2188.
280. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TL, Essebag V; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. *N Engl J Med* 2013;**368**:2084–2093.
281. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, Gulizia M, Halvorsen S, Hindricks G, Kuck KH, Moya A, Potpara T, Roldan V, Tilz R, Lip GY. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). *Europace* 2015;**17**:1197–1214.
282. Narouze S, Benzon HT, Provenzano DA, Buvanendran A, De Andres J, Deer TR, Rauck R, Huntoon MA. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. *Reg Anesth Pain Med* 2015;**40**:182–212.
283. Albaladejo P, Bonhomme F, Blais N, Collet JP, Faraoni D, Fontana P, Godier A, Llaou J, Longrois D, Marret E, Mismetti P, Roscher N, Rouillet S, Samama CM, Schved JF, Sie P, Steib A, Susen S; French Working Group on Perioperative Hemostasis (GIHP). Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP)—September 2015. *Anaesth Crit Care Pain Med* 2017;**36**:73–76.
284. Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications (Second Edition): guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. *Reg Anesth Pain Med* 2017; [Epub ahead of print].
285. Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. *J Thromb Haemost* 2016;**14**:2559–2561.
286. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen P-S, Chen S-A, Chung MK, Nielsen JC, Curtis AB, Wyn Davies D, Day JD, D'Avila A, de Groot NMS, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao H-M, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. *J Interv Card Electrophysiol* 2017;**50**:1–55.
287. Hauesler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic stroke. *Stroke* 2012;**43**:265–270.
288. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi C, Forleo G, Pelargonio G, Narducci ML, Russo AD, Casella M, Fassini G, Tondo C, Schweikert RA, Natale A. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. *Circulation* 2014;**129**:2638–2644.
289. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. *N Engl J Med* 2017;**376**:1627–1636.

290. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramanian R, De Chillou C, Davies DW, Fields LE, Natale A; VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. *Eur Heart J* 2015;**36**:1805–1811.
291. Di Biase L, Callans D, Hæusler KG, Hindricks G, Al-Khalidi H, Mont L, Cosedis Nielsen J, Piccini JP, Schotten U, Kirchhof P. Rationale and design of AXAFA-AFNET S: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. *Europace* 2017;**19**:132–138.
292. Ukaigwe A, Shrestha P, Karmacharya P, Hussain SK, Samii S, Gonzalez MD, Wolbrette D, Naccarelli GV. Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. *J Interv Card Electrophysiol* 2017;**48**:223–233.
293. Steffel J, Ruff CT, Hamerschock RA, Murphy SA, Senior R, Roy D, Lanz HJ, Mercuri MF, Antman EM, Giugliano RP. First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. *Int J Cardiol* 2017;**244**:192–195.
294. Kottmaier M, Bourier F, Pausch H, Reents T, Semmler V, Telishevska M, Koch-Buttner K, Lengerer C, Lengaer S, Kormayer M, Rousseau E, Brooks S, Brkic A, Ammar-Busch S, Kaess B, Dillier R, Grebner C, Kolb C, Hessling G, Deisenhofer I. Safety of uninterrupted periprocedural edoxaban versus phenprocoumon for patients who underwent left atrial catheter ablation procedures. *Am J Cardiol* 2018;**121**:445–449.
295. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. *Br J Haematol* 2003;**123**:676–682.
296. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, Martin DO, Hussein A, Khoury M, Abi-Saleh B, Alam S, Sengupta J, Borek PP, Baranowski B, Niebauer M, Callahan T, Varma N, Chung M, Tchou PJ, Kanj M, Dresing T, Lindsay BD, Wazni O. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. *Circ Arrhythm Electrophysiol* 2013;**6**:460–466.
297. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S, Mohanty P, Prakash S, Bai R, Reddy M, Gianni C, Horton R, Bailey S, Sigmund E, Derndorfer M, Schade A, Mueller P, Szoelloes A, Sanchez J, Al-Ahmad A, Hranitzky P, Gallinhouse GJ, Hongo RH, Beheiry S, Püerfellner H, Burkhardt JD, Natale A. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. *Heart Rhythm* 2015;**12**:1162–1168.
298. Death NCEiPoA. *The NCEPOD Classification of Intervention*. <http://www.ncepod.org.uk/classification.html> (8 March 2018).
299. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. *J Thromb Haemost* 2016;**14**:623–627.
300. Gwyn JCV, Thomas MR, Kirchhof P. Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint. *Eur Heart J Cardiovasc Pharmacother* 2017;**3**:157–162.
301. Lopes RD, Li L, Granger CB, Wang TY, Foody JM, Funk M, Peterson ED, Alexander KP. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. *Am J Med* 2012;**125**:897–905.
302. Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, Goto S, Hanna M, Huber K, Husted S, Lewis BS, McMurray JJ, Pais P, Pouleur H, Steg PG, Verheugt FW, Wojdyla DM, Granger CB, Wallentin L. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Eur Heart J* 2014;**35**:224–232.
303. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijssen JG, van 't Hof AW, ten Berg JM; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet* 2013;**381**:1107–1115.
304. Rubboli A, Saia F, Sciahbasi A, Leone AM, Palmieri C, Bacchi-Reggiani ML, Calabro P, Bordon B, Piccolo G, Franco N, Nicolino A, Magnavacchi P, Vignali L, Mameli S, Dallago M, Maggolini S, Steffanon L, Piovaccari G, Di Pasquale G. Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: insights from the Warfarin and Coronary Stenting (War-Stent) Registry. *Cardiovasc Revasc Med* 2017;**18**:425–430.
305. Sra S, Tan MK, Mehta SR, Fisher HN, Dery JP, Welsh RC, Eisenberg MJ, Overgaard CB, Rose BF, Siega AJ, Cheema AN, Wong BY, Henderson MA, Lutchmedial S, Lavi S, Goodman SG, Yan AT. Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: insights from the Canadian observational AntiPlatelet sTudy. *Am Heart J* 2016;**180**:82–89.
306. Lopes RD, Rao M, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey P, Piccini JP, Singer DE, Chang P, Peterson ED, Mahaffey KW. Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. *Am J Med* 2016;**129**:592–599.e1.
307. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet* 2006;**367**:1903–1912.
308. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Janus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. *N Engl J Med* 2016;**375**:2423–2434.
309. Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. *N Engl J Med* 2017;**377**:1580–1582.
310. Vranckx P, Lewalter T, Valgimigli M, Tijssen JG, Reimtz P-E, Eckardt L, Lanz H-J, Zierhut W, Smolnik R, Goette A. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial. *Am Heart J* 2016;**196**:105–112.
311. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox KA. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). *Am Heart J* 2015;**169**:472–478.e5.
312. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, Sundstrom J. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. *Eur Heart J* 2013;**34**:1670–1680.
313. Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, Shi M, Mercuri M, Antman EM, Braunwald E. Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 Trial. *J Am Heart Assoc* 2016;**5**:e002587.
314. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J, Richardt G, Iniguez A, Brunel P, Valdes-Chavarrri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC. Polymer-free drug-coated coronary stents in patients at high bleeding risk. *N Engl J Med* 2015;**373**:2038–2047.
315. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrie D, Hovasse T, Garot P, El Mahmoud R, Spaulding C, Helft G, Diaz Fernandez JF, Brugaletta S, Pinar-Bermudez E, Mauri Ferre J, Commeau P, Teiger E, Bogaerts K, Sabate M, Morice MC, Sinnaeve PR. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. *Lancet* 2018;**391**:41–50.
316. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torricca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;**35**:2541–2619.
317. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhilber JN, Weber MA, Fabry-Ribaud L, Hu T, Topol EJ, Fox KA. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. *J Am Coll Cardiol* 2007;**49**:1982–1988.
318. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand S-LT, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N Engl J Med* 2014;**371**:2155–2166.
319. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med* 2015;**372**:1791–1800.
320. Karjalainen PP, Vikman S, Niemela M, Porela P, Ylitalo A, Vaitinen MA, Puurunen M, Airaksinen TJ, Nyman K, Vahlberg T, Airaksinen KE. Safety of

- percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. *Eur Heart J* 2008;**29**:1001–1010.
321. Vranckx P, Verheugt FV, de Maat MP, Ullmans VA, Regar E, Smits P, ten Berg JM, Lindeboom W, Jones RL, Friedman J, Reilly P, Leebeek FW. A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. *EurIntervention* 2013;**8**:1052–1060.
 322. Vranckx P, Leebeek FW, Tijssen JGP, Koolen J, Stammen F, Herman J-PR, de Winter RJ, van T Hof AWJ, Backx B, Lindeboom W, Kim S-Y, Kirsch B, van Eickels M, Misselwitz F, Verheugt FWA. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLOER trial. *Thromb Haemost* 2015;**114**:258–267.
 323. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhilb SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA* 2004;**292**:45–54.
 324. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. *Lancet* 2015;**385**:2465–2476.
 325. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document R, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). *Eur Heart J* 2014;**35**:3155–3179.
 326. Povic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, Mundt H, Welsh R, Bode C, Gibson CM. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: the design of the GEMINI-ACS-1 phase II study. *Am Heart J* 2016;**174**:120–128.
 327. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2016;**37**:267–315.
 328. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. *Circulation* 2012;**126**:1185–1193.
 329. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. *Circulation* 2012;**125**:669–676.
 330. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013;**369**:799–808.
 331. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med* 2009;**361**:2342–2352.
 332. Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwöcho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med* 2013;**369**:1406–1415.
 333. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovello F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med* 2010;**363**:2499–2510.
 334. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med* 2012;**366**:1287–1297.
 335. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. *N Engl J Med* 2013;**368**:699–708.
 336. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvanne AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med* 2013;**368**:709–718.
 337. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. *N Engl J Med* 2017;**376**:1211–1222.
 338. Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. *Thromb Haemost* 2010;**105**:245.
 339. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. *Thromb Haemost* 2011;**105**:721–729.
 340. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, VAN Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *J Thromb Haemost* 2007;**5**:2178–2185.
 341. Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T, Ibusuki K, Ushida H, Abe K, Tachibana S. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. *Thromb Res* 2014;**134**:1198–1204.
 342. Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Fukuzawa M, Abe K, Tachibana S. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. *Thromb J* 2015;**13**:27.
 343. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med* 2008;**358**:2765–2775.
 344. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet* 2008;**372**:31–39.
 345. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med* 2008;**358**:2776–2786.
 346. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushman FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet* 2009;**373**:1673–1680.
 347. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusuf K, Steg PG, Metsarinne KP, Cook BR, N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med* 2017;**377**:1319–1330.
 348. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellnor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the

- American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation* 2014;**130**:e199–e267.
349. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH; X-VerT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. *Eur Heart J* 2014;**35**:3346–3355.
 350. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. *Lancet* 2016;**388**:1995–2003.
 351. McCready JW, Nunn L, Lambiasi PD, Ahsan SY, Segal OR, Rowland E, Lowe MD, Chow AW. Incidence of left atrial thrombus prior to atrial fibrillation ablation: is pre-procedural transoesophageal echocardiography mandatory? *Europace* 2010;**12**:927–932.
 352. Puwanant S, Varr BC, Shrestha K, Hussain SK, Tang WH, Gabriel RS, Wazni OM, Bhargava M, Saliba WJ, Thomas JD, Lindsay BD, Klein AL. Role of the CHADS₂ score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. *J Am Coll Cardiol* 2009;**54**:2032–2039.
 353. Scherr D, Dalal D, Chilukuri K, Dong J, Spragg D, Henrikson CA, Nazarian S, Cheng A, Berger RD, Abraham TP, Calkins H, Marine JE. Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. *J Cardiovasc Electrophysiol* 2009;**20**:379–384.
 354. Ezekowitz MD, Pollack CV, Sanders P, Halperin JL, Spahr J, Cater N, Petkun W, Breazna A, Kirchhof P, Oldgren J. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: rationale and design of the EMANATE trial. *Am Heart J* 2016;**179**:59–68.
 355. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH, Hansen J, Kober L, Husted S, Torp-Pedersen C. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. *Europace* 2015;**17**:18–23.
 356. Gronberg T, Hartikainen JE, Nuotio I, Biancari F, Ylitalo A, Airaksinen KE. Anticoagulation, CHA₂DS₂VASc score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV Study). *Am J Cardiol* 2016;**117**:1294–1298.
 357. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. *JAMA* 2014;**312**:647–649.
 358. Nagarankanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. *Circulation* 2011;**123**:131–136.
 359. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). *J Am Coll Cardiol* 2014;**63**:1082–1087.
 360. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G; ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. *J Am Coll Cardiol* 2013;**61**:1998–2006.
 361. Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, van Eickels M, Cohen A, Study XT; X-TRA study and CLOT-AF registry investigators. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). *Am Heart J* 2016;**178**:126–134.
 362. Purrucker JC, Haas K, Rizos T, Khan S, Poli S, Kraft P, Kleinschnitz C, Dziewas R, Binder A, Palm F, Jander S, Soda H, Heuschmann PU, Veltkamp R; RASUNO Investigators (Registry of Acute Stroke Under New Oral Anticoagulants). Coagulation Testing in acute ischemic stroke patients taking non-vitamin K antagonist oral anticoagulants. *Stroke* 2017;**48**:152–158.
 363. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2018; [Epub ahead of print].
 364. Tse DM, Young L, Ranta A, Barber PA. Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab. *J Neurol Neurosurg Psychiatry* 2017; [Epub ahead of print].
 365. Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cangur H, Daffertshofer M, Edelbusch S, Groschel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, Mullges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, Rother J, Rossi R, Schafer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—a national case collection. *Int J Stroke* 2017;**12**:383–391.
 366. Seiffge DJ, Traenka C, Polymeris AA, Thilemann S, Wagner B, Hert L, Muller MD, Gensicke H, Peters N, Nickel CH, Stippich C, Sutter R, Marsch S, Fisch U, Guzman R, De Marchis GM, Lyrer PA, Bonati LH, Tsakiris DA, Engelter ST. Intravenous thrombolysis in patients with stroke taking rivaroxaban using drug specific plasma levels: experience with a standard operation procedure in clinical practice. *J Stroke* 2017;**19**:347–355.
 367. Xian Y, Federspiel JJ, Hernandez AF, Laskowitz DT, Schwamm LH, Bhatt DL, Smith EE, Fonarow GC, Peterson ED. Use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who take non-vitamin K antagonist oral anticoagulants before stroke. *Circulation* 2017;**135**:1024–1035.
 368. Ebner M, Birschmann I, Peter A, Hartig F, Spencer C, Kuhn J, Blumenstock G, Zuern CS, Ziemann U, Poli S. Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions. *Stroke* 2017;**48**:2457–2463.
 369. Ebner M, Birschmann I, Peter A, Spencer C, Hartig F, Kuhn J, Blumenstock G, Zuern CS, Ziemann U, Poli S. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. *Crit Care* 2017;**21**:32.
 370. Drouet L, Bal Dit Sollier C, Steiner T, Purrucker J. Measuring non-vitamin K antagonist oral anticoagulant levels: when is it appropriate and which methods should be used? *Int J Stroke* 2016;**11**:748–758.
 371. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, Campbell BC, Nogueira RG, Demchuk AM, Tomasello A, Cardona P, Devlin TG, Frei DF, Du Mesnil de Rochemont R, Berkhemer OA, Jovin TG, Siddiqui AH, van Zwam WH, Davis SM, Castano C, Sapkota BL, Franssen PS, Molina C, van Oostenbrugge RJ, Chamorro A, Lingsma H, Silver FL, Donnan GA, Shuaib A, Brown S, Stouch B, Mitchell PJ, Davalos A, Roos YB, Hill MD; HERMES Collaborators. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. *JAMA* 2016;**316**:1279–1288.
 372. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP, Baxter BVV, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L, Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ, Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot JM, Tekle WG, Shields R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. *N Engl J Med* 2018;**378**:11–21.
 373. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP, Lansberg MG, Investigators D. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med* 2018; [Epub ahead of print].
 374. Wahlgren N, Moreira T, Michel P, Steiner T, Jansen O, Cognard C, Mattle HP, van Zwam W, Holmin S, Tatlisumak T, Petersson J, Caso V, Hacke W, Mazighi M, Arnold M, Fischer U, Szikora I, Pierot L, Fiehler J, Gralla J, Fazekas F, Lees KR; ESO-KSU, ESO, ESMINT, ESNR and EAN. Mechanical thrombectomy in acute ischemic stroke: consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN. *Int J Stroke* 2016;**11**:134–147.
 375. Purrucker JC, Wolf M, Haas K, Rizos T, Khan S, Dziewas R, Kleinschnitz C, Binder A, Groschel K, Hennerici MG, Lobotesis K, Poli S, Seidel G, Neumann-Haefelin T, Ringleb PA, Heuschmann PU, Veltkamp R. Safety of endovascular thrombectomy in patients receiving non-vitamin K antagonist oral anticoagulants. *Stroke* 2016;**47**:1127–1130.
 376. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? *Curr Cardiol Rep* 2014;**16**:480.
 377. Lopes RD, Guimaraes PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, Easton JD, Thomas L, Wallentin L, Al-Khatib SM, Held C, Gabriel Melo de Barros ESP, Alexander JH, Granger CB, Diener HC. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. *Blood* 2017;**129**:2980–2987.

378. Wilson D, Seiffge DJ, Traenka C, Basir G, Purruicker JC, Rizos T, Sobowale OA, Sallinen H, Yeh SJ, Wu TY, Ferrigno M, Houben R, Schreuder F, Perry LA, Tanaka J, Boulanger M, Al-Shahi Salman R, Jager HR, Ambler G, Shakeshaft C, Yakushiji Y, Choi PMC, Staals J, Cordonnier C, Jeng JS, Veltkamp R, Dowlatabadi D, Engelter ST, Parry-Jones AR, Meretoja A, Werring DJ. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. *Neurology* 2017;**88**:1693–1700.
379. Inohara T, Xian Y, Liang L, Matsouka RA, Saver JL, Smith EE, Schwamm LH, Reeves MJ, Hernandez AF, Bhatt DL, Peterson ED, Fonarow GC. Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. *JAMA* 2018;**319**:463–473.
380. Hemphill JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2015;**46**:2032–2060.
381. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, Hamann GF, Huwel J, Hagemann G, Barber B, Terborg C, Trostorf F, Bazner H, Roth A, Wöhrle J, Keller M, Schwarz M, Reimann G, Volkmann J, Mullges W, Kraft P, Classen J, Hohom C, Horn M, Milewski A, Reichmann H, Schneider H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann-Haefelin T, Racs AE, Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, Schwab S, Huttner HB. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. *JAMA* 2015;**313**:824–836.
382. Gerner ST, Kuramatsu JB, Sembill JA, Sprugel MI, Endres M, Haeusler KG, Vajkoczy P, Ringleb PA, Purruicker J, Rizos T, Erbguth F, Schellinger PD, Fink GR, Stetefeld H, Schneider H, Neugebauer H, Rother J, Classen J, Michalski D, Dorfler A, Schwab S, Huttner HB, Investigators RI. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. *Ann Neurol* 2018;**83**:186–196.
383. Paciaroni M, Agnelli G, Falocci N, Tsigoulis G, Vadikolias K, Liantinioti C, Chondrogiani M, Bovi P, Carletti M, Cappellari M, Zedde M, Ntaios G, Karagiorgi E, Athanasakis G, Makaritsis K, Silvestrelli G, Lanari A, Ciccone A, Putaala J, Tomppo L, Tatlisumak T, Abdul-Rahim AH, Lees KR, Alberti A, Venti M, Acciarresi M, D'Amore C, Becattini C, Mosconi MG, Cimini LA, Soloperto R, Masotti L, Vannucchi V, Lorenzini G, Tassi R, Guideri F, Acampa M, Martini G, Sohn SI, Marcheselli S, Mumoli N, De Lodovici ML, Bono G, Furie KL, Tadi P, Yaghi S, Toni D, Letteri F, Tassinari T, Kargiotis O, Lotti EM, Flamin Y, Mancuso M, Maccarrone M, Giannini N, Bandini F, Pezzini A, Poli L, Padovani A, Scoditti U, Denti L, Consoli D, Galati F, Sacco S, Carolei A, Tiseo C, Gurbali V, Orlandi G, Giuntini M, Chiti A, Giorli E, Gialdini G, Corea F, Ageno W, Bellesini M, Colombo G, Monaco S, Maimone Baronello M, Karapanayiotides T, Caso V. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study. *J Am Heart Assoc* 2017;**6**:e007034.
384. Ahmed N, Steiner T, Caso V, Wahlgren N. Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13–15 November 2016. *Eur Stroke J* 2017;**2**:95–102.
385. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert C, Pezzini A, Poli L, Padovani A, Csiba L, Szabó L, Sohn S-I, Tassinari T, Abdul-Rahim AH, Michel P, Cordier M, Vanacker P, Remillard S, Alberti A, Venti M, Scoditti U, Denti L, Orlandi G, Chiti A, Gialdini G, Bovi P, Carletti M, Rigatelli A, Putaala J, Tatlisumak T, Masotti L, Lorenzini G, Tassi R, Guideri F, Martini G, Tsigoulis G, Vadikolias K, Liantinioti C, Corea F, Del Sette M, Ageno W, De Lodovici ML, Bono G, Baldi A, D'Anna S, Sacco S, Carolei A, Tiseo C, Acciarresi M, D'Amore C, Imberti D, Zabzuni D, Doronin B, Volodina V, Consoli D, Galati F, Pieroni A, Toni D, Monaco S, Baronello MM, Barlinn K, Pallesen L-P, Kepplinger J, Bodechtel U, Gerber J, Deleu D, Melikyan G, Ibrahim F, Akhtar N, Mosconi MG, Bubba V, Silvestri I, Lees KR. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. *Stroke* 2015;**46**:2175–2182.
386. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. *Stroke* 2007;**38**:423–430.
387. Orrapin S, Rerkasem K. Carotid endarterectomy for symptomatic carotid stenosis. *Cochrane Database Syst Rev* 2017;**6**:CD001081.
388. Brønnum Nielsen P, Larsen TB, Gørst-Rasmussen A, Skjøth F, Rasmussen LH, Lip GYH. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. *Chest* 2015;**147**:1651–1658.
389. Korompoki E, Filippidis FT, Nielsen PB, Del Giudice A, Lip GYH, Kuramatsu JB, Huttner HB, Fang J, Schulman S, Marti-Fabregas J, Gathier CS, Viswanathan A, Biffi A, Poli D, Weimar C, Malzahn U, Heuschmann P, Veltkamp R. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. *Neurology* 2017;**89**:687–696.
390. Banerjee G, Carare R, Cordonnier C, Greenberg SM, Schneider JA, Smith EE, Buchem MV, Grond JV, Verbeek MM, Werring DJ. The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. *J Neurol Neurosurg Psychiatry* 2017;**88**:982–994.
391. Biffi A, Kuramatsu JB, Leasure A, Kamel H, Kourkoulis C, Schwab K, Ayres AM, Elm J, Gurol ME, Greenberg SM, Viswanathan A, Anderson CD, Schwab S, Rosand J, Testai FD, Woo D, Huttner HB, Sheth KN. Oral anticoagulation and functional outcome after intracerebral hemorrhage. *Ann Neurol* 2017;**82**:755–765.
392. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHA2DS2) risk stratification scheme. *Am Heart J* 2008;**156**:57–64.
393. Wolff A, Shantsila E, Lip GY, Lane DA. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. *Age Ageing* 2015;**44**:874–878.
394. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991;**22**:983–988.
395. Fohrting RB, Novak E, Rich MW. Effect of new oral anticoagulants on prescribing practices for atrial fibrillation in older adults. *J Am Geriatr Soc* 2017;**65**:2405–2412.
396. Bai Y, Guo SD, Deng H, Shantsila A, Fauchier L, Ma CS, Lip GYH. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. *Age Ageing* 2018;**47**:9–17.
397. Fumagalli S, Potpara TS, Bjerregaard Larsen T, Haugaa KH, Dobreaanu D, Proclemer A, Dagres N. Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey. *Europace* 2017;**19**:1896–1902.
398. Wehling M, Collins R, Gil VM, Hanon O, Hardt R, Hoffmeister M, Monteiro P, Quinn TJ, Ropers D, Sergi G, Verheugt FWA. Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016). *Drugs Aging* 2017;**34**:499–507.
399. Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. *J Am Heart Assoc* 2016;**5**:e003432.
400. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigator. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). *Circulation* 2014;**130**:138–146.
401. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. *Eur Heart J* 2014;**35**:1864–1872.
402. Okumura K, Lip GYH, Akao M, Tanizawa K, Fukuzawa M, Abe K, Akishita M, Yamashita T. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of the ELDERCARE-AF study. *Am Heart J* 2017;**194**:99–106.
403. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;**56**:M146–M156.
404. Rockwood K, Stadnyk K, MacKnight C, McDowell I, Hebert R, Hogan DB. A brief clinical instrument to classify frailty in elderly people. *Lancet* 1999;**353**:205–206.
405. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. *CMAJ* 2005;**173**:489–495.
406. Rubenstein LZ. Falls in older people: epidemiology, risk factors and strategies for prevention. *Age Ageing* 2006;**35**(Suppl 2):ii37–ii41.
407. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. *Stroke* 2006;**37**:1075–1080.
408. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. *Arch Intern Med* 1999;**159**:677–685.
409. Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB; Apixaban for Reduction in

- Stroke Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. *Am J Med* 2018;**131**:269–275.
410. Tiedemann A, Lord SR, Sherrington C. The development and validation of a brief performance-based fall risk assessment tool for use in primary care. *J Gerontol A Biol Sci Med Sci* 2010;**65**:896–903.
 411. Hanon O, Assayag P, Belmin J, Collet JP, Emeriau JP, Fauchier L, Forette F, Friocourt P, Gentric A, Leclercq C, Komajda M, Le Heuzey JY; French Society of Geriatrics, Gerontology, French Society of Cardiology. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. *Arch Cardiovasc Dis* 2013;**106**:303–323.
 412. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC. Effective exercise for the prevention of falls: a systematic review and meta-analysis. *J Am Geriatr Soc* 2008;**56**:2234–2243.
 413. Tricco AC, Thomas SM, Veroniki AA, Hamid JS, Cogo E, Striffler L, Khan PA, Robson R, Sibley KM, MacDonald H, Riva JJ, Thavorn K, Wilson C, Holroyd-Leduc J, Kerr GD, Feldman F, Majumdar SR, Jaglal SB, Hui W, Straus SE. Comparisons of interventions for preventing falls in older adults: a systematic review and meta-analysis. *JAMA* 2017;**318**:1687–1699.
 414. García-Ptacek S, Contreras Escamez B, Zupanec E, Religa D, von Koch L, Johnell K, von Euler M, Kåreholt I, Eriksson M. Prestroke mobility and dementia as predictors of stroke outcomes in patients over 65 years of age: a cohort study from the Swedish Dementia and Stroke Registries. *J Am Med Dir Assoc* 2018;**19**:154–161.
 415. Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. *Eur Heart J* 2018;**39**:453–460.
 416. Dietzel J, Haeusler KG, Endres M. Does atrial fibrillation cause cognitive decline and dementia? *Eurpace* 2018;**20**:408.
 417. World Health Organization. *Obesity and Overweight Fact Sheet*. <http://www.who.int/mediacentre/factsheets/fs311/en/> (8 March 2018).
 418. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. *JAMA* 2004;**292**:2471–2477.
 419. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. *J Am Coll Cardiol* 2017;**70**:2022–2035.
 420. Sivasambu B, Balouch MA, Zghaib T, Bajwa RJ, Chrispin J, Berger RD, Ashikaga H, Nazarian S, Marine JE, Calkins H, Spragg DD. Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients. *J Cardiovasc Electrophysiol* 2018;**29**:239–245.
 421. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA* 2013;**310**:2050–2060.
 422. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafer U. Glomerular hemodynamics in severe obesity. *Am J Physiol Renal Physiol* 2000;**278**:F817–F822.
 423. Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison L, Alabdan NA, Sands CW, Self TH. Comparison of initial warfarin response in obese patients versus non-obese patients. *J Thromb Thrombolysis* 2013;**36**:96–101.
 424. Kubitz D, Becka M, Zuehlendorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. *J Clin Pharmacol* 2007;**47**:218–226.
 425. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost CE. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. *Br J Clin Pharmacol* 2013;**76**:908–916.
 426. Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. *Eur J Clin Pharmacol* 2014;**70**:1339–1351.
 427. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. *J Thromb Haemost* 2016;**14**:1308–1313.
 428. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. *J Thromb Thrombolysis* 2016;**41**:206–232.
 429. Breuer L, Ringwald J, Schwab S, Kohrmann M. Ischemic stroke in an obese patient receiving dabigatran. *N Engl J Med* 2013;**368**:2440–2442.
 430. Safouris A, Demulder A, Triantafyllou N, Tsigoulis G. Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient. *J Neurol Sci* 2014;**346**:366–367.
 431. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. *Eur Heart J* 2016;**37**:2869–2878.
 432. Balla SR, Cyr DD, Likhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR. Relation of risk of stroke in patients with atrial fibrillation to body mass index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). *Am J Cardiol* 2017;**119**:1989–1996.
 433. Braekkan SK, van der Graaf Y, Visseren FL, Algra A. Obesity and risk of bleeding: the SMART study. *J Thromb Haemost* 2016;**14**:65–72.
 434. Lee CH, Lin TY, Chang SH, Chen CH, Hsu YJ, Hung KC, Wen MS. Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran. *Int J Cardiol* 2017;**228**:771–778.
 435. De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight—a systematic literature review. *Clin Res Cardiol* 2017;**106**:565–572.
 436. Van Eijkeren MA, Christiaens GC, Sixma JJ, Haspels AA. Menorrhagia: a review. *Obstet Gynecol Surv* 1989;**44**:421–429.
 437. Huq FY, Tvarkova K, Arafa A, Kadir RA. Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. *Contraception* 2011;**84**:128–132.
 438. De Crem N, Peerlinck K, Vanassche T, Vanheule K, Debaveye B, Middeldorp S, Verhamme P, Peetermans M. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. *Thromb Res* 2015;**136**:749–753.
 439. Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Trajanovic M, Gebel M, Lam P, Wells PS, Prins MH. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. *Blood* 2016;**127**:1417–1425.
 440. Beyer-Westendorf J, Michalski F, Tittel L, Hauswald-Dörschel S, Marten S. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. *Lancet Haematol* 2016;**3**:e480–e488.
 441. Rolden HJA, Maas A, van der Wilt GJ, Grutters JPC. Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed. *BMC Cardiovasc Disord* 2017;**17**:260.
 442. Tobenkin A, Mohamoud M, Munoz M, Waldron P. Direct oral anticoagulants and menorrhagia in premenopausal women: data from the food and drug administration adverse event reporting system and US drug utilization. *Haemophilia* 2017;**23**(Suppl 3):43.
 443. Nielsen JR, Wachtell K, Abdulla J. The relationship between physical activity and risk of atrial fibrillation—a systematic review and meta-analysis. *J Atr Fibrillation* 2013;**5**:789.
 444. Zhu WG, Wan R, Din Y, Xu Z, Yang X, Hong K. Sex differences in the association between regular physical activity and incident atrial fibrillation: a meta-analysis of 13 prospective studies. *Clin Cardiol* 2016;**39**:360–367.
 445. Kwok CS, Anderson SG, Myint PK, Mamas MA, Loke YK. Physical activity and incidence of atrial fibrillation: a systematic review and meta-analysis. *Int J Cardiol* 2014;**177**:467–476.
 446. Heidebuchel H, Anne W, Willems R, Adriaenssens B, Van de Werf F, Ector H. Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. *Int J Cardiol* 2006;**107**:67–72.
 447. Caselli S, Vaquer Sequi A, Lemme E, Quattrini F, Milan A, D'Ascenzi F, Spataro A, Pelliccia A. Prevalence and Management of Systemic Hypertension in Athletes. *Am J Cardiol* 2017;**119**:1616–1622.
 448. Stefanidou M, Das RR, Beiser AS, Sundar B, Kelly-Hayes M, Kase CS, Devinsky O, Seshadri S, Friedman D. Incidence of seizures following initial ischemic stroke in a community-based cohort: the Framingham Heart Study. *Seizure* 2017;**47**:105–110.
 449. Beghi E, D'Alessandro R, Beretta S, Consoli D, Crespi V, Delaj L, Gandolfo C, Greco G, La Neve A, Manfredi M, Mattana F, Musolino R, Provinciali L, Santangelo M, Specchio LM, Zaccara G, Epistroke G. Incidence and predictors of acute symptomatic seizures after stroke. *Neurology* 2011;**77**:1785–1793.
 450. Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. *Epilepsia* 2009;**50**:1102–1108.
 451. Hu YF, Liu CJ, Chang PM, Tsao HM, Lin YJ, Chang SL, Lo LW, Tuan TC, Li CH, Chao TF, Chung FP, Liao JN, Chen TJ, Chen SA. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. *Int J Cardiol* 2013;**165**:355–357.
 452. Onaitis M, D'Amico T, Zhao Y, O'Brien S, Harpole D. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. *Ann Thorac Surg* 2010;**90**:368–374.

453. Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB. Introducing a new entity: chemotherapy-induced arrhythmia. *Europace* 2009;**11**:1579–1586.
454. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. *J Am Coll Cardiol* 2014;**63**:945–953.
455. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. *PLoS Med* 2012;**9**:e1001275.
456. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. *Neoplasia* 2002;**4**:465–473.
457. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. *Circ Res* 2016;**118**:1008–1020.
458. Raskob GE, van Es N, Verhamme P, Carrier M, D, Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JL, Weitz JL, Buller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. *N Engl J Med* 2018;**378**:615–624.
459. Posch F, Konigsbrugge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. *Thromb Res* 2015;**136**:582–589.
460. Brunetti ND, Gesuete E, De Gennaro L, Correale M, Caldarola P, Gaglione A, Di Biase M. Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: a meta-analysis study. *Int J Cardiol* 2017;**230**:214–221.
461. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, Douglas PS, Alexander JH, Lopes RD. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial. *Am J Med* 2017;**130**:1440–1448.
462. Ording AG, Horváth-Puhó E, Adelborg K, Pedersen L, Prandoni P, Sørensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. *Cancer Med* 2017;**6**:1165–1172.
463. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; Authors/Task Force Members; ESC Committee for Practice Guidelines(CPG); Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J* 2016;**37**:2768–2801.
464. Zhang Y, de Boer A, Verhoef TI, van der Meer FJM, Le Cessie S, Maitland-van der Zee AH, Barallon R, de Boer A, Daly A, Maitland-van der Zee A-H, Redekop K, Stingl J, Manolopoulos VG, Rosendaal FR, Wadelius M. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. *Thromb Res* 2015;**136**:94–100.
465. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. *JAMA Intern Med* 2014;**174**:1330–1338.
466. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, Boyle E, Wells PS. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. *Ann Intern Med* 2003;**138**:714–719.
467. Garcia P, Ruiz W, Loza Munarriz C. Warfarin initiation nomograms for venous thromboembolism. *Cochrane Database Syst Rev* 2016;**1**:CD007699.
468. Belley-Cote EP, Hanif H, D'Aragon F, Eikelboom JW, Anderson JL, Borgman M, Jonas DE, Kimmel SE, Manolopoulos VG, Baranova E, Maitland-van der Zee AH, Pirmohamed M, Whitlock RP. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. *Thromb Haemost* 2015;**114**:768–777.
469. van Schie RM, Wessels JA, Le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee AH; EU-PACT Study Group. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. *Eur Heart J* 2011;**32**:1909–1917.
470. Mahtani KR, Heneghan CJ, Nunan D, Bankhead C, Keeling D, Ward AM, Harrison SE, Roberts NW, Hobbs FD, Perera R. Optimal loading dose of warfarin for the initiation of oral anticoagulation. *Cochrane Database Syst Rev* 2012;**12**:CD008685.
471. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. *Heart* 2005;**91**:472–477.
472. Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaet R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. *Circulation* 2012;**126**:2309–2316.
473. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, Investigators R. L. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. *Lancet* 2010;**376**:975–983.
474. Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. *Arch Intern Med* 2000;**160**:2343–2348.
475. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, Anderson DR. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. *CMAJ* 2003;**169**:293–298.
476. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, Alonso-Coello P, Fitzmaurice D, Mahtani KR, Onakpoya IJ. Self-monitoring and self-management of oral anticoagulation. *Cochrane Database Syst Rev* 2016;**7**:CD003839.